US10093630B2 - Pyrazole compounds and methods of making and using same - Google Patents
Pyrazole compounds and methods of making and using same Download PDFInfo
- Publication number
- US10093630B2 US10093630B2 US15/312,998 US201515312998A US10093630B2 US 10093630 B2 US10093630 B2 US 10093630B2 US 201515312998 A US201515312998 A US 201515312998A US 10093630 B2 US10093630 B2 US 10093630B2
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- another embodiment
- pyrazol
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 [1*]C1=CN(C(=O)N2CCN(C([2*])([3*])[4*])CC2)N=C1 Chemical compound [1*]C1=CN(C(=O)N2CCN(C([2*])([3*])[4*])CC2)N=C1 0.000 description 47
- WHUDORYWARUULG-UHFFFAOYSA-N CC(C)C(=O)N1CCC1.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)NC1CC1 Chemical compound CC(C)C(=O)N1CCC1.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)NC1CC1 WHUDORYWARUULG-UHFFFAOYSA-N 0.000 description 8
- SREDUUSCWDQNQK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=CC=N2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=CC=N2)CC1 SREDUUSCWDQNQK-UHFFFAOYSA-N 0.000 description 4
- ZZMBEPNTLVSVSJ-UHFFFAOYSA-N CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1 Chemical compound CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1 ZZMBEPNTLVSVSJ-UHFFFAOYSA-N 0.000 description 4
- IZNGEFGTKYCDSJ-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCOCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCOCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 IZNGEFGTKYCDSJ-UHFFFAOYSA-N 0.000 description 4
- NQMMBUJVCLWDCT-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 NQMMBUJVCLWDCT-UHFFFAOYSA-N 0.000 description 4
- WBLUJCJCDPWOAP-UHFFFAOYSA-N CC1=CC(CN2CCCN(C(=O)N3C=C(C#N)C=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCCN(C(=O)N3C=C(C#N)C=N3)CC2)=CC=C1 WBLUJCJCDPWOAP-UHFFFAOYSA-N 0.000 description 4
- SHGQBXRYNZEDTJ-UHFFFAOYSA-N CC1=CC(CN2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=CC=C1 SHGQBXRYNZEDTJ-UHFFFAOYSA-N 0.000 description 4
- QXPXGLUTPCQTRZ-UHFFFAOYSA-N CC1=CC(CN2CCN(C(=O)N3C=C(C)C=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCN(C(=O)N3C=C(C)C=N3)CC2)=CC=C1 QXPXGLUTPCQTRZ-UHFFFAOYSA-N 0.000 description 4
- QJJMTZORYDMUOC-UHFFFAOYSA-N CC1=CC=C(CN2CCCN(C(=O)N3C=C(C#N)C=N3)CC2)C=C1 Chemical compound CC1=CC=C(CN2CCCN(C(=O)N3C=C(C#N)C=N3)CC2)C=C1 QJJMTZORYDMUOC-UHFFFAOYSA-N 0.000 description 4
- CMTQXQAVHRAHNP-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1 CMTQXQAVHRAHNP-UHFFFAOYSA-N 0.000 description 4
- WQIFYSVCYDXZLJ-UHFFFAOYSA-N O=C(N1CCCCC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCCCC1)N1C=C(C2=CC=CC=C2)C=N1 WQIFYSVCYDXZLJ-UHFFFAOYSA-N 0.000 description 4
- XNQRZEPEIBJXNF-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)N1C=C(C)C=N1 Chemical compound CC(=O)N(C)CCN(C)C(=O)N1C=C(C)C=N1 XNQRZEPEIBJXNF-UHFFFAOYSA-N 0.000 description 3
- QSLCFDKXKCZUOY-UHFFFAOYSA-N CC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 QSLCFDKXKCZUOY-UHFFFAOYSA-N 0.000 description 3
- AUGQKZKZIKTCMG-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CC(=O)N1CCN(C(=O)N2C=C(C#N)C=N2)CC1 AUGQKZKZIKTCMG-UHFFFAOYSA-N 0.000 description 3
- RGKUVKSXXJWZBV-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1 RGKUVKSXXJWZBV-UHFFFAOYSA-N 0.000 description 3
- VFWKGXGTICIANN-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C#N)C=N2)CC1 VFWKGXGTICIANN-UHFFFAOYSA-N 0.000 description 3
- DWSGGILHURQSQX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C#N)C=N2)CC1 DWSGGILHURQSQX-UHFFFAOYSA-N 0.000 description 3
- RARYPZFXIFBJJF-UHFFFAOYSA-N CC(C)C(=O)N1CCC1 Chemical compound CC(C)C(=O)N1CCC1 RARYPZFXIFBJJF-UHFFFAOYSA-N 0.000 description 3
- KHGRSURBPFQREH-UHFFFAOYSA-N CC(C)C(=O)N1CCCCC1 Chemical compound CC(C)C(=O)N1CCCCC1 KHGRSURBPFQREH-UHFFFAOYSA-N 0.000 description 3
- MZKNSTYQEMDKTP-UHFFFAOYSA-N CC(C)C(=O)NC1CC1 Chemical compound CC(C)C(=O)NC1CC1 MZKNSTYQEMDKTP-UHFFFAOYSA-N 0.000 description 3
- UGZNQUJUYKSOEL-UHFFFAOYSA-N CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(Cl)C=C1.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1 Chemical compound CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(Cl)C=C1.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1 UGZNQUJUYKSOEL-UHFFFAOYSA-N 0.000 description 3
- WUEUSADIODWQHE-UHFFFAOYSA-N CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC=C(Cl)C=C1 Chemical compound CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC=C(Cl)C=C1 WUEUSADIODWQHE-UHFFFAOYSA-N 0.000 description 3
- ZKTDYRVLWHPDNM-UHFFFAOYSA-N CC(C)C1=CC=C(C2=C(Cl)C=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC1=C(C2=CC=C(C(C)C)C=C2)C=CC=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(C2=C(Cl)C=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC1=C(C2=CC=C(C(C)C)C=C2)C=CC=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1 ZKTDYRVLWHPDNM-UHFFFAOYSA-N 0.000 description 3
- JNTNFFOSNFPEHK-UHFFFAOYSA-N CC(C)C1=CC=CC=C1.CC1=C(C(C)C)C=CC=C1.CC1=C(C(C)C)C=CC=C1.CC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=CC=C1.CC1=C(C(C)C)C=CC=C1.CC1=C(C(C)C)C=CC=C1.CC1=CC=C(C(C)C)C=C1 JNTNFFOSNFPEHK-UHFFFAOYSA-N 0.000 description 3
- MQWRHHVMVSKHSG-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=CC=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=CC=N3)CC2)C=CC(C2=CC=CC=C2)=C1 MQWRHHVMVSKHSG-UHFFFAOYSA-N 0.000 description 3
- ZLGIFZMCPPDHCG-UHFFFAOYSA-N CC1=CC(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=C2C=CC=CC2=N1 ZLGIFZMCPPDHCG-UHFFFAOYSA-N 0.000 description 3
- OGWFKBLFWLXJQC-UHFFFAOYSA-N CC1=CN(C(=O)N(C)CCN(C)C(=O)OC(C)(C)C)N=C1 Chemical compound CC1=CN(C(=O)N(C)CCN(C)C(=O)OC(C)(C)C)N=C1 OGWFKBLFWLXJQC-UHFFFAOYSA-N 0.000 description 3
- RFFLMWRWBRNJGG-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCN(C(=O)C3=CC=CC=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCN(C(=O)C3=CC=CC=C3)CC2)N=C1 RFFLMWRWBRNJGG-UHFFFAOYSA-N 0.000 description 3
- AZSRKRXMUVRCSP-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(C)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(C)CC2)N=C1 AZSRKRXMUVRCSP-UHFFFAOYSA-N 0.000 description 3
- OWPKBJRFTJRHPP-UHFFFAOYSA-N CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C#N)C=N1 OWPKBJRFTJRHPP-UHFFFAOYSA-N 0.000 description 3
- QKIAHCCQFCFVNP-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C#N)C=N1 QKIAHCCQFCFVNP-UHFFFAOYSA-N 0.000 description 3
- VHBKTHISWKERCN-UHFFFAOYSA-N CCN(CC1=CC(OC)=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC(OC)=CC=C1)C(=O)N1C=C(Cl)C=N1 VHBKTHISWKERCN-UHFFFAOYSA-N 0.000 description 3
- NMIDAODDYKSEDW-UHFFFAOYSA-N CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C#N)C=N1 NMIDAODDYKSEDW-UHFFFAOYSA-N 0.000 description 3
- VUKZRXXRSIKPOZ-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C(=O)OC(C)(C)C Chemical compound CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C(=O)OC(C)(C)C VUKZRXXRSIKPOZ-UHFFFAOYSA-N 0.000 description 3
- IMNRTTYXNMTOLD-UHFFFAOYSA-N CN1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CN1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 IMNRTTYXNMTOLD-UHFFFAOYSA-N 0.000 description 3
- ZDWCWRPTEFKZSN-UHFFFAOYSA-N CNC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound CNC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 ZDWCWRPTEFKZSN-UHFFFAOYSA-N 0.000 description 3
- KRZNCGLIDWPWKF-UHFFFAOYSA-N COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 KRZNCGLIDWPWKF-UHFFFAOYSA-N 0.000 description 3
- ZCLPSRVVEQGYCP-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCN(C(=O)C3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCN(C(=O)C3=CC=CC=C3)CC2)N=C1 ZCLPSRVVEQGYCP-UHFFFAOYSA-N 0.000 description 3
- SGMHSJNFTRORGK-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1 SGMHSJNFTRORGK-UHFFFAOYSA-N 0.000 description 3
- LEBGEOOMHBZHNF-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3)CC2)N=C1 LEBGEOOMHBZHNF-UHFFFAOYSA-N 0.000 description 3
- DUTLMHFKWYFTSE-UHFFFAOYSA-N NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 DUTLMHFKWYFTSE-UHFFFAOYSA-N 0.000 description 3
- FKTBJVLRUNIMFV-UHFFFAOYSA-N NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1 Chemical compound NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1 FKTBJVLRUNIMFV-UHFFFAOYSA-N 0.000 description 3
- ZECVWPHRMGQPOV-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3OCC3=CC=CC=C3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3OCC3=CC=CC=C3)CC2)N=C1)N1CCCC1 ZECVWPHRMGQPOV-UHFFFAOYSA-N 0.000 description 3
- JYIOQMPYHJKKGF-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCC1 JYIOQMPYHJKKGF-UHFFFAOYSA-N 0.000 description 3
- BBEXEGZCNKJJJZ-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCOCC1 BBEXEGZCNKJJJZ-UHFFFAOYSA-N 0.000 description 3
- WETSQHILHXLALN-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C2=CC=C(C3=CC=CC=C3)C=C2)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C2=CC=C(C3=CC=CC=C3)C=C2)C=N1 WETSQHILHXLALN-UHFFFAOYSA-N 0.000 description 3
- OAQIMEPYKVLSBS-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=CC=N1 OAQIMEPYKVLSBS-UHFFFAOYSA-N 0.000 description 3
- QTYFGYPPYMJMNL-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(OC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=C(OC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 QTYFGYPPYMJMNL-UHFFFAOYSA-N 0.000 description 3
- PDAIPOVVXVNPBK-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2C(F)(F)F)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2C(F)(F)F)CC1)N1C=C(C(F)(F)F)C=N1 PDAIPOVVXVNPBK-UHFFFAOYSA-N 0.000 description 3
- MCDBMEXJEQGXMR-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2N2CCCC2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2N2CCCC2)CC1)N1C=C(C(F)(F)F)C=N1 MCDBMEXJEQGXMR-UHFFFAOYSA-N 0.000 description 3
- SOLIPHVUYOIPRI-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CN=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CN=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 SOLIPHVUYOIPRI-UHFFFAOYSA-N 0.000 description 3
- YQRWALXMNKRKFP-UHFFFAOYSA-N O=C(NCC1=CC2=C(C=CC=C2)C=C1)N1C=CC=N1 Chemical compound O=C(NCC1=CC2=C(C=CC=C2)C=C1)N1C=CC=N1 YQRWALXMNKRKFP-UHFFFAOYSA-N 0.000 description 3
- UJHDXVGWUYNVSD-UHFFFAOYSA-N O=C(NCCCCC1=CC=CC=C1)N1C=CC=N1 Chemical compound O=C(NCCCCC1=CC=CC=C1)N1C=CC=N1 UJHDXVGWUYNVSD-UHFFFAOYSA-N 0.000 description 3
- REHZTJNSAPEHGW-UHFFFAOYSA-N O=C(O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound O=C(O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 REHZTJNSAPEHGW-UHFFFAOYSA-N 0.000 description 3
- GQDLSQGEYDQLMU-UHFFFAOYSA-N C.CC(C)C(=O)N1CCC1.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)NC1CC1 Chemical compound C.CC(C)C(=O)N1CCC1.CC(C)C(=O)N1CCCCC1.CC(C)C(=O)NC1CC1 GQDLSQGEYDQLMU-UHFFFAOYSA-N 0.000 description 2
- DDWCTUDIMPTRIJ-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)N1C=C(C#N)C=N1 Chemical compound CC(=O)N(C)CCN(C)C(=O)N1C=C(C#N)C=N1 DDWCTUDIMPTRIJ-UHFFFAOYSA-N 0.000 description 2
- IFYDEOBFJVVXJL-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CC(=O)N(C)CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1 IFYDEOBFJVVXJL-UHFFFAOYSA-N 0.000 description 2
- CEYAQDZXUYHQES-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)N1C=C(Cl)C=N1 Chemical compound CC(=O)N(C)CCN(C)C(=O)N1C=C(Cl)C=N1 CEYAQDZXUYHQES-UHFFFAOYSA-N 0.000 description 2
- NJKFCRSVMSDQOB-UHFFFAOYSA-N CC(=O)N1CCCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CC(=O)N1CCCN(C(=O)N2C=C(C#N)C=N2)CC1 NJKFCRSVMSDQOB-UHFFFAOYSA-N 0.000 description 2
- FFRATOCFEVWEAH-UHFFFAOYSA-N CC(=O)N1CCCN(C(=O)N2C=C(C)C=N2)CC1 Chemical compound CC(=O)N1CCCN(C(=O)N2C=C(C)C=N2)CC1 FFRATOCFEVWEAH-UHFFFAOYSA-N 0.000 description 2
- CWKNWVQEJMJLEX-UHFFFAOYSA-N CC(=O)N1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CC(=O)N1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 CWKNWVQEJMJLEX-UHFFFAOYSA-N 0.000 description 2
- VIIFGBNZSZTQPF-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 VIIFGBNZSZTQPF-UHFFFAOYSA-N 0.000 description 2
- GRGLDQFQTGDDPW-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)N2C=C(C)C=N2)CC1 Chemical compound CC(=O)N1CCN(C(=O)N2C=C(C)C=N2)CC1 GRGLDQFQTGDDPW-UHFFFAOYSA-N 0.000 description 2
- PIDDVESLLHPMSV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCNCC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCNCC1 PIDDVESLLHPMSV-UHFFFAOYSA-N 0.000 description 2
- PTANHFGPGVCEMD-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=CC=N2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=CC=N2)CC1 PTANHFGPGVCEMD-UHFFFAOYSA-N 0.000 description 2
- LWAXRVOSAFLBKM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCNCC1.CC1=C(C=O)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC(C)(C)OC(=O)N1CCNCC1.CC1=C(C=O)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C=CC(C2=CC=CC=C2)=C1 LWAXRVOSAFLBKM-UHFFFAOYSA-N 0.000 description 2
- QLMJMHVHFWACDO-UHFFFAOYSA-N CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1F.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1F Chemical compound CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1F.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1F QLMJMHVHFWACDO-UHFFFAOYSA-N 0.000 description 2
- QFDGLUQQBPCFJZ-UHFFFAOYSA-N CC(C)C1=CN(C(=O)N2CCN(CC3=C(N4CCCC4)C=CC=C3C(F)(F)F)CC2)N=C1 Chemical compound CC(C)C1=CN(C(=O)N2CCN(CC3=C(N4CCCC4)C=CC=C3C(F)(F)F)CC2)N=C1 QFDGLUQQBPCFJZ-UHFFFAOYSA-N 0.000 description 2
- RYDKXKJVRHMGKU-UHFFFAOYSA-N CC(C)CC1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)CC1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)CC1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)CC1=CC=C(OCC2=CC=CC=C2)C=C1 Chemical compound CC(C)CC1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)CC1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)CC1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)CC1=CC=C(OCC2=CC=CC=C2)C=C1 RYDKXKJVRHMGKU-UHFFFAOYSA-N 0.000 description 2
- RNNJKCSNERCLAK-UHFFFAOYSA-N CC(C)N1C=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C(C2=CC=CC=C2)=N1 Chemical compound CC(C)N1C=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C(C2=CC=CC=C2)=N1 RNNJKCSNERCLAK-UHFFFAOYSA-N 0.000 description 2
- UYBYMUULAVUXIF-UHFFFAOYSA-N CC.CC.CC.CC(C)C1=CC(N2CCCC2)=CC=C1.CC(C)C1=CC(N2CCOCC2)=CC=C1.CC(C)C1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1N1CCCC1.CC(C)C1=CC=CC=C1N1CCOCC1.CCl.CF Chemical compound CC.CC.CC.CC(C)C1=CC(N2CCCC2)=CC=C1.CC(C)C1=CC(N2CCOCC2)=CC=C1.CC(C)C1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1N1CCCC1.CC(C)C1=CC=CC=C1N1CCOCC1.CCl.CF UYBYMUULAVUXIF-UHFFFAOYSA-N 0.000 description 2
- VHVOSZLXKWEVOH-UHFFFAOYSA-N CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1 Chemical compound CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1 VHVOSZLXKWEVOH-UHFFFAOYSA-N 0.000 description 2
- VLJNAECZYCAFMS-UHFFFAOYSA-N CC1=C(C2=CN(C(=O)N3CCN(CC4=C(C5=CC=C(Cl)C=C5)C=C(Cl)C=C4)CC3)N=C2)C=CC=C1 Chemical compound CC1=C(C2=CN(C(=O)N3CCN(CC4=C(C5=CC=C(Cl)C=C5)C=C(Cl)C=C4)CC3)N=C2)C=CC=C1 VLJNAECZYCAFMS-UHFFFAOYSA-N 0.000 description 2
- PHDSFGPUUAIXQC-UHFFFAOYSA-N CC1=C(C2=CN(C(=O)N3CCN(CC4=C(N5CCCC5)C=CC=C4C(F)(F)F)CC3)N=C2)C=CC=C1 Chemical compound CC1=C(C2=CN(C(=O)N3CCN(CC4=C(N5CCCC5)C=CC=C4C(F)(F)F)CC3)N=C2)C=CC=C1 PHDSFGPUUAIXQC-UHFFFAOYSA-N 0.000 description 2
- IGKBZOFZUWAMPW-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 IGKBZOFZUWAMPW-UHFFFAOYSA-N 0.000 description 2
- RKHQEYCNSGSCKO-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 RKHQEYCNSGSCKO-UHFFFAOYSA-N 0.000 description 2
- GISIDSBYVFYLMO-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCCCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=C(C(=O)N4CCCCC4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 GISIDSBYVFYLMO-UHFFFAOYSA-N 0.000 description 2
- LMPFRTPIGHBOHL-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)C=CC(C2=CC=CC=C2)=C1 LMPFRTPIGHBOHL-UHFFFAOYSA-N 0.000 description 2
- STLNIZRGBFXDET-UHFFFAOYSA-N CC1=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCNCC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC1=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCNCC2)C=CC(C2=CC=CC=C2)=C1 STLNIZRGBFXDET-UHFFFAOYSA-N 0.000 description 2
- NVEQHMGJZGQXHM-UHFFFAOYSA-N CC1=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=CC=C1 Chemical compound CC1=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=CC=C1 NVEQHMGJZGQXHM-UHFFFAOYSA-N 0.000 description 2
- PHGPXRNIKWMMPG-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 PHGPXRNIKWMMPG-UHFFFAOYSA-N 0.000 description 2
- SIIGDLMMALQQTC-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 SIIGDLMMALQQTC-UHFFFAOYSA-N 0.000 description 2
- PUPXONLWVRNTOQ-UHFFFAOYSA-N CC1=CC(CN2CCCN(C(=O)N3C=C(C)C=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCCN(C(=O)N3C=C(C)C=N3)CC2)=CC=C1 PUPXONLWVRNTOQ-UHFFFAOYSA-N 0.000 description 2
- MRYSWBYIOHXVLM-UHFFFAOYSA-N CC1=CC(CN2CCN(C(=O)N3C=C(C#N)C=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCN(C(=O)N3C=C(C#N)C=N3)CC2)=CC=C1 MRYSWBYIOHXVLM-UHFFFAOYSA-N 0.000 description 2
- NNCRJZDYMDMOFD-UHFFFAOYSA-N CC1=CC(CN2CCN(C(=O)N3C=CC=N3)CC2)=CC=C1 Chemical compound CC1=CC(CN2CCN(C(=O)N3C=CC=N3)CC2)=CC=C1 NNCRJZDYMDMOFD-UHFFFAOYSA-N 0.000 description 2
- NLHUYNIXRAPXGS-UHFFFAOYSA-N CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(C4=CC=C(C(F)(F)F)C=C4)C=N3)CC2)C=C1 Chemical compound CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(C4=CC=C(C(F)(F)F)C=C4)C=N3)CC2)C=C1 NLHUYNIXRAPXGS-UHFFFAOYSA-N 0.000 description 2
- MSDLIGGMVIOPOJ-UHFFFAOYSA-N CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(C4=CC=CC=C4C)C=N3)CC2)C=C1 Chemical compound CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(C4=CC=CC=C4C)C=N3)CC2)C=C1 MSDLIGGMVIOPOJ-UHFFFAOYSA-N 0.000 description 2
- JDVPGWVWGDAMES-UHFFFAOYSA-N CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C=C1 Chemical compound CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C=C1 JDVPGWVWGDAMES-UHFFFAOYSA-N 0.000 description 2
- YCTHNZDQGAYIIJ-UHFFFAOYSA-N CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(F)C=N3)CC2)C=C1 Chemical compound CC1=CC(N2CCCC2)=C(CN2CCN(C(=O)N3C=C(F)C=N3)CC2)C=C1 YCTHNZDQGAYIIJ-UHFFFAOYSA-N 0.000 description 2
- ZUKQWKNBMXWUCO-UHFFFAOYSA-N CC1=CC(N2CCN(C(=O)N3C=C(C#N)C=N3)CC2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N2CCN(C(=O)N3C=C(C#N)C=N3)CC2)=C2C=CC=CC2=N1 ZUKQWKNBMXWUCO-UHFFFAOYSA-N 0.000 description 2
- DDXDGJHPWYFNAT-UHFFFAOYSA-N CC1=CC(N2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)=C2C=CC=CC2=N1 DDXDGJHPWYFNAT-UHFFFAOYSA-N 0.000 description 2
- QYPKZSGJGYGNCW-UHFFFAOYSA-N CC1=CC(N2CCN(C(=O)N3C=C(Cl)C=N3)CC2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(N2CCN(C(=O)N3C=C(Cl)C=N3)CC2)=C2C=CC=CC2=N1 QYPKZSGJGYGNCW-UHFFFAOYSA-N 0.000 description 2
- VVBDWGBWOLZQSP-UHFFFAOYSA-N CC1=CC(N2CCOCC2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CC1=CC(N2CCOCC2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 VVBDWGBWOLZQSP-UHFFFAOYSA-N 0.000 description 2
- OUXZQNNPTSMHRJ-UHFFFAOYSA-N CC1=CC=C(C2=CN(C(=O)N3CCCC3)N=C2)C=C1 Chemical compound CC1=CC=C(C2=CN(C(=O)N3CCCC3)N=C2)C=C1 OUXZQNNPTSMHRJ-UHFFFAOYSA-N 0.000 description 2
- UQTWNGITJFDQPU-UHFFFAOYSA-N CC1=CC=C(CN2CCCN(C(=O)N3C=C(C)C=N3)CC2)C=C1 Chemical compound CC1=CC=C(CN2CCCN(C(=O)N3C=C(C)C=N3)CC2)C=C1 UQTWNGITJFDQPU-UHFFFAOYSA-N 0.000 description 2
- NFTAPGCJSJZYQZ-UHFFFAOYSA-N CC1=CC=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C=C1 Chemical compound CC1=CC=C(CN2CCN(C(=O)N3C=C(Cl)C=N3)CC2)C=C1 NFTAPGCJSJZYQZ-UHFFFAOYSA-N 0.000 description 2
- OKJVNOWCJVMVGT-UHFFFAOYSA-N CC1=CC=C(CNC(=O)N2C=C(C)C=N2)C=C1 Chemical compound CC1=CC=C(CNC(=O)N2C=C(C)C=N2)C=C1 OKJVNOWCJVMVGT-UHFFFAOYSA-N 0.000 description 2
- KLBATWZWZHULFL-UHFFFAOYSA-N CC1=CC=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=C1 Chemical compound CC1=CC=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=C1 KLBATWZWZHULFL-UHFFFAOYSA-N 0.000 description 2
- WYUCTKIBEZRXTL-UHFFFAOYSA-N CC1=CC=CC(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=C1 Chemical compound CC1=CC=CC(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)=C1 WYUCTKIBEZRXTL-UHFFFAOYSA-N 0.000 description 2
- APYPOEAXBOCESQ-UHFFFAOYSA-N CC1=CC=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CC1=CC=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 APYPOEAXBOCESQ-UHFFFAOYSA-N 0.000 description 2
- ZCPQPSYQAQCXJC-UHFFFAOYSA-N CC1=CN(C(=O)N(C)CCN(C)C(=O)C2=CC=CC=C2)N=C1 Chemical compound CC1=CN(C(=O)N(C)CCN(C)C(=O)C2=CC=CC=C2)N=C1 ZCPQPSYQAQCXJC-UHFFFAOYSA-N 0.000 description 2
- FIBXINIPXJWPRF-UHFFFAOYSA-N CC1=CN(C(=O)N(C)CCN(C)CC2=CC=CC=C2)N=C1 Chemical compound CC1=CN(C(=O)N(C)CCN(C)CC2=CC=CC=C2)N=C1 FIBXINIPXJWPRF-UHFFFAOYSA-N 0.000 description 2
- MDXIYMSNMZATMV-UHFFFAOYSA-N CC1=CN(C(=O)N(C)CCN(C)C[SH](=O)=O)N=C1 Chemical compound CC1=CN(C(=O)N(C)CCN(C)C[SH](=O)=O)N=C1 MDXIYMSNMZATMV-UHFFFAOYSA-N 0.000 description 2
- OSNDHJDVIJJVOE-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCCC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCCC2)N=C1 OSNDHJDVIJJVOE-UHFFFAOYSA-N 0.000 description 2
- CXPKONGEDQYMCW-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCN(C(=O)OC(C)(C)C)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCN(C(=O)OC(C)(C)C)CC2)N=C1 CXPKONGEDQYMCW-UHFFFAOYSA-N 0.000 description 2
- YDHXZOCEAVIBRX-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCN(C)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCN(C)CC2)N=C1 YDHXZOCEAVIBRX-UHFFFAOYSA-N 0.000 description 2
- TVBFHSXUPXSECF-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCN(CC3=CC=CC=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCN(CC3=CC=CC=C3)CC2)N=C1 TVBFHSXUPXSECF-UHFFFAOYSA-N 0.000 description 2
- QXLQMYAMUFBAFI-UHFFFAOYSA-N CC1=CN(C(=O)N2CCCN(C[SH](=O)=O)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCCN(C[SH](=O)=O)CC2)N=C1 QXLQMYAMUFBAFI-UHFFFAOYSA-N 0.000 description 2
- JYBFIDRHMZFASN-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(C(=O)C3=CC=CC=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(C(=O)C3=CC=CC=C3)CC2)N=C1 JYBFIDRHMZFASN-UHFFFAOYSA-N 0.000 description 2
- HJQWRDQCFRVZTL-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2)N=C1 HJQWRDQCFRVZTL-UHFFFAOYSA-N 0.000 description 2
- LDYWITCBNKBBMH-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 LDYWITCBNKBBMH-UHFFFAOYSA-N 0.000 description 2
- DNVZBKSKZICOSK-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=C(N4CCCC4)C=CC=C3C(F)(F)F)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=C(N4CCCC4)C=CC=C3C(F)(F)F)CC2)N=C1 DNVZBKSKZICOSK-UHFFFAOYSA-N 0.000 description 2
- DNCWRSCWBREESA-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3)CC2)N=C1 DNCWRSCWBREESA-UHFFFAOYSA-N 0.000 description 2
- OMWIDGPVQUAJDH-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1 OMWIDGPVQUAJDH-UHFFFAOYSA-N 0.000 description 2
- IWTMREHDGHVQRU-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1 IWTMREHDGHVQRU-UHFFFAOYSA-N 0.000 description 2
- DCDUAPIMELMNRT-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 DCDUAPIMELMNRT-UHFFFAOYSA-N 0.000 description 2
- DMCUEJQOGMGYGQ-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=CC=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=CC=C3)CC2)N=C1 DMCUEJQOGMGYGQ-UHFFFAOYSA-N 0.000 description 2
- VGVFXHWBNRUBNB-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(C[SH](=O)=O)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(C[SH](=O)=O)CC2)N=C1 VGVFXHWBNRUBNB-UHFFFAOYSA-N 0.000 description 2
- KLHWWNWCLHWCRV-UHFFFAOYSA-N CC1=CN(C(=O)NC2=CC=C3C=CC=CC3=C2)N=C1 Chemical compound CC1=CN(C(=O)NC2=CC=C3C=CC=CC3=C2)N=C1 KLHWWNWCLHWCRV-UHFFFAOYSA-N 0.000 description 2
- WYWPYHXQJDPXGC-UHFFFAOYSA-N CC1=CN(C(=O)NCCCC2=CC=CC=C2)N=C1 Chemical compound CC1=CN(C(=O)NCCCC2=CC=CC=C2)N=C1 WYWPYHXQJDPXGC-UHFFFAOYSA-N 0.000 description 2
- YHGPOJBHMKMDRL-UHFFFAOYSA-N CC1=CN(C(=O)NCCCCCC2=CC=CC=C2)N=C1 Chemical compound CC1=CN(C(=O)NCCCCCC2=CC=CC=C2)N=C1 YHGPOJBHMKMDRL-UHFFFAOYSA-N 0.000 description 2
- CNWRPVREVAOMHK-UHFFFAOYSA-N CCN(CC1=C(C)C=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=C(C)C=CC=C1)C(=O)N1C=C(Cl)C=N1 CNWRPVREVAOMHK-UHFFFAOYSA-N 0.000 description 2
- YUSBKTIKBHELOR-UHFFFAOYSA-N CCN(CC1=C(Cl)C=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=C(Cl)C=CC=C1)C(=O)N1C=C(Cl)C=N1 YUSBKTIKBHELOR-UHFFFAOYSA-N 0.000 description 2
- DERLXVFHJXJYMA-UHFFFAOYSA-N CCN(CC1=C(OC)C=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=C(OC)C=CC=C1)C(=O)N1C=C(Cl)C=N1 DERLXVFHJXJYMA-UHFFFAOYSA-N 0.000 description 2
- ZTMOWIDCXQNEKE-UHFFFAOYSA-N CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C#N)C=N1 ZTMOWIDCXQNEKE-UHFFFAOYSA-N 0.000 description 2
- ZIFZPDTWHCPSPT-UHFFFAOYSA-N CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 ZIFZPDTWHCPSPT-UHFFFAOYSA-N 0.000 description 2
- HKYUWRFFHWVWAD-UHFFFAOYSA-N CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(C)C=N1 HKYUWRFFHWVWAD-UHFFFAOYSA-N 0.000 description 2
- PHEHFCOCCZMFGD-UHFFFAOYSA-N CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC(C)=CC=C1)C(=O)N1C=C(Cl)C=N1 PHEHFCOCCZMFGD-UHFFFAOYSA-N 0.000 description 2
- KRMZUIOQIJEBBL-UHFFFAOYSA-N CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C#N)C=N1 KRMZUIOQIJEBBL-UHFFFAOYSA-N 0.000 description 2
- UPJGODYFABGJKO-UHFFFAOYSA-N CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 UPJGODYFABGJKO-UHFFFAOYSA-N 0.000 description 2
- BHHPNJALWABJFJ-UHFFFAOYSA-N CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC(CO)=CC=C1)C(=O)N1C=C(C)C=N1 BHHPNJALWABJFJ-UHFFFAOYSA-N 0.000 description 2
- PFTQWYQCPSXPFE-UHFFFAOYSA-N CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 PFTQWYQCPSXPFE-UHFFFAOYSA-N 0.000 description 2
- PSFHTMNGNARSMZ-UHFFFAOYSA-N CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(C)C=N1 PSFHTMNGNARSMZ-UHFFFAOYSA-N 0.000 description 2
- AVKBOLWJKBDMAY-UHFFFAOYSA-N CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC(Cl)=CC=C1)C(=O)N1C=C(Cl)C=N1 AVKBOLWJKBDMAY-UHFFFAOYSA-N 0.000 description 2
- QVOAQYJJFGDUEU-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 QVOAQYJJFGDUEU-UHFFFAOYSA-N 0.000 description 2
- YTGTWYSAHURVHJ-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C)C=N1 YTGTWYSAHURVHJ-UHFFFAOYSA-N 0.000 description 2
- IMIKMPFDNWQYSF-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(Cl)C=N1 IMIKMPFDNWQYSF-UHFFFAOYSA-N 0.000 description 2
- HJGBBWLLYBLHMN-UHFFFAOYSA-N CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C#N)C=N1 HJGBBWLLYBLHMN-UHFFFAOYSA-N 0.000 description 2
- MPFYHNRTQXGUJD-UHFFFAOYSA-N CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 MPFYHNRTQXGUJD-UHFFFAOYSA-N 0.000 description 2
- QSHKURUSLUUGEU-UHFFFAOYSA-N CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(C)C=N1 QSHKURUSLUUGEU-UHFFFAOYSA-N 0.000 description 2
- PESCHFNZFHNGSK-UHFFFAOYSA-N CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC=C(C)C=C1)C(=O)N1C=C(Cl)C=N1 PESCHFNZFHNGSK-UHFFFAOYSA-N 0.000 description 2
- QSTUGYSJGSWEJL-UHFFFAOYSA-N CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C#N)C=N1 QSTUGYSJGSWEJL-UHFFFAOYSA-N 0.000 description 2
- DMRQXBSYKBUTIU-UHFFFAOYSA-N CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 DMRQXBSYKBUTIU-UHFFFAOYSA-N 0.000 description 2
- XFIUQQXKPYHNOG-UHFFFAOYSA-N CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC=C(CO)C=C1)C(=O)N1C=C(C)C=N1 XFIUQQXKPYHNOG-UHFFFAOYSA-N 0.000 description 2
- NJVYKAPUHXAUIT-UHFFFAOYSA-N CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 NJVYKAPUHXAUIT-UHFFFAOYSA-N 0.000 description 2
- MMBLVCAXFULVLF-UHFFFAOYSA-N CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(C)C=N1 MMBLVCAXFULVLF-UHFFFAOYSA-N 0.000 description 2
- CVJNRRBHLINFRL-UHFFFAOYSA-N CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC=C(Cl)C=C1)C(=O)N1C=C(Cl)C=N1 CVJNRRBHLINFRL-UHFFFAOYSA-N 0.000 description 2
- TXDAKSOTTZBYRS-UHFFFAOYSA-N CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C#N)C=N1 TXDAKSOTTZBYRS-UHFFFAOYSA-N 0.000 description 2
- VRWMRICEGBIBTQ-UHFFFAOYSA-N CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C(F)(F)F)C=N1 VRWMRICEGBIBTQ-UHFFFAOYSA-N 0.000 description 2
- KHPHMGRWCAIILM-UHFFFAOYSA-N CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C)C=N1 Chemical compound CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(C)C=N1 KHPHMGRWCAIILM-UHFFFAOYSA-N 0.000 description 2
- MRYWADVNHGZVRE-UHFFFAOYSA-N CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC=C(N2CCOCC2)C=C1)C(=O)N1C=C(Cl)C=N1 MRYWADVNHGZVRE-UHFFFAOYSA-N 0.000 description 2
- PAAKVYMZTOVRGN-UHFFFAOYSA-N CCN(CC1=CC=C(OC)C=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CCN(CC1=CC=C(OC)C=C1)C(=O)N1C=C(Cl)C=N1 PAAKVYMZTOVRGN-UHFFFAOYSA-N 0.000 description 2
- UERAULMRRJKGBL-UHFFFAOYSA-N CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C#N)C=N1 Chemical compound CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C#N)C=N1 UERAULMRRJKGBL-UHFFFAOYSA-N 0.000 description 2
- RKYTXQLRNPTPIR-UHFFFAOYSA-N CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 Chemical compound CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C(F)(F)F)C=N1 RKYTXQLRNPTPIR-UHFFFAOYSA-N 0.000 description 2
- PEJSRWXISNOIBB-UHFFFAOYSA-N CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C2=CC=CC=C2)C=N1 PEJSRWXISNOIBB-UHFFFAOYSA-N 0.000 description 2
- COOSPIYELJNCHU-UHFFFAOYSA-N CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(Cl)C=N1 Chemical compound CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(Cl)C=N1 COOSPIYELJNCHU-UHFFFAOYSA-N 0.000 description 2
- WRBUNECIGCGRIK-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C(=O)C1=CC=CC=C1 Chemical compound CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C(=O)C1=CC=CC=C1 WRBUNECIGCGRIK-UHFFFAOYSA-N 0.000 description 2
- CQBDQOOBUVXMKQ-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C[SH](=O)=O Chemical compound CN(CCN(C)C(=O)N1C=C(C#N)C=N1)C[SH](=O)=O CQBDQOOBUVXMKQ-UHFFFAOYSA-N 0.000 description 2
- CDEFLTZBWBKLMS-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C(=O)C1=CC=CC=C1 Chemical compound CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C(=O)C1=CC=CC=C1 CDEFLTZBWBKLMS-UHFFFAOYSA-N 0.000 description 2
- JJSCUPFIOCOHEM-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C[SH](=O)=O Chemical compound CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C[SH](=O)=O JJSCUPFIOCOHEM-UHFFFAOYSA-N 0.000 description 2
- RQCMSBGPWVNNOL-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(Cl)C=N1)C(=O)C1=CC=CC=C1 Chemical compound CN(CCN(C)C(=O)N1C=C(Cl)C=N1)C(=O)C1=CC=CC=C1 RQCMSBGPWVNNOL-UHFFFAOYSA-N 0.000 description 2
- WORNISXPYCLZPK-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(Cl)C=N1)C[SH](=O)=O Chemical compound CN(CCN(C)C(=O)N1C=C(Cl)C=N1)C[SH](=O)=O WORNISXPYCLZPK-UHFFFAOYSA-N 0.000 description 2
- YEPRRJPGFVACBT-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=CC=N1)C(=O)OC(C)(C)C Chemical compound CN(CCN(C)C(=O)N1C=CC=N1)C(=O)OC(C)(C)C YEPRRJPGFVACBT-UHFFFAOYSA-N 0.000 description 2
- XBXSLIUWOHUJOY-UHFFFAOYSA-N CN1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CN1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 XBXSLIUWOHUJOY-UHFFFAOYSA-N 0.000 description 2
- UKJLBTOMDGMJHU-UHFFFAOYSA-N CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 UKJLBTOMDGMJHU-UHFFFAOYSA-N 0.000 description 2
- IYRKQLYAXCRQQR-UHFFFAOYSA-N CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 IYRKQLYAXCRQQR-UHFFFAOYSA-N 0.000 description 2
- AXWGWJFZFNTFNO-UHFFFAOYSA-N CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1 AXWGWJFZFNTFNO-UHFFFAOYSA-N 0.000 description 2
- QPLINORHMTZTAJ-UHFFFAOYSA-N CNC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1 Chemical compound CNC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1 QPLINORHMTZTAJ-UHFFFAOYSA-N 0.000 description 2
- HZJUKWAPMUWQBZ-UHFFFAOYSA-N COC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 Chemical compound COC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 HZJUKWAPMUWQBZ-UHFFFAOYSA-N 0.000 description 2
- PHINZBYMVACZJO-UHFFFAOYSA-N COC1=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=CC=C1 Chemical compound COC1=C(N2CCN(C(=O)N3C=C(C(F)(F)F)C=N3)CC2)C=CC=C1 PHINZBYMVACZJO-UHFFFAOYSA-N 0.000 description 2
- CCGSMNBQPPIMRS-UHFFFAOYSA-N COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 Chemical compound COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C#N)C=N2)CC1 CCGSMNBQPPIMRS-UHFFFAOYSA-N 0.000 description 2
- VSUHZDKGOOEANE-UHFFFAOYSA-N COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(=O)N3CCCC3)C=N2)CC1 Chemical compound COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(=O)N3CCCC3)C=N2)CC1 VSUHZDKGOOEANE-UHFFFAOYSA-N 0.000 description 2
- SSKKSXQQMGZGAI-UHFFFAOYSA-N COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound COC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 SSKKSXQQMGZGAI-UHFFFAOYSA-N 0.000 description 2
- HQGOVGRYWNGZCZ-UHFFFAOYSA-N COC1=CC=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound COC1=CC=CC=C1CN1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 HQGOVGRYWNGZCZ-UHFFFAOYSA-N 0.000 description 2
- AXTKKWGLGNGFIP-UHFFFAOYSA-N ClC1=CC=C(CN2CCNCC2)C=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 Chemical compound ClC1=CC=C(CN2CCNCC2)C=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 AXTKKWGLGNGFIP-UHFFFAOYSA-N 0.000 description 2
- MUQUNMVVLSUQCZ-UHFFFAOYSA-N FC(F)(F)C1=CNN=C1.O=C(Cl)OC1=CC=C([N+](=O)[O-])C=C1.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 Chemical compound FC(F)(F)C1=CNN=C1.O=C(Cl)OC1=CC=C([N+](=O)[O-])C=C1.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 MUQUNMVVLSUQCZ-UHFFFAOYSA-N 0.000 description 2
- SVAKPURGRYCHGQ-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCC2)N=C1 SVAKPURGRYCHGQ-UHFFFAOYSA-N 0.000 description 2
- RPILUPLZIDIEEV-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCCC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCCC2)N=C1 RPILUPLZIDIEEV-UHFFFAOYSA-N 0.000 description 2
- QCBLUVPNQFWWNO-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCCCC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCCCC2)N=C1 QCBLUVPNQFWWNO-UHFFFAOYSA-N 0.000 description 2
- DAJGVSSRMOXINP-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCN(CC3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCN(CC3=CC=CC=C3)CC2)N=C1 DAJGVSSRMOXINP-UHFFFAOYSA-N 0.000 description 2
- RRVANYYXJGKWAX-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCCN(C[SH](=O)=O)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCCN(C[SH](=O)=O)CC2)N=C1 RRVANYYXJGKWAX-UHFFFAOYSA-N 0.000 description 2
- MJVODMTUVKIRFL-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(C(=O)C3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(C(=O)C3=CC=CC=C3)CC2)N=C1 MJVODMTUVKIRFL-UHFFFAOYSA-N 0.000 description 2
- SDBSITVFWCYBAY-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(C3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(C3=CC=CC=C3)CC2)N=C1 SDBSITVFWCYBAY-UHFFFAOYSA-N 0.000 description 2
- PMXUYMMUICZWHM-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCC4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCC4)C=C3)CC2)N=C1 PMXUYMMUICZWHM-UHFFFAOYSA-N 0.000 description 2
- PXDFWLYZIWOUNY-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=C(F)C=C(C(=O)N4CCC4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=C(F)C=C(C(=O)N4CCC4)C=C3)CC2)N=C1 PXDFWLYZIWOUNY-UHFFFAOYSA-N 0.000 description 2
- PSSQYDKVXYUSDR-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=C(F)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=C(F)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1 PSSQYDKVXYUSDR-UHFFFAOYSA-N 0.000 description 2
- VRZCJHAFFUJJCC-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3OCC3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3OCC3=CC=CC=C3)CC2)N=C1 VRZCJHAFFUJJCC-UHFFFAOYSA-N 0.000 description 2
- ATQGOVCLTGCFSF-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1 ATQGOVCLTGCFSF-UHFFFAOYSA-N 0.000 description 2
- ZILXFBHJNDWIIP-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1 ZILXFBHJNDWIIP-UHFFFAOYSA-N 0.000 description 2
- WUONWIDYVGZPKC-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1 WUONWIDYVGZPKC-UHFFFAOYSA-N 0.000 description 2
- SFVIMXVIVZADHD-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=CC=CC=C3)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=CC=CC=C3)CC2)N=C1 SFVIMXVIVZADHD-UHFFFAOYSA-N 0.000 description 2
- JIMOYMIIKSAEJN-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(C[SH](=O)=O)CC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCN(C[SH](=O)=O)CC2)N=C1 JIMOYMIIKSAEJN-UHFFFAOYSA-N 0.000 description 2
- VMHIEPDMZDCPAY-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCOCC2)N=C1 Chemical compound N#CC1=CN(C(=O)N2CCOCC2)N=C1 VMHIEPDMZDCPAY-UHFFFAOYSA-N 0.000 description 2
- JFAFYHUGEPVMLU-UHFFFAOYSA-N N#CC1=CN(C(=O)NC2=CC=C3C=CC=CC3=C2)N=C1 Chemical compound N#CC1=CN(C(=O)NC2=CC=C3C=CC=CC3=C2)N=C1 JFAFYHUGEPVMLU-UHFFFAOYSA-N 0.000 description 2
- LJWFCILVMNRZDS-UHFFFAOYSA-N N#CC1=CN(C(=O)NCC2=CC3=C(C=CC=C3)C=C2)N=C1 Chemical compound N#CC1=CN(C(=O)NCC2=CC3=C(C=CC=C3)C=C2)N=C1 LJWFCILVMNRZDS-UHFFFAOYSA-N 0.000 description 2
- CXMGXIYDUADQNL-UHFFFAOYSA-N N#CC1=CN(C(=O)NCCCC2=CC=CC=C2)N=C1 Chemical compound N#CC1=CN(C(=O)NCCCC2=CC=CC=C2)N=C1 CXMGXIYDUADQNL-UHFFFAOYSA-N 0.000 description 2
- PEGSVZCGVFZWOF-UHFFFAOYSA-N N#CC1=CN(C(=O)NCCCCC2=CC=CC=C2)N=C1 Chemical compound N#CC1=CN(C(=O)NCCCCC2=CC=CC=C2)N=C1 PEGSVZCGVFZWOF-UHFFFAOYSA-N 0.000 description 2
- FKNPQTDHLJYZTM-UHFFFAOYSA-N N#CC1=CN(C(=O)NCCCCCC2=CC=CC=C2)N=C1 Chemical compound N#CC1=CN(C(=O)NCCCCCC2=CC=CC=C2)N=C1 FKNPQTDHLJYZTM-UHFFFAOYSA-N 0.000 description 2
- SATKLKGQPANCGP-UHFFFAOYSA-N O=C(C1=CC=CC=C1)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound O=C(C1=CC=CC=C1)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 SATKLKGQPANCGP-UHFFFAOYSA-N 0.000 description 2
- FYORVAOBOFCBPK-UHFFFAOYSA-N O=C(C1=CC=CC=C1)N1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound O=C(C1=CC=CC=C1)N1CCCN(C(=O)N2C=C(Cl)C=N2)CC1 FYORVAOBOFCBPK-UHFFFAOYSA-N 0.000 description 2
- FIVSLYDYHGDXCY-UHFFFAOYSA-N O=C(C1=CC=CC=C1)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 Chemical compound O=C(C1=CC=CC=C1)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1 FIVSLYDYHGDXCY-UHFFFAOYSA-N 0.000 description 2
- IAOQUEKAJBPESJ-UHFFFAOYSA-N O=C(C1=CC=CC=C1)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1 Chemical compound O=C(C1=CC=CC=C1)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1 IAOQUEKAJBPESJ-UHFFFAOYSA-N 0.000 description 2
- QXJQIDGEVYZKML-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCC1 QXJQIDGEVYZKML-UHFFFAOYSA-N 0.000 description 2
- ULLAKTHDRQFCTC-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCC1 ULLAKTHDRQFCTC-UHFFFAOYSA-N 0.000 description 2
- HHUWQBSOJUDJJJ-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCCC1 HHUWQBSOJUDJJJ-UHFFFAOYSA-N 0.000 description 2
- IBYISJHMKXEZTO-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCOCC1 IBYISJHMKXEZTO-UHFFFAOYSA-N 0.000 description 2
- XDHHBDFHZWNYMR-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCC1 XDHHBDFHZWNYMR-UHFFFAOYSA-N 0.000 description 2
- CZXXKZUFRORRAD-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCCC1 CZXXKZUFRORRAD-UHFFFAOYSA-N 0.000 description 2
- JAQDUMUCZAZXHZ-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCCCC1 JAQDUMUCZAZXHZ-UHFFFAOYSA-N 0.000 description 2
- ZVCHYQYNFJWAJU-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCOCC1 ZVCHYQYNFJWAJU-UHFFFAOYSA-N 0.000 description 2
- ROIKVVSIIKDYOA-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1)N1CCCC1 ROIKVVSIIKDYOA-UHFFFAOYSA-N 0.000 description 2
- LCEWNNUQBAIYQD-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCC1 LCEWNNUQBAIYQD-UHFFFAOYSA-N 0.000 description 2
- BEWNHIXHDIRUMS-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCCC1 BEWNHIXHDIRUMS-UHFFFAOYSA-N 0.000 description 2
- OHGBJCVBFMUVHV-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCCCC1 OHGBJCVBFMUVHV-UHFFFAOYSA-N 0.000 description 2
- GYHOQUPTHABEMV-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CC=N3)CC2)N=C1)N1CCOCC1 GYHOQUPTHABEMV-UHFFFAOYSA-N 0.000 description 2
- XYIVJSMWIGASDV-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCCC1 XYIVJSMWIGASDV-UHFFFAOYSA-N 0.000 description 2
- USGMLGCHBVSHCI-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCCCC1 USGMLGCHBVSHCI-UHFFFAOYSA-N 0.000 description 2
- DSQCBRDUCBOGPB-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=CN=C3)CC2)N=C1)N1CCOCC1 DSQCBRDUCBOGPB-UHFFFAOYSA-N 0.000 description 2
- IMNINIQPLKPJHF-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCC1 IMNINIQPLKPJHF-UHFFFAOYSA-N 0.000 description 2
- CJTXKBGBHOZCLR-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCCC1 CJTXKBGBHOZCLR-UHFFFAOYSA-N 0.000 description 2
- ULAUKPIQPXTSTC-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCCCC1 ULAUKPIQPXTSTC-UHFFFAOYSA-N 0.000 description 2
- IQWSVQZBKDDNGN-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=C3)CC2)N=C1)N1CCOCC1 IQWSVQZBKDDNGN-UHFFFAOYSA-N 0.000 description 2
- IKZFDAWUOKEKJR-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCC1 IKZFDAWUOKEKJR-UHFFFAOYSA-N 0.000 description 2
- GDFNFVGYAPUTIN-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCCC1 GDFNFVGYAPUTIN-UHFFFAOYSA-N 0.000 description 2
- LYWLBCYAQZFNOD-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCCCC1 LYWLBCYAQZFNOD-UHFFFAOYSA-N 0.000 description 2
- UILGTWBDXSXIRB-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=NC=N3)CC2)N=C1)N1CCOCC1 UILGTWBDXSXIRB-UHFFFAOYSA-N 0.000 description 2
- SYTOKBHFDMYGPT-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCC1 SYTOKBHFDMYGPT-UHFFFAOYSA-N 0.000 description 2
- GAFHMLPMEZKSFI-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCCC1 GAFHMLPMEZKSFI-UHFFFAOYSA-N 0.000 description 2
- BGSWEAZFMQZMNM-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CN=CN=C3)CC2)N=C1)N1CCCCC1 BGSWEAZFMQZMNM-UHFFFAOYSA-N 0.000 description 2
- MNNLNLICWNRDFI-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCC1 MNNLNLICWNRDFI-UHFFFAOYSA-N 0.000 description 2
- PSKJVTSKDUCVTC-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCCC1 PSKJVTSKDUCVTC-UHFFFAOYSA-N 0.000 description 2
- CYZOSAZNZXUHSV-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCCCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCCCC1 CYZOSAZNZXUHSV-UHFFFAOYSA-N 0.000 description 2
- ZFNVOSATCMPFGP-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCOCC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=NC=CS3)CC2)N=C1)N1CCOCC1 ZFNVOSATCMPFGP-UHFFFAOYSA-N 0.000 description 2
- COEIAGSFRSKSLP-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C(F)(F)F)C=N1 COEIAGSFRSKSLP-UHFFFAOYSA-N 0.000 description 2
- ACWMHTAKZAFJIP-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C2=CC=C(C3=C(CO)C=CC=C3)C=C2)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C2=CC=C(C3=C(CO)C=CC=C3)C=C2)C=N1 ACWMHTAKZAFJIP-UHFFFAOYSA-N 0.000 description 2
- JHHLJVBHAIYHHS-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C2=CC=C(C3=C(Cl)C=CC=C3)C=C2)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C2=CC=C(C3=C(Cl)C=CC=C3)C=C2)C=N1 JHHLJVBHAIYHHS-UHFFFAOYSA-N 0.000 description 2
- AOTIJCUXSAFWCX-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C2=CC=C(Cl)C=C2)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C2=CC=C(Cl)C=C2)C=N1 AOTIJCUXSAFWCX-UHFFFAOYSA-N 0.000 description 2
- PGZNTGYHMYBCMH-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(C2=CC=CC=C2)C=N1 PGZNTGYHMYBCMH-UHFFFAOYSA-N 0.000 description 2
- IRHSTPDNKJZQNM-UHFFFAOYSA-N O=C(N1CCCC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCCC1)N1C=C(Cl)C=N1 IRHSTPDNKJZQNM-UHFFFAOYSA-N 0.000 description 2
- MVMBVBVTVJKSIE-UHFFFAOYSA-N O=C(N1CCCCC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCCCC1)N1C=C(C(F)(F)F)C=N1 MVMBVBVTVJKSIE-UHFFFAOYSA-N 0.000 description 2
- SELARMOALKYKAV-UHFFFAOYSA-N O=C(N1CCCCC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCCCC1)N1C=C(Cl)C=N1 SELARMOALKYKAV-UHFFFAOYSA-N 0.000 description 2
- RVUWRYIKKXZWFA-UHFFFAOYSA-N O=C(N1CCCCC1)N1C=CC=N1 Chemical compound O=C(N1CCCCC1)N1C=CC=N1 RVUWRYIKKXZWFA-UHFFFAOYSA-N 0.000 description 2
- GRFRZLUOGSIHTE-UHFFFAOYSA-N O=C(N1CCCN(CC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCCN(CC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 GRFRZLUOGSIHTE-UHFFFAOYSA-N 0.000 description 2
- FXHPENVDCQNJNH-UHFFFAOYSA-N O=C(N1CCCN(CC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCCN(CC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 FXHPENVDCQNJNH-UHFFFAOYSA-N 0.000 description 2
- IXXVROHPASEQFS-UHFFFAOYSA-N O=C(N1CCCN(C[SH](=O)=O)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCCN(C[SH](=O)=O)CC1)N1C=C(C(F)(F)F)C=N1 IXXVROHPASEQFS-UHFFFAOYSA-N 0.000 description 2
- VKVDMUYIDBMTAY-UHFFFAOYSA-N O=C(N1CCCN(C[SH](=O)=O)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCCN(C[SH](=O)=O)CC1)N1C=C(Cl)C=N1 VKVDMUYIDBMTAY-UHFFFAOYSA-N 0.000 description 2
- SRBRMSDGAHSWFH-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 SRBRMSDGAHSWFH-UHFFFAOYSA-N 0.000 description 2
- BZTQOIPFSIXWDH-UHFFFAOYSA-N O=C(N1CCN(C2=C(Cl)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=C(Cl)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 BZTQOIPFSIXWDH-UHFFFAOYSA-N 0.000 description 2
- ZTZNJEBECYQVOU-UHFFFAOYSA-N O=C(N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 ZTZNJEBECYQVOU-UHFFFAOYSA-N 0.000 description 2
- BYQBTYXKTYNNIJ-UHFFFAOYSA-N O=C(N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 BYQBTYXKTYNNIJ-UHFFFAOYSA-N 0.000 description 2
- BZHQROMDIAACDQ-UHFFFAOYSA-N O=C(N1CCN(C2=CC(CO)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC(CO)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 BZHQROMDIAACDQ-UHFFFAOYSA-N 0.000 description 2
- LFTCBWWGHMLPMH-UHFFFAOYSA-N O=C(N1CCN(C2=CC(Cl)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC(Cl)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 LFTCBWWGHMLPMH-UHFFFAOYSA-N 0.000 description 2
- PJPQVRWMRSAYNR-UHFFFAOYSA-N O=C(N1CCN(C2=CC(N3CCCC3)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC(N3CCCC3)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 PJPQVRWMRSAYNR-UHFFFAOYSA-N 0.000 description 2
- CZSJOSRRGQTNCJ-UHFFFAOYSA-N O=C(N1CCN(C2=CC(N3CCOCC3)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC(N3CCOCC3)=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 CZSJOSRRGQTNCJ-UHFFFAOYSA-N 0.000 description 2
- QKVXYYAVGQUVSS-UHFFFAOYSA-N O=C(N1CCN(C2=CC=C(CO)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC=C(CO)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 QKVXYYAVGQUVSS-UHFFFAOYSA-N 0.000 description 2
- CMLOTNMUXWCXCL-UHFFFAOYSA-N O=C(N1CCN(C2=CC=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 CMLOTNMUXWCXCL-UHFFFAOYSA-N 0.000 description 2
- REARHHJOTKSULB-UHFFFAOYSA-N O=C(N1CCN(C2=CC=C(N3CCCC3)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC=C(N3CCCC3)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 REARHHJOTKSULB-UHFFFAOYSA-N 0.000 description 2
- TZIVZFZGYZHJRQ-UHFFFAOYSA-N O=C(N1CCN(C2=CC=C(N3CCOCC3)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC=C(N3CCOCC3)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 TZIVZFZGYZHJRQ-UHFFFAOYSA-N 0.000 description 2
- FVZZOXDURLBPRJ-UHFFFAOYSA-N O=C(N1CCN(C2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 FVZZOXDURLBPRJ-UHFFFAOYSA-N 0.000 description 2
- DEWWMKXEUFCGKX-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C(F)(F)F)C=CC=C2N2CCCC2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=C(C(F)(F)F)C=CC=C2N2CCCC2)CC1)N1C=C(Cl)C=N1 DEWWMKXEUFCGKX-UHFFFAOYSA-N 0.000 description 2
- KGTPHVLJYGYFJN-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 KGTPHVLJYGYFJN-UHFFFAOYSA-N 0.000 description 2
- RONHLYMCOYHGSQ-UHFFFAOYSA-N O=C(N1CCN(CC2=C(Cl)C=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=C(Cl)C=CC=C2)CC1)N1C=C(Cl)C=N1 RONHLYMCOYHGSQ-UHFFFAOYSA-N 0.000 description 2
- XZXSPHIBNOYKGN-UHFFFAOYSA-N O=C(N1CCN(CC2=C(N3CCC4(CCOCC4)C3)C=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=C(N3CCC4(CCOCC4)C3)C=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 XZXSPHIBNOYKGN-UHFFFAOYSA-N 0.000 description 2
- TZEYBZKXUANVNW-UHFFFAOYSA-N O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(C(F)(F)F)C=N1 TZEYBZKXUANVNW-UHFFFAOYSA-N 0.000 description 2
- DQBFTPVHJWXYSP-UHFFFAOYSA-N O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(C2=CC=CC=C2)C=N1 DQBFTPVHJWXYSP-UHFFFAOYSA-N 0.000 description 2
- FBQHTMCFJWWDRN-UHFFFAOYSA-N O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(F)C=N1 Chemical compound O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(F)C=N1 FBQHTMCFJWWDRN-UHFFFAOYSA-N 0.000 description 2
- GALXJKHMJQZXNR-UHFFFAOYSA-N O=C(N1CCN(CC2=CC(Cl)=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC(Cl)=CC=C2)CC1)N1C=C(Cl)C=N1 GALXJKHMJQZXNR-UHFFFAOYSA-N 0.000 description 2
- XAPVOZOXVWIWEE-UHFFFAOYSA-N O=C(N1CCN(CC2=CC3=C(C=C2)OCO3)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CC3=C(C=C2)OCO3)CC1)N1C=C(C2=CC=CC=C2)C=N1 XAPVOZOXVWIWEE-UHFFFAOYSA-N 0.000 description 2
- VBTZHMZIPNJLLH-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 VBTZHMZIPNJLLH-UHFFFAOYSA-N 0.000 description 2
- DOKLRDYIZQXCJF-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1)N1C=C(C(F)(F)F)C=N1 DOKLRDYIZQXCJF-UHFFFAOYSA-N 0.000 description 2
- NINIDLHVTJPIHP-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1)N1C=C(Cl)C=N1 NINIDLHVTJPIHP-UHFFFAOYSA-N 0.000 description 2
- FXGXZBQKSZJDFG-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2OCC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2OCC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 FXGXZBQKSZJDFG-UHFFFAOYSA-N 0.000 description 2
- NWCUMVWIFASUCX-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2OCC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2OCC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 NWCUMVWIFASUCX-UHFFFAOYSA-N 0.000 description 2
- AZOUFNKGOPBTIH-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(CN3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(CN3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1 AZOUFNKGOPBTIH-UHFFFAOYSA-N 0.000 description 2
- OKQPBWASVZVWNJ-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(Cl)C(Cl)=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(Cl)C(Cl)=C2)CC1)N1C=C(Cl)C=N1 OKQPBWASVZVWNJ-UHFFFAOYSA-N 0.000 description 2
- VPWZKJSVOOPGGG-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 VPWZKJSVOOPGGG-UHFFFAOYSA-N 0.000 description 2
- HHWFRHSFAQANTM-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(Cl)C=C2N2CCCC2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(Cl)C=C2N2CCCC2)CC1)N1C=C(Cl)C=N1 HHWFRHSFAQANTM-UHFFFAOYSA-N 0.000 description 2
- QALCTHAFPYJPBN-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(N3CCCC3)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(N3CCCC3)C=C2)CC1)N1C=C(Cl)C=N1 QALCTHAFPYJPBN-UHFFFAOYSA-N 0.000 description 2
- SJDUCFOISJKMEZ-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(N3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(N3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1 SJDUCFOISJKMEZ-UHFFFAOYSA-N 0.000 description 2
- IDKIWSBAUWXKAS-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(OCC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=C(OCC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 IDKIWSBAUWXKAS-UHFFFAOYSA-N 0.000 description 2
- BBYIOAMFALUCTR-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=C(Br)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=C(Br)C=N1 BBYIOAMFALUCTR-UHFFFAOYSA-N 0.000 description 2
- OPBMZDPVUURNKM-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=C(I)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=C(I)C=N1 OPBMZDPVUURNKM-UHFFFAOYSA-N 0.000 description 2
- YLXCAQDUFRLKBA-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1)N1C=CC=N1 YLXCAQDUFRLKBA-UHFFFAOYSA-N 0.000 description 2
- VGUDXCFTUKKZHX-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(CO)=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(CO)=C2)CC1)N1C=C(C(F)(F)F)C=N1 VGUDXCFTUKKZHX-UHFFFAOYSA-N 0.000 description 2
- UEYCXXMQEYSNCQ-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(Cl)=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(Cl)=C2)CC1)N1C=C(C(F)(F)F)C=N1 UEYCXXMQEYSNCQ-UHFFFAOYSA-N 0.000 description 2
- OJZVIYPIYGSUSD-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(F)=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(F)=C2)CC1)N1C=C(C(F)(F)F)C=N1 OJZVIYPIYGSUSD-UHFFFAOYSA-N 0.000 description 2
- GBGDSXONKVBRTB-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(N3CCCC3)=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(N3CCCC3)=C2)CC1)N1C=C(C(F)(F)F)C=N1 GBGDSXONKVBRTB-UHFFFAOYSA-N 0.000 description 2
- VRTHMDYRYBIGNX-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(N3CCOCC3)=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(N3CCOCC3)=C2)CC1)N1C=C(C(F)(F)F)C=N1 VRTHMDYRYBIGNX-UHFFFAOYSA-N 0.000 description 2
- ZQXJWGXJMQUSNC-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1)N1C=C(Cl)C=N1 ZQXJWGXJMQUSNC-UHFFFAOYSA-N 0.000 description 2
- GHIWFFUWGVOEKF-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 GHIWFFUWGVOEKF-UHFFFAOYSA-N 0.000 description 2
- HDQBZQWIIZZPTR-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=C(Cl)C=N1 HDQBZQWIIZZPTR-UHFFFAOYSA-N 0.000 description 2
- VDUCASWEOFMWAI-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=CC=N1 VDUCASWEOFMWAI-UHFFFAOYSA-N 0.000 description 2
- SRRJLTSADCMWHF-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2Cl)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2Cl)CC1)N1C=C(C(F)(F)F)C=N1 SRRJLTSADCMWHF-UHFFFAOYSA-N 0.000 description 2
- MUZJNASBPKZRAL-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2F)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2F)CC1)N1C=C(C(F)(F)F)C=N1 MUZJNASBPKZRAL-UHFFFAOYSA-N 0.000 description 2
- WBKYLLMFCSYUQS-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2N2CCOCC2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2N2CCOCC2)CC1)N1C=C(C(F)(F)F)C=N1 WBKYLLMFCSYUQS-UHFFFAOYSA-N 0.000 description 2
- WBOSXEOLEMRIRP-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=N2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=N2)CC1)N1C=C(C2=CC=CC=C2)C=N1 WBOSXEOLEMRIRP-UHFFFAOYSA-N 0.000 description 2
- WHEJPMAFGOPGLP-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=NC=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CC=NC=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 WHEJPMAFGOPGLP-UHFFFAOYSA-N 0.000 description 2
- YULOUTHECIRQGE-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=NC=N2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CC=NC=N2)CC1)N1C=C(C2=CC=CC=C2)C=N1 YULOUTHECIRQGE-UHFFFAOYSA-N 0.000 description 2
- DPKSQAYSYOWOSJ-UHFFFAOYSA-N O=C(N1CCN(CC2=CN=CN=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=CN=CN=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 DPKSQAYSYOWOSJ-UHFFFAOYSA-N 0.000 description 2
- PPKCTVAIDHPUOR-UHFFFAOYSA-N O=C(N1CCN(CC2=NC=CS2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=NC=CS2)CC1)N1C=C(C2=CC=CC=C2)C=N1 PPKCTVAIDHPUOR-UHFFFAOYSA-N 0.000 description 2
- XSQLLTLECKCIQZ-UHFFFAOYSA-N O=C(N1CCN(CC2CC2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2CC2)CC1)N1C=C(Cl)C=N1 XSQLLTLECKCIQZ-UHFFFAOYSA-N 0.000 description 2
- JSEHZLZXTVYTOU-UHFFFAOYSA-N O=C(N1CCN(C[SH](=O)=O)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(C[SH](=O)=O)CC1)N1C=C(C(F)(F)F)C=N1 JSEHZLZXTVYTOU-UHFFFAOYSA-N 0.000 description 2
- XOSOEETTWPDMAG-UHFFFAOYSA-N O=C(N1CCN(C[SH](=O)=O)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(C[SH](=O)=O)CC1)N1C=C(Cl)C=N1 XOSOEETTWPDMAG-UHFFFAOYSA-N 0.000 description 2
- OVJUCUNPKIQRGP-UHFFFAOYSA-N O=C(N1CCOCC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCOCC1)N1C=C(C(F)(F)F)C=N1 OVJUCUNPKIQRGP-UHFFFAOYSA-N 0.000 description 2
- GPAOWQNBALULKM-UHFFFAOYSA-N O=C(N1CCOCC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCOCC1)N1C=C(Cl)C=N1 GPAOWQNBALULKM-UHFFFAOYSA-N 0.000 description 2
- MJRWLNAFYCDOSI-UHFFFAOYSA-N O=C(NC1=CC=C2C=CC=CC2=C1)N1C=CC=N1 Chemical compound O=C(NC1=CC=C2C=CC=CC2=C1)N1C=CC=N1 MJRWLNAFYCDOSI-UHFFFAOYSA-N 0.000 description 2
- LZPZBSQLJUTGTP-UHFFFAOYSA-N O=C(NC1CC1)C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound O=C(NC1CC1)C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 LZPZBSQLJUTGTP-UHFFFAOYSA-N 0.000 description 2
- JXKJGTZJXLBVCZ-UHFFFAOYSA-N O=C(NCCCC1=CC=CC=C1)N1C=CC=N1 Chemical compound O=C(NCCCC1=CC=CC=C1)N1C=CC=N1 JXKJGTZJXLBVCZ-UHFFFAOYSA-N 0.000 description 2
- CLDBYFZEIMPYTR-UHFFFAOYSA-N O=C(NCCCCCC1=CC=CC=C1)N1C=CC=N1 Chemical compound O=C(NCCCCCC1=CC=CC=C1)N1C=CC=N1 CLDBYFZEIMPYTR-UHFFFAOYSA-N 0.000 description 2
- SDCSDDYSWMJBFK-UHFFFAOYSA-N BrC1=C(N2CCOCC2)C=CC=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1 Chemical compound BrC1=C(N2CCOCC2)C=CC=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1 SDCSDDYSWMJBFK-UHFFFAOYSA-N 0.000 description 1
- KDVZDMWOMNNFAA-UHFFFAOYSA-N BrC1=CC=C(I)C=C1.OCC1=C(B(O)O)C=CC=C1.OCC1=C(C2=CC=C(Br)C=C2)C=CC=C1 Chemical compound BrC1=CC=C(I)C=C1.OCC1=C(B(O)O)C=CC=C1.OCC1=C(C2=CC=C(Br)C=C2)C=CC=C1 KDVZDMWOMNNFAA-UHFFFAOYSA-N 0.000 description 1
- HNUOATPMGFEMTL-UHFFFAOYSA-N BrC1=CC=C2COCC2=C1.OC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 Chemical compound BrC1=CC=C2COCC2=C1.OC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 HNUOATPMGFEMTL-UHFFFAOYSA-N 0.000 description 1
- YQWBNQOABNLAQT-UHFFFAOYSA-N BrC1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.BrC1=CNN=C1.ClC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound BrC1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.BrC1=CNN=C1.ClC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 YQWBNQOABNLAQT-UHFFFAOYSA-N 0.000 description 1
- VAVWWAVHNQJQFK-UHFFFAOYSA-N BrC1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.CC1=CC=CC=C1C1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.OB(O)C1=CC=CC=C1C(F)(F)F Chemical compound BrC1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.CC1=CC=CC=C1C1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.OB(O)C1=CC=CC=C1C(F)(F)F VAVWWAVHNQJQFK-UHFFFAOYSA-N 0.000 description 1
- ZXTQNJLCVRSTFJ-UHFFFAOYSA-N BrC1=CNN=C1.CC1=C(B(O)O)C=CC=C1.CC1=C(C2=CNN=C2)C=CC=C1 Chemical compound BrC1=CNN=C1.CC1=C(B(O)O)C=CC=C1.CC1=C(C2=CNN=C2)C=CC=C1 ZXTQNJLCVRSTFJ-UHFFFAOYSA-N 0.000 description 1
- WMWYHXNCKDKPOP-UHFFFAOYSA-N BrCC1=CC=C2C=CC=CC2=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1 Chemical compound BrCC1=CC=C2C=CC=CC2=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1 WMWYHXNCKDKPOP-UHFFFAOYSA-N 0.000 description 1
- XAPMKFNOCTXJJO-UHFFFAOYSA-N BrCCCCBr.CC(C)(C)OC(=O)N1CCN(C2=C(N)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 Chemical compound BrCCCCBr.CC(C)(C)OC(=O)N1CCN(C2=C(N)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 XAPMKFNOCTXJJO-UHFFFAOYSA-N 0.000 description 1
- LPTOHAUDUNQMPK-UHFFFAOYSA-N C.C1=CNN=C1.O=C(Cl)Cl.O=C(Cl)N1C=CC=N1.O=C(N1CCCCC1)N1C=CC=N1 Chemical compound C.C1=CNN=C1.O=C(Cl)Cl.O=C(Cl)N1C=CC=N1.O=C(N1CCCCC1)N1C=CC=N1 LPTOHAUDUNQMPK-UHFFFAOYSA-N 0.000 description 1
- GQKOVVBYZCCLBX-UHFFFAOYSA-N C.C1CCNCC1.CCC.CCN1CCCCC1.CCN1CCNCC1.Cl.[KH] Chemical compound C.C1CCNCC1.CCC.CCN1CCCCC1.CCN1CCNCC1.Cl.[KH] GQKOVVBYZCCLBX-UHFFFAOYSA-N 0.000 description 1
- MFDZFCFVPIWXPQ-UHFFFAOYSA-N C.CC(C)(C)OC(=O)NCCN.CCC.CCNCCN.CCNCCNC(=O)OC(C)(C)C.Cl.N.P Chemical compound C.CC(C)(C)OC(=O)NCCN.CCC.CCNCCN.CCNCCNC(=O)OC(C)(C)C.Cl.N.P MFDZFCFVPIWXPQ-UHFFFAOYSA-N 0.000 description 1
- LYMXXIUTAAOYOS-UHFFFAOYSA-N C.CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1C1=CC=CC=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 Chemical compound C.CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1C1=CC=CC=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 LYMXXIUTAAOYOS-UHFFFAOYSA-N 0.000 description 1
- DEKXNCCHYKPENE-UHFFFAOYSA-N C.CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1.CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1.CC1=CC=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=C1.O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound C.CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1.CC1=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=CC=C1.CC1=CC=C(C2=CN(C(=O)N3CCN(C(C4=CC=C(Cl)C=C4)C4=CC=C(Cl)C=C4)CC3)N=C2)C=C1.O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 DEKXNCCHYKPENE-UHFFFAOYSA-N 0.000 description 1
- VNDXCLKRHMQQGX-JFXLULTRSA-N C/C(=N\NC(C)C)C1=CC=CC=C1.CC(=O)C1=CC=CC=C1.CC(C)CN.Cl Chemical compound C/C(=N\NC(C)C)C1=CC=CC=C1.CC(=O)C1=CC=CC=C1.CC(C)CN.Cl VNDXCLKRHMQQGX-JFXLULTRSA-N 0.000 description 1
- IFKLPQZWHCTJMB-OXEOGTFPSA-N C/C(=N\NC(C)C)C1=CC=CC=C1.CC(C)N1C=C(C=O)C(C2=CC=CC=C2)=N1.[Cl-].[H]C(Cl)=[N+](C)C Chemical compound C/C(=N\NC(C)C)C1=CC=CC=C1.CC(C)N1C=C(C=O)C(C2=CC=CC=C2)=N1.[Cl-].[H]C(Cl)=[N+](C)C IFKLPQZWHCTJMB-OXEOGTFPSA-N 0.000 description 1
- NFWUQPMNDAJHDO-UHFFFAOYSA-N C1=C2COCC2=CC(C(C2=CC=C3COCC3=C2)N2CCNCC2)=C1.CC(C)(C)OC(=O)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1 Chemical compound C1=C2COCC2=CC(C(C2=CC=C3COCC3=C2)N2CCNCC2)=C1.CC(C)(C)OC(=O)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1 NFWUQPMNDAJHDO-UHFFFAOYSA-N 0.000 description 1
- GHEBAFGCGQGYBB-UHFFFAOYSA-N C1=C2COCC2=CC(C(C2=CC=C3COCC3=C2)N2CCNCC2)=C1.O=C(Cl)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1 Chemical compound C1=C2COCC2=CC(C(C2=CC=C3COCC3=C2)N2CCNCC2)=C1.O=C(Cl)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1 GHEBAFGCGQGYBB-UHFFFAOYSA-N 0.000 description 1
- VTAOQJONICVPCI-UHFFFAOYSA-N C1=CC(N2CCCC2)=C(N2CCNCC2)C=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 Chemical compound C1=CC(N2CCCC2)=C(N2CCNCC2)C=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 VTAOQJONICVPCI-UHFFFAOYSA-N 0.000 description 1
- FGLZCUSEVZEWDB-UHFFFAOYSA-N C1=CC(N2CCCC2)=C(N2CCNCC2)C=C1.O=C(Cl)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 Chemical compound C1=CC(N2CCCC2)=C(N2CCNCC2)C=C1.O=C(Cl)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1 FGLZCUSEVZEWDB-UHFFFAOYSA-N 0.000 description 1
- GNVLAVALPVKWIA-UHFFFAOYSA-N C1=CC(N2CCNCC2)=C(N2CCOCC2)C=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1 Chemical compound C1=CC(N2CCNCC2)=C(N2CCOCC2)C=C1.CC(C)(C)OC(=O)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1 GNVLAVALPVKWIA-UHFFFAOYSA-N 0.000 description 1
- WVGYVJOCCURCGR-UHFFFAOYSA-N C1=CC(N2CCNCC2)=C(N2CCOCC2)C=C1.O=C(Cl)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1 Chemical compound C1=CC(N2CCNCC2)=C(N2CCOCC2)C=C1.O=C(Cl)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1 WVGYVJOCCURCGR-UHFFFAOYSA-N 0.000 description 1
- ISUNJJMXWHVEQE-UHFFFAOYSA-N C1=CC2=CC=C(CN3CCNCC3)C=C2C=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1 Chemical compound C1=CC2=CC=C(CN3CCNCC3)C=C2C=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C3C=CC=CC3=C2)CC1 ISUNJJMXWHVEQE-UHFFFAOYSA-N 0.000 description 1
- NRNBUPGQQFJRCL-UHFFFAOYSA-N C1=CC=C(C2=CNN=C2)C=C1.CC1=CC(N2CCN(C(=O)Cl)CC2)=C2/C=C\C=C/C2=N1.CC1=CC(N2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)=C2/C=C\C=C/C2=N1 Chemical compound C1=CC=C(C2=CNN=C2)C=C1.CC1=CC(N2CCN(C(=O)Cl)CC2)=C2/C=C\C=C/C2=N1.CC1=CC(N2CCN(C(=O)N3C=C(C4=CC=CC=C4)C=N3)CC2)=C2/C=C\C=C/C2=N1 NRNBUPGQQFJRCL-UHFFFAOYSA-N 0.000 description 1
- UIWKLWRSKNGBCF-UHFFFAOYSA-N C1=CC=C(C2=CNN=C2)C=C1.CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)Cl.CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound C1=CC=C(C2=CNN=C2)C=C1.CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)Cl.CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)N1C=C(C2=CC=CC=C2)C=N1 UIWKLWRSKNGBCF-UHFFFAOYSA-N 0.000 description 1
- FIVCDINFMMELKX-UHFFFAOYSA-N C1=CC=C(C2=CNN=C2)C=C1.O=C(Cl)N1CCCCC1.O=C(N1CCCCC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound C1=CC=C(C2=CNN=C2)C=C1.O=C(Cl)N1CCCCC1.O=C(N1CCCCC1)N1C=C(C2=CC=CC=C2)C=N1 FIVCDINFMMELKX-UHFFFAOYSA-N 0.000 description 1
- ARIFARVUUBTJSS-UHFFFAOYSA-N C1=CC=C(OC2=CC(CN3CCNCC3)=CC=C2)C=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.O=C(O)C(F)(F)F Chemical compound C1=CC=C(OC2=CC(CN3CCNCC3)=CC=C2)C=C1.CC(C)(C)OC(=O)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.O=C(O)C(F)(F)F ARIFARVUUBTJSS-UHFFFAOYSA-N 0.000 description 1
- CELVWZSCCSFUPY-UHFFFAOYSA-N C1=CC=C(OC2=CC(CN3CCNCC3)=CC=C2)C=C1.O=C(Cl)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1 Chemical compound C1=CC=C(OC2=CC(CN3CCNCC3)=CC=C2)C=C1.O=C(Cl)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1 CELVWZSCCSFUPY-UHFFFAOYSA-N 0.000 description 1
- BDSCZWIKUHOJER-UHFFFAOYSA-N C1=CNN=C1.CC1=C(CN2CCN(C(=O)N3C=CC=N3)CC2)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCNCC2)C=CC(C2=CC=CC=C2)=C1 Chemical compound C1=CNN=C1.CC1=C(CN2CCN(C(=O)N3C=CC=N3)CC2)C=CC(C2=CC=CC=C2)=C1.CC1=C(CN2CCNCC2)C=CC(C2=CC=CC=C2)=C1 BDSCZWIKUHOJER-UHFFFAOYSA-N 0.000 description 1
- BNTLSBSMIYJVGM-UHFFFAOYSA-N C1=CNN=C1.ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1.O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=CC=N1 Chemical compound C1=CNN=C1.ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1.O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=CC=N1 BNTLSBSMIYJVGM-UHFFFAOYSA-N 0.000 description 1
- YSNCSWPGGSWQSK-UHFFFAOYSA-N C1CCCC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)C1=CNN=C1 Chemical compound C1CCCC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)C1=CNN=C1 YSNCSWPGGSWQSK-UHFFFAOYSA-N 0.000 description 1
- HPCXDSFJGLBCLD-UHFFFAOYSA-N C1CCCC1.O=CC1=C(F)C=CC=C1C(F)(F)F.O=CC1=C(N2CCCC2)C=CC=C1C(F)(F)F Chemical compound C1CCCC1.O=CC1=C(F)C=CC=C1C(F)(F)F.O=CC1=C(N2CCCC2)C=CC=C1C(F)(F)F HPCXDSFJGLBCLD-UHFFFAOYSA-N 0.000 description 1
- WDPHEHVVRDACSB-UHFFFAOYSA-N C1CCNC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)C1=CNN=C1 Chemical compound C1CCNC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)C1=CNN=C1 WDPHEHVVRDACSB-UHFFFAOYSA-N 0.000 description 1
- OXMVXBKRTVWMSV-UHFFFAOYSA-N C1CCNC1.O=C(Cl)N1CCCC1 Chemical compound C1CCNC1.O=C(Cl)N1CCCC1 OXMVXBKRTVWMSV-UHFFFAOYSA-N 0.000 description 1
- HTMCJGYYWGKLLO-UHFFFAOYSA-N C1CCNCC1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)O)C=C2Cl)CC1 Chemical compound C1CCNCC1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1.CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)O)C=C2Cl)CC1 HTMCJGYYWGKLLO-UHFFFAOYSA-N 0.000 description 1
- BVEOBJWUPMBVPK-UHFFFAOYSA-N C1CCNCC1.O=C(C1=CNN=C1)N1CCCCC1.O=C(O)C1=CNN=C1 Chemical compound C1CCNCC1.O=C(C1=CNN=C1)N1CCCCC1.O=C(O)C1=CNN=C1 BVEOBJWUPMBVPK-UHFFFAOYSA-N 0.000 description 1
- GKZFTXXQQICJLF-UHFFFAOYSA-N C1CCNCC1.O=C(Cl)N1CCCCC1 Chemical compound C1CCNCC1.O=C(Cl)N1CCCCC1 GKZFTXXQQICJLF-UHFFFAOYSA-N 0.000 description 1
- VSUNXOICHHAONI-UHFFFAOYSA-N C1COCCN1.N#CC1=CC=C(CBr)C=C1.N#CC1=CC=C(CN2CCOCC2)C=C1 Chemical compound C1COCCN1.N#CC1=CC=C(CBr)C=C1.N#CC1=CC=C(CN2CCOCC2)C=C1 VSUNXOICHHAONI-UHFFFAOYSA-N 0.000 description 1
- AJESJTLIIXFOGF-UHFFFAOYSA-N C1COCCN1.O=C(N1CCOCC1)N1C=CC=N1.O=C(O)N1C=CC=N1 Chemical compound C1COCCN1.O=C(N1CCOCC1)N1C=CC=N1.O=C(O)N1C=CC=N1 AJESJTLIIXFOGF-UHFFFAOYSA-N 0.000 description 1
- WGRPWNUEUKTJAF-UHFFFAOYSA-N C1COCCN1.O=CC1=CC(Br)=CC=C1.O=CC1=CC(N2CCOCC2)=CC=C1 Chemical compound C1COCCN1.O=CC1=CC(Br)=CC=C1.O=CC1=CC(N2CCOCC2)=CC=C1 WGRPWNUEUKTJAF-UHFFFAOYSA-N 0.000 description 1
- JQHGVWXROUHFMU-UHFFFAOYSA-N C1COCCN1.O=CC1=CC=C(Cl)C=C1F.O=CC1=CC=C(Cl)C=C1N1CCOCC1 Chemical compound C1COCCN1.O=CC1=CC=C(Cl)C=C1F.O=CC1=CC=C(Cl)C=C1N1CCOCC1 JQHGVWXROUHFMU-UHFFFAOYSA-N 0.000 description 1
- GLXGWXUBUFYMQF-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1.CNCCN(C)C(C)=O.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 Chemical compound CC(=O)N(C)CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1.CNCCN(C)C(C)=O.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 GLXGWXUBUFYMQF-UHFFFAOYSA-N 0.000 description 1
- BVSJNRONDXUAPX-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)OC(C)(C)C.CC(=O)OC(C)=O.CNCCN(C)C(=O)OC(C)(C)C Chemical compound CC(=O)N(C)CCN(C)C(=O)OC(C)(C)C.CC(=O)OC(C)=O.CNCCN(C)C(=O)OC(C)(C)C BVSJNRONDXUAPX-UHFFFAOYSA-N 0.000 description 1
- AOMCMMRCUFWZFT-UHFFFAOYSA-N CC(=O)N(C)CCN(C)C(=O)OC(C)(C)C.CNCCN(C)C(C)=O.O=C(O)C(F)(F)F Chemical compound CC(=O)N(C)CCN(C)C(=O)OC(C)(C)C.CNCCN(C)C(C)=O.O=C(O)C(F)(F)F AOMCMMRCUFWZFT-UHFFFAOYSA-N 0.000 description 1
- NBVRSMXZEYCDCO-UHFFFAOYSA-N CC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(=O)OC(C)=O.O=C(N1CCCNCC1)N1C=C(C(F)(F)F)C=N1 Chemical compound CC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(=O)OC(C)=O.O=C(N1CCCNCC1)N1C=C(C(F)(F)F)C=N1 NBVRSMXZEYCDCO-UHFFFAOYSA-N 0.000 description 1
- INIFDAUEMIJHRR-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)Cl)CC1.CC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.ClC1=CNN=C1 Chemical compound CC(=O)N1CCN(C(=O)Cl)CC1.CC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.ClC1=CNN=C1 INIFDAUEMIJHRR-UHFFFAOYSA-N 0.000 description 1
- PCFSRZRGFIQMBR-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)Cl)CC1.CC(=O)N1CCNCC1 Chemical compound CC(=O)N1CCN(C(=O)Cl)CC1.CC(=O)N1CCNCC1 PCFSRZRGFIQMBR-UHFFFAOYSA-N 0.000 description 1
- BMDQSBOPBMWYHE-UHFFFAOYSA-N CC(C)(C)OC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.CC(C)(C)OC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 Chemical compound CC(C)(C)OC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.CC(C)(C)OC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 BMDQSBOPBMWYHE-UHFFFAOYSA-N 0.000 description 1
- VXLYTHXCXQKESH-UHFFFAOYSA-N CC(C)(C)OC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.O=C(O)C(F)(F)F.O=C(O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound CC(C)(C)OC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.O=C(O)C(F)(F)F.O=C(O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1 VXLYTHXCXQKESH-UHFFFAOYSA-N 0.000 description 1
- OJGGPFNCLIHZSE-UHFFFAOYSA-M CC(C)(C)OC(=O)C1=CN(C(=O)OC(C)(C)C)N=C1.CC(C)(C)OC(=O)C1=CNN=C1.O[Na] Chemical compound CC(C)(C)OC(=O)C1=CN(C(=O)OC(C)(C)C)N=C1.CC(C)(C)OC(=O)C1=CNN=C1.O[Na] OJGGPFNCLIHZSE-UHFFFAOYSA-M 0.000 description 1
- AHOAIDLQEYJYJN-UHFFFAOYSA-N CC(C)(C)OC(=O)C1=CN(C(=O)OC(C)(C)C)N=C1.O=C(O)C1=CNN=C1 Chemical compound CC(C)(C)OC(=O)C1=CN(C(=O)OC(C)(C)C)N=C1.O=C(O)C1=CNN=C1 AHOAIDLQEYJYJN-UHFFFAOYSA-N 0.000 description 1
- PLYLUTOXMBDWKM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(C)(C)OC(=O)N1CCCNCC1.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 Chemical compound CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(C)(C)OC(=O)N1CCCNCC1.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 PLYLUTOXMBDWKM-UHFFFAOYSA-N 0.000 description 1
- IJPWAJARODBKEH-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.O=C(N1CCCNCC1)N1C=C(C(F)(F)F)C=N1.O=C(O)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.O=C(N1CCCNCC1)N1C=C(C(F)(F)F)C=N1.O=C(O)C(F)(F)F IJPWAJARODBKEH-UHFFFAOYSA-N 0.000 description 1
- SQZJIBHPQWBVJC-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(=O)N3CCOCC3)C=N2)CC1.O=C(C1=CNN=C1)N1CCOCC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(=O)N3CCOCC3)C=N2)CC1.O=C(C1=CNN=C1)N1CCOCC1 SQZJIBHPQWBVJC-UHFFFAOYSA-N 0.000 description 1
- PCCUAICVPFQYEQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1.ClC1=CNN=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1.CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1.ClC1=CNN=C1 PCCUAICVPFQYEQ-UHFFFAOYSA-N 0.000 description 1
- WYPBWERZPMHNIN-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(=O)N3CCOCC3)C=N2)CC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1.O=C(O)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(=O)N3CCOCC3)C=N2)CC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1.O=C(O)C(F)(F)F WYPBWERZPMHNIN-UHFFFAOYSA-N 0.000 description 1
- SSXWLQQERTVHJN-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(C)(C)OC(=O)N1CCNCC1.FC(F)(F)C1=CNN=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.CC(C)(C)OC(=O)N1CCNCC1.FC(F)(F)C1=CNN=C1 SSXWLQQERTVHJN-UHFFFAOYSA-N 0.000 description 1
- YTOGSXKSVCPNQM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.O=C(N1CCNCC1)N1C=C(C(F)(F)F)C=N1.O=C(O)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(C(F)(F)F)C=N2)CC1.O=C(N1CCNCC1)N1C=C(C(F)(F)F)C=N1.O=C(O)C(F)(F)F YTOGSXKSVCPNQM-UHFFFAOYSA-N 0.000 description 1
- XSIPSKQNXFWOHK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1.O=C(N1CCNCC1)N1C=C(Cl)C=N1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=C(Cl)C=N2)CC1.O=C(N1CCNCC1)N1C=C(Cl)C=N1 XSIPSKQNXFWOHK-UHFFFAOYSA-N 0.000 description 1
- OJWPJTMWFIKIRB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(=O)N2C=CC=N2)CC1.O=C(N1CCNCC1)N1C=CC=N1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)N2C=CC=N2)CC1.O=C(N1CCNCC1)N1C=CC=N1 OJWPJTMWFIKIRB-UHFFFAOYSA-N 0.000 description 1
- CSWRODVLXCVDDO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1 CSWRODVLXCVDDO-UHFFFAOYSA-N 0.000 description 1
- UURXODBJYAPYNM-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1.ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1.ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1 UURXODBJYAPYNM-UHFFFAOYSA-N 0.000 description 1
- BXLXIOUWUJQGIQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.ClC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.ClC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 BXLXIOUWUJQGIQ-UHFFFAOYSA-N 0.000 description 1
- JNEKYHYVOACAFY-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C2=C(N)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=C([N+](=O)[O-])C=CC=C2)CC1 Chemical compound CC(C)(C)OC(=O)N1CCN(C2=C(N)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCN(C2=C([N+](=O)[O-])C=CC=C2)CC1 JNEKYHYVOACAFY-UHFFFAOYSA-N 0.000 description 1
- UYSFQYAJIFSHAF-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C2=C([N+](=O)[O-])C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=[N+]([O-])C1=C(F)C=CC=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(C2=C([N+](=O)[O-])C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=[N+]([O-])C1=C(F)C=CC=C1 UYSFQYAJIFSHAF-UHFFFAOYSA-N 0.000 description 1
- RHUVBNUIOJPSMU-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(Cl)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(Cl)C=CC=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(Cl)C=CC=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(Cl)C=CC=C1 RHUVBNUIOJPSMU-UHFFFAOYSA-N 0.000 description 1
- LWSHAVRQNQZJFE-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(Cl)C=CC=C2)CC1.ClC1=C(CN2CCNCC2)C=CC=C1.O=C(O)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(Cl)C=CC=C2)CC1.ClC1=C(CN2CCNCC2)C=CC=C1.O=C(O)C(F)(F)F LWSHAVRQNQZJFE-UHFFFAOYSA-N 0.000 description 1
- LEPCATKWVXJYBK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(N2CCCC2)C=CC=C1C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(N2CCCC2)C=CC=C1C(F)(F)F LEPCATKWVXJYBK-UHFFFAOYSA-N 0.000 description 1
- WLYTYDNJCZNWOB-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.FC(F)(F)C1=CC=CC(N2CCCC2)=C1CN1CCNCC1.O=C(O)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.FC(F)(F)C1=CC=CC(N2CCCC2)=C1CN1CCNCC1.O=C(O)C(F)(F)F WLYTYDNJCZNWOB-UHFFFAOYSA-N 0.000 description 1
- MFPIMWGFVAFZIT-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCOCC3)C=C(Cl)C=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(N2CCOCC2)C=C(Cl)C=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCOCC3)C=C(Cl)C=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=C(N2CCOCC2)C=C(Cl)C=C1 MFPIMWGFVAFZIT-UHFFFAOYSA-N 0.000 description 1
- UBWILBGRPBKOKQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCOCC3)C=C(Cl)C=C2)CC1.ClC1=CC(N2CCOCC2)=C(CN2CCNCC2)C=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=C(N3CCOCC3)C=C(Cl)C=C2)CC1.ClC1=CC(N2CCOCC2)=C(CN2CCNCC2)C=C1 UBWILBGRPBKOKQ-UHFFFAOYSA-N 0.000 description 1
- CWOCWMRLZQIXHL-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1.O=C(C1=CC=C(CN2CCNCC2)C(Cl)=C1)N1CCCCC1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1.O=C(C1=CC=C(CN2CCNCC2)C(Cl)=C1)N1CCCCC1 CWOCWMRLZQIXHL-UHFFFAOYSA-N 0.000 description 1
- ALTRLVKBWNTCGA-UHFFFAOYSA-M CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)O)C=C2Cl)CC1.COC(=O)C1=CC=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(Cl)=C1.[Li]O Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=CC=C(C(=O)O)C=C2Cl)CC1.COC(=O)C1=CC=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(Cl)=C1.[Li]O ALTRLVKBWNTCGA-UHFFFAOYSA-M 0.000 description 1
- LYHWGDQSWUABJK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=CC=CC(OC2=CC=CC=C2)=C1 Chemical compound CC(C)(C)OC(=O)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1.CC(C)(C)OC(=O)N1CCNCC1.O=CC1=CC=CC(OC2=CC=CC=C2)=C1 LYHWGDQSWUABJK-UHFFFAOYSA-N 0.000 description 1
- IXJDYROOTZEHKV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCNCC1.CC(C)N1C=C(C=O)C(C2=CC=CC=C2)=N1.CC(C)N1C=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(C2=CC=CC=C2)=N1 Chemical compound CC(C)(C)OC(=O)N1CCNCC1.CC(C)N1C=C(C=O)C(C2=CC=CC=C2)=N1.CC(C)N1C=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(C2=CC=CC=C2)=N1 IXJDYROOTZEHKV-UHFFFAOYSA-N 0.000 description 1
- BCVHZYLGECYSFU-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCNCC1.COC(=O)C1=CC=C(C=O)C(Cl)=C1.COC(=O)C1=CC=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(Cl)=C1 Chemical compound CC(C)(C)OC(=O)N1CCNCC1.COC(=O)C1=CC=C(C=O)C(Cl)=C1.COC(=O)C1=CC=C(CN2CCN(C(=O)OC(C)(C)C)CC2)C(Cl)=C1 BCVHZYLGECYSFU-UHFFFAOYSA-N 0.000 description 1
- NCIQNWYJLAAFAH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(Cl)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(Cl)=O)=O NCIQNWYJLAAFAH-UHFFFAOYSA-N 0.000 description 1
- KXCYILUWBVQLBY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C([n]1ncc(Cl)c1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C([n]1ncc(Cl)c1)=O)=O KXCYILUWBVQLBY-UHFFFAOYSA-N 0.000 description 1
- KXJJQRNDOSSCGC-UHFFFAOYSA-N CC(C)(C)OC(c1c[n](C(OC(C)(C)C)=O)nc1)=O Chemical compound CC(C)(C)OC(c1c[n](C(OC(C)(C)C)=O)nc1)=O KXJJQRNDOSSCGC-UHFFFAOYSA-N 0.000 description 1
- KKONJVVXAHBWBN-NJAOIOQDSA-N CC(C)/N=C(\N)C(C)C.CC(C)/N=C(\O)C(C)C.CC(C)C.CC(C)C.CC(C)C(=N)O.CC(C)C(N)=O.CC(C)C1=NN=NC1.CC(C)C1=NN=NN1.CC(C)C1=NNN=N1.CC(C)C1=NNN=N1.CC(C)NC(=N)C(C)C.O=C1C=CC=CN1.OC1=NC=CC=C1.[H]/C(=C(/O)C(C)C)C(C)C.[H]C([H])(C(=O)C(C)C)C(C)C.[H]N(C(=O)C(C)C)C(C)C.[H]N1C(C(C)C)=CN=C1C(C)C.[H]N1C=C(C(C)C)N=C1C(C)C Chemical compound CC(C)/N=C(\N)C(C)C.CC(C)/N=C(\O)C(C)C.CC(C)C.CC(C)C.CC(C)C(=N)O.CC(C)C(N)=O.CC(C)C1=NN=NC1.CC(C)C1=NN=NN1.CC(C)C1=NNN=N1.CC(C)C1=NNN=N1.CC(C)NC(=N)C(C)C.O=C1C=CC=CN1.OC1=NC=CC=C1.[H]/C(=C(/O)C(C)C)C(C)C.[H]C([H])(C(=O)C(C)C)C(C)C.[H]N(C(=O)C(C)C)C(C)C.[H]N1C(C(C)C)=CN=C1C(C)C.[H]N1C=C(C(C)C)N=C1C(C)C KKONJVVXAHBWBN-NJAOIOQDSA-N 0.000 description 1
- VLRZOWLJGHPSMB-UHFFFAOYSA-N CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(Cl)C=C(Cl)C=C1.CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1F.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1F.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.CCOC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(Cl)C=C(Cl)C=C1.CC(C)C1=C(N2CCC3(CCCCC3)C2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCC2)C=C1F.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1F.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.CCOC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 VLRZOWLJGHPSMB-UHFFFAOYSA-N 0.000 description 1
- KQPSIULKJMKIKM-UHFFFAOYSA-N CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(OCC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC(Cl)=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(OCC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC(Cl)=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 KQPSIULKJMKIKM-UHFFFAOYSA-N 0.000 description 1
- KYFLAHUCSASRNT-UHFFFAOYSA-N CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC(Cl)=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.CCOC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 Chemical compound CC(C)C1=C(Cl)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=C(N2CCCC2)C=C(Cl)C=C1.CC(C)C1=C(N2CCCC2)C=CC=C1C(F)(F)F.CC(C)C1=C(N2CCOCC2)C=C(Cl)C=C1.CC(C)C1=C(OC2=CC=CC=C2)C=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC(Cl)=C(Cl)C=C1.CC(C)C1=CC2=C(C=C1)COC2.CC(C)C1=CC2=C(C=C1)OCO2.CC(C)C1=CC=C(C(=O)N2CCCCC2)C=C1Cl.CC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.CC1=C(C(C)C)C=CC(N2CCOCC2)=C1.CC1=CC(N2CCCC2)=C(C(C)C)C=C1.CCOC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1.COC1=C(C(C)C)C=CC(C2=CC=CC=C2)=C1 KYFLAHUCSASRNT-UHFFFAOYSA-N 0.000 description 1
- QYSSVVDPUFPOPJ-UHFFFAOYSA-N CC(C)C1=CC(N2CCCC2)=CC=C1.CC(C)C1=CC(N2CCOCC2)=CC=C1.CC(C)C1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1N1CCCC1.CC(C)C1=CC=CC=C1N1CCCCC1 Chemical compound CC(C)C1=CC(N2CCCC2)=CC=C1.CC(C)C1=CC(N2CCOCC2)=CC=C1.CC(C)C1=CC(OC2=CC=CC=C2)=CC=C1.CC(C)C1=CC(OCC2=CC=CC=C2)=CC=C1.CC(C)C1=CC2=CC=CC=C2C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(OC2=CC=CC=C2)C=C1.CC(C)C1=CC=C(OCC2=CC=CC=C2)C=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1N1CCCC1.CC(C)C1=CC=CC=C1N1CCCCC1 QYSSVVDPUFPOPJ-UHFFFAOYSA-N 0.000 description 1
- UPWRGXVQMQITCK-UHFFFAOYSA-N CC(C)C1=CC=C(C2=C(Cl)C=CC=C2)C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(Cl)C=C1.CC(C)C1=CC=CC=C1.CC1=C(C2=CC=C(C(C)C)C=C2)C=CC=C1.CC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(C2=C(Cl)C=CC=C2)C=C1.CC(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)C1=CC=C(Cl)C=C1.CC(C)C1=CC=CC=C1.CC1=C(C2=CC=C(C(C)C)C=C2)C=CC=C1.CC1=CC=C(C(C)C)C=C1 UPWRGXVQMQITCK-UHFFFAOYSA-N 0.000 description 1
- VORFHUWOSWVSFF-UHFFFAOYSA-N CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 Chemical compound CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 VORFHUWOSWVSFF-UHFFFAOYSA-N 0.000 description 1
- AOMGJONZYWTTOE-UHFFFAOYSA-N CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1C1=CC=CC=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 Chemical compound CC(C)C1=CC=CC=N1.CC(C)C1=CC=CN=C1.CC(C)C1=CC=NC=C1.CC(C)C1=CC=NC=N1.CC(C)C1=CN(C(C)C)N=C1C1=CC=CC=C1.CC(C)C1=CN=CN=C1.CC(C)C1=NC=CS1 AOMGJONZYWTTOE-UHFFFAOYSA-N 0.000 description 1
- BJEVACOENDZTKG-UHFFFAOYSA-N CC(C)C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 Chemical compound CC(C)C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1 BJEVACOENDZTKG-UHFFFAOYSA-N 0.000 description 1
- WZKCWNDGEJLZQK-UHFFFAOYSA-N CC(C)C1=CN(C(=O)N2CCN(CC3=C(C4=CC=C(Cl)C=C4)C=C(Cl)C=C3)CC2)N=C1 Chemical compound CC(C)C1=CN(C(=O)N2CCN(CC3=C(C4=CC=C(Cl)C=C4)C=C(Cl)C=C3)CC2)N=C1 WZKCWNDGEJLZQK-UHFFFAOYSA-N 0.000 description 1
- SAJPGULNDDWHTL-UHFFFAOYSA-N CC(C)[n](cc1C=O)nc1-c1ccccc1 Chemical compound CC(C)[n](cc1C=O)nc1-c1ccccc1 SAJPGULNDDWHTL-UHFFFAOYSA-N 0.000 description 1
- MVPIOKQGSNIPJF-UHFFFAOYSA-N CC(C)c(cc1)ccc1OCc1ccccc1 Chemical compound CC(C)c(cc1)ccc1OCc1ccccc1 MVPIOKQGSNIPJF-UHFFFAOYSA-N 0.000 description 1
- UJHIOLUOUDCINT-UHFFFAOYSA-N CC(C)c(cc1)ccc1Oc1ccccc1 Chemical compound CC(C)c(cc1)ccc1Oc1ccccc1 UJHIOLUOUDCINT-UHFFFAOYSA-N 0.000 description 1
- DXVWETLMNIDMBN-UHFFFAOYSA-N CC.CC.CC.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CCl.CF Chemical compound CC.CC.CC.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CC(C)C1=CC=CC=C1.CCl.CF DXVWETLMNIDMBN-UHFFFAOYSA-N 0.000 description 1
- XIFMDLQXYJXCRM-UHFFFAOYSA-N CC1(C)OB(C2=CNN=C2)OC1(C)C.CC1=CC=C(Br)C=C1.CC1=CC=C(C2=CNN=C2)C=C1 Chemical compound CC1(C)OB(C2=CNN=C2)OC1(C)C.CC1=CC=C(Br)C=C1.CC1=CC=C(C2=CNN=C2)C=C1 XIFMDLQXYJXCRM-UHFFFAOYSA-N 0.000 description 1
- KWXCLNYHQQXRBQ-UHFFFAOYSA-N CC1=C(C=O)C=CC(Br)=C1.CC1=C(C=O)C=CC(C2=CC=CC=C2)=C1.OBOC1=CC=CC=C1 Chemical compound CC1=C(C=O)C=CC(Br)=C1.CC1=C(C=O)C=CC(C2=CC=CC=C2)=C1.OBOC1=CC=CC=C1 KWXCLNYHQQXRBQ-UHFFFAOYSA-N 0.000 description 1
- HLSFBVMVGVBXIC-UHFFFAOYSA-N CC1=CC(Br)=CC=C1C=O.CC1=CC(C2=CC=CC=C2)=CC=C1C=O.OB(O)C1=CC=CC=C1 Chemical compound CC1=CC(Br)=CC=C1C=O.CC1=CC(C2=CC=CC=C2)=CC=C1C=O.OB(O)C1=CC=CC=C1 HLSFBVMVGVBXIC-UHFFFAOYSA-N 0.000 description 1
- XGNYHERHMDSUFM-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)Cl)CC1.CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1.ClC1=CNN=C1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)Cl)CC1.CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)N2C=C(Cl)C=N2)CC1.ClC1=CNN=C1 XGNYHERHMDSUFM-UHFFFAOYSA-N 0.000 description 1
- UYMUSIMQELQNOJ-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)Cl)CC1.CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCNCC1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCN(C(=O)Cl)CC1.CC1=CC(C2=CC=CC=C2)=CC=C1CN1CCNCC1 UYMUSIMQELQNOJ-UHFFFAOYSA-N 0.000 description 1
- YTBXRORFAKNQIQ-UHFFFAOYSA-N CC1=CC(N2CCN(C(=O)Cl)CC2)=C2/C=C\C=C/C2=N1.CC1=CC(N2CCNCC2)=C2/C=C\C=C/C2=N1 Chemical compound CC1=CC(N2CCN(C(=O)Cl)CC2)=C2/C=C\C=C/C2=N1.CC1=CC(N2CCNCC2)=C2/C=C\C=C/C2=N1 YTBXRORFAKNQIQ-UHFFFAOYSA-N 0.000 description 1
- UAVZPQIUFSCTSD-UHFFFAOYSA-N CC1=CC=CC=C1C1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.CC1=CC=CC=C1C1=CNN=C1 Chemical compound CC1=CC=CC=C1C1=CN(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)N=C1.CC1=CC=CC=C1C1=CNN=C1 UAVZPQIUFSCTSD-UHFFFAOYSA-N 0.000 description 1
- WOSYVFHJOBAAOX-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=C(C4=CC=C(Cl)C=C4)C=C(Cl)C=C3)CC2)N=C1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=C(C4=CC=C(Cl)C=C4)C=C(Cl)C=C3)CC2)N=C1 WOSYVFHJOBAAOX-UHFFFAOYSA-N 0.000 description 1
- AZZCRUUWFVOKOC-UHFFFAOYSA-N CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.O=C(N1CCN(CC2=CC=C(OC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1.O=C(N1CCN(CC2=CC=C(OCC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 Chemical compound CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C(OC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C(OCC4=CC=CC=C4)C=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.CC1=CN(C(=O)N2CCN(CC3=CC=C4C=CC=CC4=C3)CC2)N=C1.O=C(N1CCN(CC2=CC=C(OC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1.O=C(N1CCN(CC2=CC=C(OCC3=CC=CC=C3)C=C2)CC1)N1C=CC=N1 AZZCRUUWFVOKOC-UHFFFAOYSA-N 0.000 description 1
- KUHIHZNOJDUDTF-UHFFFAOYSA-N CC1=CN(C(=O)NCC2=CC3=C(C=CC=C3)C=C2)N=C1 Chemical compound CC1=CN(C(=O)NCC2=CC3=C(C=CC=C3)C=C2)N=C1 KUHIHZNOJDUDTF-UHFFFAOYSA-N 0.000 description 1
- CNJTYYSAEAUODO-UHFFFAOYSA-N CC1=CN(C(=O)NCCCCC2=CC=CC=C2)N=C1 Chemical compound CC1=CN(C(=O)NCCCCC2=CC=CC=C2)N=C1 CNJTYYSAEAUODO-UHFFFAOYSA-N 0.000 description 1
- SMZOUEYKFYQMMF-UHFFFAOYSA-N CCN(CC1=C(OC)C=CC=C1)C(=O)Cl.CCN(CC1=C(OC)C=CC=C1)C(=O)N1C=C(Cl)C=N1.ClC1=CNN=C1 Chemical compound CCN(CC1=C(OC)C=CC=C1)C(=O)Cl.CCN(CC1=C(OC)C=CC=C1)C(=O)N1C=C(Cl)C=N1.ClC1=CNN=C1 SMZOUEYKFYQMMF-UHFFFAOYSA-N 0.000 description 1
- UOHZESYQUIOMJI-UHFFFAOYSA-N CCN(CC1=C(OC)C=CC=C1)C(=O)Cl.CCNCC1=C(OC)C=CC=C1 Chemical compound CCN(CC1=C(OC)C=CC=C1)C(=O)Cl.CCNCC1=C(OC)C=CC=C1 UOHZESYQUIOMJI-UHFFFAOYSA-N 0.000 description 1
- NYFKTVXXLLVYEE-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)Cl.CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C#N)C=N1.N#CC1=CNN=C1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)Cl.CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)N1C=C(C#N)C=N1.N#CC1=CNN=C1 NYFKTVXXLLVYEE-UHFFFAOYSA-N 0.000 description 1
- BQEGIHUPKNHQEY-UHFFFAOYSA-N CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)Cl.CCNCC1=CC(N2CCOCC2)=CC=C1 Chemical compound CCN(CC1=CC(N2CCOCC2)=CC=C1)C(=O)Cl.CCNCC1=CC(N2CCOCC2)=CC=C1 BQEGIHUPKNHQEY-UHFFFAOYSA-N 0.000 description 1
- GQWFTKPQIYAPNX-UHFFFAOYSA-N CCN(Cc1cc(N2CCOCC2)ccc1)C(Cl)=O Chemical compound CCN(Cc1cc(N2CCOCC2)ccc1)C(Cl)=O GQWFTKPQIYAPNX-UHFFFAOYSA-N 0.000 description 1
- QVAWQIBFZUFOPT-UHFFFAOYSA-N CCN.CCNCC1=CC(N2CCOCC2)=CC=C1.O=CC1=CC(N2CCOCC2)=CC=C1 Chemical compound CCN.CCNCC1=CC(N2CCOCC2)=CC=C1.O=CC1=CC(N2CCOCC2)=CC=C1 QVAWQIBFZUFOPT-UHFFFAOYSA-N 0.000 description 1
- GBNJZIYKVFMGJC-UHFFFAOYSA-N CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)Cl.CNCC1=CC(C2=CC=NC=C2)=CC=C1 Chemical compound CN(CC1=CC(C2=CC=NC=C2)=CC=C1)C(=O)Cl.CNCC1=CC(C2=CC=NC=C2)=CC=C1 GBNJZIYKVFMGJC-UHFFFAOYSA-N 0.000 description 1
- XKVQAYZRVDHKPH-UHFFFAOYSA-N CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C[SH](=O)=O.CNCCN(C)C[SH](=O)=O.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 Chemical compound CN(CCN(C)C(=O)N1C=C(C(F)(F)F)C=N1)C[SH](=O)=O.CNCCN(C)C[SH](=O)=O.O=C(OC1=CC=C([N+](=O)[O-])C=C1)N1C=C(C(F)(F)F)C=N1 XKVQAYZRVDHKPH-UHFFFAOYSA-N 0.000 description 1
- AOZQOMXTQSNVFM-UHFFFAOYSA-N CN(CCN(C)C(=O)OC(C)(C)C)C[SH](=O)=O.CNCCN(C)C[SH](=O)=O.O=C(O)C(F)(F)F Chemical compound CN(CCN(C)C(=O)OC(C)(C)C)C[SH](=O)=O.CNCCN(C)C[SH](=O)=O.O=C(O)C(F)(F)F AOZQOMXTQSNVFM-UHFFFAOYSA-N 0.000 description 1
- FGUQJHFJVNYXOY-UHFFFAOYSA-N C[ClH]C(N1CCCCC1)=O Chemical compound C[ClH]C(N1CCCCC1)=O FGUQJHFJVNYXOY-UHFFFAOYSA-N 0.000 description 1
- WEXUGGCDEPREAA-UHFFFAOYSA-N Cc(c(Cl)c1)ccc1C(N1CCC1)=O Chemical compound Cc(c(Cl)c1)ccc1C(N1CCC1)=O WEXUGGCDEPREAA-UHFFFAOYSA-N 0.000 description 1
- ASBAKDGUHPRHGA-UHFFFAOYSA-N Cc1c[n](C(N(C)CCN(C)S(C)(=O)=O)=O)nc1 Chemical compound Cc1c[n](C(N(C)CCN(C)S(C)(=O)=O)=O)nc1 ASBAKDGUHPRHGA-UHFFFAOYSA-N 0.000 description 1
- DAKKMPYFVSKZEA-UHFFFAOYSA-N Cc1cc(-c2ccccc2)ccc1CN1CCNCC1 Chemical compound Cc1cc(-c2ccccc2)ccc1CN1CCNCC1 DAKKMPYFVSKZEA-UHFFFAOYSA-N 0.000 description 1
- GZBQXGIVAKRSKP-UHFFFAOYSA-N ClC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1.OC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 Chemical compound ClC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1.OC(C1=CC=C2COCC2=C1)C1=CC=C2COCC2=C1 GZBQXGIVAKRSKP-UHFFFAOYSA-N 0.000 description 1
- OBPMGQPUTBHASR-UHFFFAOYSA-N ClC1=C(CN2CCNCC2)C=CC=C1.ClC1=CNN=C1.O=C(N1CCN(CC2=C(Cl)C=CC=C2)CC1)N1C=C(Cl)C=N1 Chemical compound ClC1=C(CN2CCNCC2)C=CC=C1.ClC1=CNN=C1.O=C(N1CCN(CC2=C(Cl)C=CC=C2)CC1)N1C=C(Cl)C=N1 OBPMGQPUTBHASR-UHFFFAOYSA-N 0.000 description 1
- LZSOWGUMOBKLEF-UHFFFAOYSA-N ClC1=C(N2CCNCC2)C=CC=C1.O=C(Cl)N1CCN(C2=C(Cl)C=CC=C2)CC1 Chemical compound ClC1=C(N2CCNCC2)C=CC=C1.O=C(Cl)N1CCN(C2=C(Cl)C=CC=C2)CC1 LZSOWGUMOBKLEF-UHFFFAOYSA-N 0.000 description 1
- VFEMQNCLFWLYSY-UHFFFAOYSA-N ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1.O=C(Cl)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1 Chemical compound ClC1=CC=C(C(C2=CC=C(Cl)C=C2)N2CCNCC2)C=C1.O=C(Cl)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1 VFEMQNCLFWLYSY-UHFFFAOYSA-N 0.000 description 1
- XRKKSXMLHOZHPC-UHFFFAOYSA-N ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1.O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCOCC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1 Chemical compound ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1.O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCOCC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1 XRKKSXMLHOZHPC-UHFFFAOYSA-N 0.000 description 1
- QRQQLQIFDWMJOZ-UHFFFAOYSA-N ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1.OC(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1 Chemical compound ClC1=CC=C(C(Cl)C2=CC=C(Cl)C=C2)C=C1.OC(C1=CC=C(Cl)C=C1)C1=CC=C(Cl)C=C1 QRQQLQIFDWMJOZ-UHFFFAOYSA-N 0.000 description 1
- JYAQKHQOYULDKR-UHFFFAOYSA-N ClC1=CNN=C1.O=C(Cl)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1.O=C(N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 Chemical compound ClC1=CNN=C1.O=C(Cl)N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1.O=C(N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 JYAQKHQOYULDKR-UHFFFAOYSA-N 0.000 description 1
- ANPWEASMNAFNMW-UHFFFAOYSA-N ClC1=CNN=C1.O=C(Cl)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(Cl)C=N1 Chemical compound ClC1=CNN=C1.O=C(Cl)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1.O=C(N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1)N1C=C(Cl)C=N1 ANPWEASMNAFNMW-UHFFFAOYSA-N 0.000 description 1
- BADSZRMNXWLUKO-UHFFFAOYSA-N Clc1c[nH]nc1 Chemical compound Clc1c[nH]nc1 BADSZRMNXWLUKO-UHFFFAOYSA-N 0.000 description 1
- PTLFMGDNZYQISN-UHFFFAOYSA-N Clc1ccc(C(c(cc2)ccc2Cl)N2CCNCC2)cc1 Chemical compound Clc1ccc(C(c(cc2)ccc2Cl)N2CCNCC2)cc1 PTLFMGDNZYQISN-UHFFFAOYSA-N 0.000 description 1
- XUYAFEUCKNIHEY-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(N2CCCC2)=C1CN1CCNCC1.O=C(Cl)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1 Chemical compound FC(F)(F)C1=CC=CC(N2CCCC2)=C1CN1CCNCC1.O=C(Cl)N1CCN(CC2=C(N3CCCC3)C=CC=C2C(F)(F)F)CC1 XUYAFEUCKNIHEY-UHFFFAOYSA-N 0.000 description 1
- JEDJSWXZZIHFAQ-UHFFFAOYSA-N FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCCC1.O=C(N1CCCC1)N1C=C(C(F)(F)F)C=N1 Chemical compound FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCCC1.O=C(N1CCCC1)N1C=C(C(F)(F)F)C=N1 JEDJSWXZZIHFAQ-UHFFFAOYSA-N 0.000 description 1
- UVXWILZZHCRZAK-UHFFFAOYSA-N FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(Cl)C=CC=C2)CC1.O=C(N1CCN(C2=C(Cl)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(Cl)C=CC=C2)CC1.O=C(N1CCN(C2=C(Cl)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 UVXWILZZHCRZAK-UHFFFAOYSA-N 0.000 description 1
- HECNZCCEEKRESG-UHFFFAOYSA-N FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1.O=C(N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1.O=C(N1CCN(C2=C(N3CCCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 HECNZCCEEKRESG-UHFFFAOYSA-N 0.000 description 1
- MJQVNOMEKYSCJN-UHFFFAOYSA-N FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1.O=C(N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound FC(F)(F)C1=CNN=C1.O=C(Cl)N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1.O=C(N1CCN(C2=C(N3CCOCC3)C=CC=C2)CC1)N1C=C(C(F)(F)F)C=N1 MJQVNOMEKYSCJN-UHFFFAOYSA-N 0.000 description 1
- KDEJQUNODYXYBJ-UHFFFAOYSA-N FC(c1c[nH]nc1)(F)F Chemical compound FC(c1c[nH]nc1)(F)F KDEJQUNODYXYBJ-UHFFFAOYSA-N 0.000 description 1
- VJSLCJUFGFNKRZ-UHFFFAOYSA-N N#CC1=CC=C(CN2CCOCC2)C=C1.O=CC1=CC=C(CN2CCOCC2)C=C1.[H]C Chemical compound N#CC1=CC=C(CN2CCOCC2)C=C1.O=CC1=CC=C(CN2CCOCC2)C=C1.[H]C VJSLCJUFGFNKRZ-UHFFFAOYSA-N 0.000 description 1
- UBTRCAGYJHZCKN-UHFFFAOYSA-N N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1.N#CC1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1 Chemical compound N#CC1=CN(C(=O)N2CCN(CC3=C(Cl)C=C(C(=O)N4CCCCC4)C=C3)CC2)N=C1.N#CC1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1 UBTRCAGYJHZCKN-UHFFFAOYSA-N 0.000 description 1
- NUGZBVBZIDWZAD-UHFFFAOYSA-N N#Cc1c[nH]nc1 Chemical compound N#Cc1c[nH]nc1 NUGZBVBZIDWZAD-UHFFFAOYSA-N 0.000 description 1
- MSYRKRNDELSFTF-UHFFFAOYSA-N NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.NC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 Chemical compound NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=C(Cl)C=C3)CC2)N=C1.NC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=C(Cl)C=C2)CC1 MSYRKRNDELSFTF-UHFFFAOYSA-N 0.000 description 1
- RKKDDHKRDUOFMS-UHFFFAOYSA-N NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1.NC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1 Chemical compound NC(=O)C1=CN(C(=O)N2CCN(CC3=CC=CC(OC4=CC=CC=C4)=C3)CC2)N=C1.NC(=O)C1=CNN=C1.O=C(Cl)N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1 RKKDDHKRDUOFMS-UHFFFAOYSA-N 0.000 description 1
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N NC(c1c[nH]nc1)=O Chemical compound NC(c1c[nH]nc1)=O ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 description 1
- LWBSTYIZBWPZPM-UHFFFAOYSA-N O=C(C1=CC=C(CN2CCNCC2)C(Cl)=C1)N1CCCCC1.O=C(Cl)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1 Chemical compound O=C(C1=CC=C(CN2CCNCC2)C(Cl)=C1)N1CCCCC1.O=C(Cl)N1CCN(CC2=CC=C(C(=O)N3CCCCC3)C=C2Cl)CC1 LWBSTYIZBWPZPM-UHFFFAOYSA-N 0.000 description 1
- UIJLFANUOWYKQY-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCCC1.O=C(C1=CNN=C1)N1CCCCC1.O=C(Cl)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(C(C3=CC=C(Cl)C=C3)C3=CC=C(Cl)C=C3)CC2)N=C1)N1CCCCC1.O=C(C1=CNN=C1)N1CCCCC1.O=C(Cl)N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1 UIJLFANUOWYKQY-UHFFFAOYSA-N 0.000 description 1
- KGIPAZOFMAATPG-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCOCC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1.O=CC1=CC2=C(C=C1)OCO2 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)N=C1)N1CCOCC1.O=C(C1=CN(C(=O)N2CCNCC2)N=C1)N1CCOCC1.O=CC1=CC2=C(C=C1)OCO2 KGIPAZOFMAATPG-UHFFFAOYSA-N 0.000 description 1
- KXTWBZUVGANUIX-UHFFFAOYSA-N O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1)N1CCCC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1 Chemical compound O=C(C1=CN(C(=O)N2CCN(CC3=CC=C(C4=CC=CC=C4)C=C3Cl)CC2)N=C1)N1CCCC1.O=C(C1=CNN=C1)N1CCCC1.O=C(Cl)N1CCN(CC2=CC=C(C3=CC=CC=C3)C=C2Cl)CC1 KXTWBZUVGANUIX-UHFFFAOYSA-N 0.000 description 1
- LEWRZMUKLSQQQZ-UHFFFAOYSA-N O=C(Cl)C1=CNN=C1.O=C(O)C1=CNN=C1.O=S(Cl)Cl Chemical compound O=C(Cl)C1=CNN=C1.O=C(O)C1=CNN=C1.O=S(Cl)Cl LEWRZMUKLSQQQZ-UHFFFAOYSA-N 0.000 description 1
- BLUIIHMOAIRLOF-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=C(C(F)(F)F)C=C2)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=C(C(F)(F)F)C=C2)C=N1 BLUIIHMOAIRLOF-UHFFFAOYSA-N 0.000 description 1
- JFZWWNCSMPWAMY-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 JFZWWNCSMPWAMY-UHFFFAOYSA-N 0.000 description 1
- GMODYTASSABEHF-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(Cl)C=N1 GMODYTASSABEHF-UHFFFAOYSA-N 0.000 description 1
- CRLGSUSPECIANH-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(F)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C2=CC=C(Cl)C=C2)CC1)N1C=C(F)C=N1 CRLGSUSPECIANH-UHFFFAOYSA-N 0.000 description 1
- RGWPNGAUBUHVCH-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C(Cl)C=C2)N2CCOCC2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C(Cl)C=C2)N2CCOCC2)CC1)N1C=C(Cl)C=N1 RGWPNGAUBUHVCH-UHFFFAOYSA-N 0.000 description 1
- LRNFUGKOUDFNKH-UHFFFAOYSA-N O=C(N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(C(C2=CC=C3COCC3=C2)C2=CC=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 LRNFUGKOUDFNKH-UHFFFAOYSA-N 0.000 description 1
- VIGZGZCEXVBOQN-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C(F)(F)F)C=N1 VIGZGZCEXVBOQN-UHFFFAOYSA-N 0.000 description 1
- VTNUQWUARUVORZ-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C2=CC=C(C(F)(F)F)C=C2)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C2=CC=C(C(F)(F)F)C=C2)C=N1 VTNUQWUARUVORZ-UHFFFAOYSA-N 0.000 description 1
- HUPBNBQHZQANRR-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(C2=CC=CC=C2)C=N1 HUPBNBQHZQANRR-UHFFFAOYSA-N 0.000 description 1
- AAPRSQYSBGKMRO-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(F)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C(Cl)C=C3)C=C(Cl)C=C2)CC1)N1C=C(F)C=N1 AAPRSQYSBGKMRO-UHFFFAOYSA-N 0.000 description 1
- FDOXUHRRYAVKIQ-UHFFFAOYSA-N O=C(N1CCN(CC2=C(C3=CC=C4CCOC4=C3)C=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=C(C3=CC=C4CCOC4=C3)C=C3COCC3=C2)CC1)N1C=C(Cl)C=N1 FDOXUHRRYAVKIQ-UHFFFAOYSA-N 0.000 description 1
- VEBILNIVCRAQNH-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(CN3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1.O=C(N1CCNCC1)N1C=C(Cl)C=N1.O=CC1=CC=C(CN2CCOCC2)C=C1 Chemical compound O=C(N1CCN(CC2=CC=C(CN3CCOCC3)C=C2)CC1)N1C=C(Cl)C=N1.O=C(N1CCNCC1)N1C=C(Cl)C=N1.O=CC1=CC=C(CN2CCOCC2)C=C1 VEBILNIVCRAQNH-UHFFFAOYSA-N 0.000 description 1
- YVWJCSZSECBXQS-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(Cl)C(Cl)=C2)CC1)N1C=C(Cl)C=N1.O=C(N1CCNCC1)N1C=C(Cl)C=N1.O=CC1=CC=C(Cl)C(Cl)=C1 Chemical compound O=C(N1CCN(CC2=CC=C(Cl)C(Cl)=C2)CC1)N1C=C(Cl)C=N1.O=C(N1CCNCC1)N1C=C(Cl)C=N1.O=CC1=CC=C(Cl)C(Cl)=C1 YVWJCSZSECBXQS-UHFFFAOYSA-N 0.000 description 1
- NMUHWSBUKWYQDL-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=C(Cl)C=C2N2CCOCC2)CC1)N1C=C(Cl)C=N1 Chemical compound O=C(N1CCN(CC2=CC=C(Cl)C=C2N2CCOCC2)CC1)N1C=C(Cl)C=N1 NMUHWSBUKWYQDL-UHFFFAOYSA-N 0.000 description 1
- WOSQIJGYYJSCAS-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC(Cl)=C2)CC1)N1C=C(C(F)(F)F)C=N1.O=C(N1CCNCC1)N1C=C(C(F)(F)F)C=N1.O=CC1=CC=CC(Cl)=C1 Chemical compound O=C(N1CCN(CC2=CC=CC(Cl)=C2)CC1)N1C=C(C(F)(F)F)C=N1.O=C(N1CCNCC1)N1C=C(C(F)(F)F)C=N1.O=CC1=CC=CC(Cl)=C1 WOSQIJGYYJSCAS-UHFFFAOYSA-N 0.000 description 1
- AWDCQTMJSBTIJK-UHFFFAOYSA-N O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=CC=N1.O=C(N1CCNCC1)N1C=CC=N1 Chemical compound O=C(N1CCN(CC2=CC=CC=C2)CC1)N1C=CC=N1.O=C(N1CCNCC1)N1C=CC=N1 AWDCQTMJSBTIJK-UHFFFAOYSA-N 0.000 description 1
- OJCWHAUBHLREMV-UHFFFAOYSA-N O=C(N1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1)Cl Chemical compound O=C(N1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1)Cl OJCWHAUBHLREMV-UHFFFAOYSA-N 0.000 description 1
- BAKQCRJCLDKMLV-UHFFFAOYSA-N O=C([n]1ncc(-c2ccc(C(F)(F)F)cc2)c1)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1 Chemical compound O=C([n]1ncc(-c2ccc(C(F)(F)F)cc2)c1)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1 BAKQCRJCLDKMLV-UHFFFAOYSA-N 0.000 description 1
- GAZXWOZVOPSJON-UHFFFAOYSA-N O=C(c1ccc(CN(CC2)CCN2C(Cl)=O)c(Cl)c1)N1CCCCC1 Chemical compound O=C(c1ccc(CN(CC2)CCN2C(Cl)=O)c(Cl)c1)N1CCCCC1 GAZXWOZVOPSJON-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N O=Cc1cc(Cl)ccc1 Chemical compound O=Cc1cc(Cl)ccc1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N OC(c1c[nH]nc1)=O Chemical compound OC(c1c[nH]nc1)=O IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1OC(Cl)=O)=O Chemical compound [O-][N+](c(cc1)ccc1OC(Cl)=O)=O NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- BMUXIJGUNSIXIX-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1OC([n]1ncc(C(F)(F)F)c1)=O)=O Chemical compound [O-][N+](c(cc1)ccc1OC([n]1ncc(C(F)(F)F)c1)=O)=O BMUXIJGUNSIXIX-UHFFFAOYSA-N 0.000 description 1
- GPGKNEKFDGOXPO-UHFFFAOYSA-N c([nH]nc1)c1-c1ccccc1 Chemical compound c([nH]nc1)c1-c1ccccc1 GPGKNEKFDGOXPO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- Monoacylglycerol lipase is an enzyme responsible for hydrolyzing endocannabinoids such as 2-AG (2-arachidonoylglycerol), an arachidonate based lipid, in the nervous system.
- the serine hydrolase ⁇ - ⁇ -hydrolase domain 6 (ABHD6) is another lipid mediator.
- Fatty acid amide hydrolase (FAAH) is another enzyme responsible for hydrolyzing endocannabinoids such as anandamide.
- This disclosure provides, for example, compounds and compositions which are modulators of one or more of MAGL, ABHD6, and FAAH, and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active ingredient.
- the disclosure also provides for the use of disclosed compounds as medicaments and/or in the manufacture of medicaments for the inhibition of one or more of MAGL, ABHD6, and FAAH activity in warm-blooded animals such as humans.
- One embodiment provides a compound of Formula (I):
- Another embodiment provides a compound of Formula (Ia):
- Another embodiment provides a compound of Formula (II):
- Another embodiment provides a compound of Formula (III):
- Another embodiment provides a compound of Formula (IIIa):
- Another embodiment provides a compound of Formula (IV):
- Another embodiment provides a compound of Formula (IVa):
- Another embodiment provides a compound of Formula (V):
- Another embodiment provides a compound of Formula (Va):
- Another embodiment provides a compound of Formula (VI):
- Another embodiment provides a compound of Formula (VIa):
- Another embodiment provides a compound of Formula (VII):
- Another embodiment provides a compound of Formula (VIIa):
- Another embodiment provides a compound of Formula (VIII):
- Another embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a pyrazole compound described herein, or a solvate, hydrate, tautomer, N-oxide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
- Another embodiment provides a method of treating a disorder selected from the group consisting of a solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, and an infection, comprising administering a therapeutically effective amount of a pyrazole compound described herein to a patient in need thereof.
- the disorder is a solid tumor cancer.
- the disorder is obesity.
- the disorder is Down's syndrome or Alzheimer's disease.
- the disorder is an infection by a bacterium, fungus, parasite, or virus.
- Another embodiment provides a method of treating a disorder selected from the group consisting of a solid tumor cancer, obesity, Down's syndrome, Alzheimer's disease, and inflammation, comprising administering a therapeutically effective amount of a pyrazole compound described herein to a patient in need thereof.
- the disorder is a solid tumor cancer.
- the disorder is obesity.
- the disorder is Down's syndrome or Alzheimer's disease.
- the disorder is inflammation.
- Another embodiment provides a method of treating pain in a patient, comprising administering a therapeutically effective amount of a pyrazole compound described herein to a patient in need thereof to treat said pain.
- Another embodiment provides a method of reducing the amount of adipose tissue in a patient, comprising administering an effective amount of a pyrazole compound described herein to a patient in need thereof to reduce the amount of adipose tissue in the patient.
- Another embodiment provides a method of treating inflammation in a patient, comprising administering a therapeutically effective amount of a pyrazole compound described herein to a patient in need thereof to treat said inflammation.
- This disclosure is directed, at least in part, to modulators or inhibitors of one or more of MAGL, ABHD6, and FAAH.
- modulators or inhibitors of one or more of MAGL, ABHD6, and FAAH are provided herein.
- compounds capable of inhibiting one or more of MAGL, ABHD6, and FAAH are provided herein.
- Amino refers to the —NH 2 radical.
- Niro refers to the —NO 2 radical.
- Oxa refers to the —O— radical.
- Oxo refers to the ⁇ O radical.
- Thioxo refers to the ⁇ S radical.
- Oximo refers to the ⁇ N—OH radical.
- Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C 1 -C 15 alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C 1 -C 13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., C 1 -C 8 alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., C 1 -C 5 alkyl).
- an alkyl comprises one to four carbon atoms (e.g., C 1 -C 4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C 1 -C 3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C 1 -C 2 alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., C 1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C 5 -C 15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C 5 -C 8 alkyl).
- an alkyl comprises two to five carbon atoms (e.g., C 2 -C 5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C 3 -C 5 alkyl).
- the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl).
- alkyl is attached to the rest of the molecule by a single bond.
- an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R f , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR f , —OC(O)—NR a R f , —N(R a )C(O)R f , —N(R a )S(O) t R f (where t is 1 or 2), —S(O) t OR a (where t is 1 or 2),
- Alkoxy refers to a radical bonded through an oxygen atom of the formula —O-alkyl, where alkyl is an alkyl chain as defined above.
- Alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.
- an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R f , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR f , —OC(O)—NR a R f , —N(R a )C(O)R f , —N(R a )S(O) t R f (where t is 1 or 2), —S(O) t OR a (where t is 1 or 2), —S(O) t R f (where t is 1 or 2),
- Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to four carbon atoms. The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
- an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R f , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR f , —OC(O)—NR a R f , —N(R a )C(O)R f , —N(R a )S(O) t R f (where t is 1 or 2), —S(O) t OR a (where t is 1 or 2), —S(O) t R f
- Alkylene or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
- the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
- the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain.
- an alkylene comprises one to eight carbon atoms (e.g., C 1 -C 8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C 1 -C 5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C 1 -C 4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C 1 -C 3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C 1 -C 2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C 1 alkylene).
- an alkylene comprises five to eight carbon atoms (e.g., C 5 -C 8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C 2 -C 5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C 3 -C 5 alkylene).
- an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, —OR a , —SR a , —OC(O)—R f , —N(R a ) 2 , —C(O)R a , —C(O)OR a , —C(O)N(R a ) 2 , —N(R a )C(O)OR f , —OC(O)—NR a R f , —N(R a )C(O)R f , —N(R a )S(O) t R f (where t is 1 or 2), —S(O) t OR a (where t is 1 or 2), —S(O) t R f (where t is 1 or 2),
- Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
- the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hückel theory.
- the ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
- aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R b —OR a , —R b —OC(O)—R a , —R b —OC(O)—OR a , —R b —OC(O)—N(R
- Aryloxy refers to a radical bonded through an oxygen atom of the formula —O-aryl, where aryl is as defined above.
- Alkyl refers to a radical of the formula —R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
- the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
- the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
- Alkyloxy refers to a radical bonded through an oxygen atom of the formula —O— aralkyl, where aralkyl is as defined above.
- Alkenyl refers to a radical of the formula —R d -aryl where R d is an alkenylene chain as defined above.
- the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
- the alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
- Alkynyl refers to a radical of the formula —R c -aryl, where R c is an alkynylene chain as defined above.
- the aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group.
- the alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
- Carbocyclyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms.
- a carbocyclyl comprises three to ten carbon atoms.
- a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond.
- Carbocyclyl are saturated, (i.e., containing single C—C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.)
- a fully saturated carbocyclyl radical is also referred to as “cycloalkyl.”
- monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- a cycloalkyl comprises three to eight carbon atoms (e.g., C 3 -C 8 cycloalkyl).
- a cycloalkyl comprises three to seven carbon atoms (e.g., C 3 -C 7 cycloalkyl). In other embodiments, a cycloalkyl comprises three to six carbon atoms (e.g., C 3 -C 6 cycloalkyl). In other embodiments, a cycloalkyl comprises three to five carbon atoms (e.g., C 3 -C 5 cycloalkyl). In other embodiments, a cycloalkyl comprises three to four carbon atoms (e.g., C 3 -C 4 cycloalkyl).
- An unsaturated carbocyclyl is also referred to as “cycloalkenyl.”
- Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
- Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
- carbocyclyl is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R b —OR a , —R b —OC(O)—R a , —R b —OC(O)—OR a , —R b —OC(O)—N(R
- Carbocyclylalkyl refers to a radical of the formula —R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
- Halo or “halogen” refers to bromo, chloro, fluoro or iodo substituents.
- Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.
- Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- the alkyl part of the fluoroalkyl radical are optionally substituted as defined above for an alkyl group.
- Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which include fused or bridged ring systems. The heteroatoms in the heterocyclyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. In some embodiments, the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s).
- heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thio
- heterocyclyl is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R b —OR a , —R b —OC(O)—R a , —R b —OC(O)—OR a , —R b —OC(O)—N(
- Heterocyclylalkyl refers to a radical of the formula —R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain.
- the heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
- Heterocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula —O—R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain.
- the heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
- Heteroaryl refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
- the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) ⁇ -electron system in accordance with the Hückel theory.
- Heteroaryl includes fused or bridged ring systems.
- the heteroatom(s) in the heteroaryl radical is optionally oxidized.
- heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
- heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothienyl (benzothion
- heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R b —OR a , —R b —OC(O)—R a , —R b —OC(O)—R a , —R b —OC(O)—R
- N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
- An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
- C-heteroaryl refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical.
- a C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
- Heteroaryloxy refers to radical bonded through an oxygen atom of the formula —O— heteroaryl, where heteroaryl is as defined above.
- Heteroarylalkyl refers to a radical of the formula —R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
- Heteroarylalkoxy refers to a radical bonded through an oxygen atom of the formula —O—R c -heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
- the alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain.
- the heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
- the compounds disclosed herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
- geometric isomer refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond.
- positional isomer refers to structural isomers around a central ring, such as ortho-, meta-, and para-isomers around a benzene ring.
- a “tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
- the compounds presented herein exist as tautomers.
- a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH.
- Optional or “optionally” means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not.
- optionally substituted aryl means that the aryl radical are or are not substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
- “Pharmaceutically acceptable salt” includes both acid and base addition salts.
- a pharmaceutically acceptable salt of any one of the pyrazole compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
- Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
- acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
- salts of amino acids such as arginates, gluconates, and galacturonates (see, for example, Berge S. M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997).
- Acid addition salts of basic compounds are prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt.
- “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al
- treatment or “treating” or “palliating” or “ameliorating” are used interchangeably herein. These terms refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder.
- the compositions are administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
- Prodrug is meant to indicate a compound that is converted under physiological conditions or by solvolysis to a biologically active compound described herein.
- the term “prodrug” refers to a precursor of a biologically active compound that is pharmaceutically acceptable.
- the prodrug is inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis.
- the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
- prodrugs as Novel Delivery Systems
- A.C.S. Symposium Series Vol. 14
- Bioreversible Carriers in Drug Design ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- prodrug is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject.
- prodrugs of an active compound, as described herein are prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
- Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amine functional groups in the active compounds and the like.
- Pyrazole compounds are described herein which are modulators of one or more of MAGL, ABHD6, and FAAH.
- the compounds are modulators of MAGL.
- the compounds are modulators of ABHD6.
- the compounds are modulators of FAAH.
- the compounds are modulators of MAGL and ABHD6.
- the compounds are modulators of MAGL and FAAH.
- the compounds are modulators of ABHD6 and FAAH.
- the compounds are modulators of MAGL, ABHD6, and FAAH.
- One embodiment provides a compound of Formula (I):
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H, C 1-4 alkyl, or C 3-8 cycloalkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H or C 1-4 alkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H or C 3-8 cycloalkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O.
- R 1 s is a compound of Formula (I), wherein R 1 s
- n 1, 2, 3, 4, or 5.
- R 1 is
- n 1, 2, 3, 4, or 5.
- R 1 is a compound of Formula (I), wherein R 1 is
- R 1 is —CO 2 R 5 .
- R 5 is H.
- R 5 is C 1-4 alkyl.
- R 1 is —CO 2 Me.
- R 8 and R 9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R 10 is H, —CF 3 , or halo.
- R 10 is —CF 3 .
- R 10 is halo.
- R 10 is chloro.
- R 8 and R 9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine.
- R 2 is optionally substituted heteroaryl.
- R 2 is optionally substituted pyrazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl, or optionally substituted pyridinyl.
- R 2 is optionally substituted pyrazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl, or optionally substituted pyridinyl.
- R 2 is
- R 2 is optionally substituted C 3-8 cycloalkyl.
- R 1 is —C(O)NR 6 R 7 .
- R 2 is optionally substituted C 3-8 cycloalkyl and R 1 is H, —CF 3 , C 1-4 alkyl, cyano, or halo.
- R 2 is optionally substituted C 3-8 cycloalkyl and R 1 is H.
- R 2 is optionally substituted C 3-8 cycloalkyl and R 1 is —CF 3 or halo.
- R 2 is optionally substituted C 3-8 cycloalkyl and R 1 is C 1-4 alkyl.
- R 2 is optionally substituted C 3-8 cycloalkyl and R 1 is cyano.
- Another embodiment provides a compound of Formula (II):
- R 2 is optionally substituted aryl.
- R 1 is,
- R 2 is bisubstituted or monosubstituted phenyl.
- R 1 is,
- R 2 is bisubstituted or monosubstituted phenyl; and R 4 is H.
- R 1 is,
- R 2 is bisubstituted or monosubstituted phenyl; and R 4 is optionally substituted phenyl.
- R 1 is,
- R 2 is optionally substituted heteroaryl.
- R 1 is —CF 3 and R 2 is optionally substituted aryl.
- a compound of Formula (II), wherein R 1 is —CF 3 and R 2 is bisubstituted or monosubstituted phenyl.
- a compound of Formula (II), wherein R 1 is —CF 3 and R 2 is optionally substituted heteroaryl.
- R 8 and R 9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R 10 is H, —CF 3 , or halo.
- R 10 is —CF 3 .
- R 10 is halo.
- R 10 is chloro.
- R 8 and R 9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine.
- R 2 is optionally substituted heteroaryl.
- R 2 is optionally substituted pyrazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl, or optionally substituted pyridinyl.
- a compound of Formula (II), wherein R 4 is H.
- R 4 is a compound of Formula (II), wherein R 4 is monosubstituted phenyl.
- Another embodiment provides a compound of Formula (III):
- R 1 is halo.
- R 1 is a compound of Formula (III), wherein R 1 is iodo or bromo.
- R 1 is iodo.
- R 1 is a compound of Formula (III), wherein R 1 is bromo.
- R 1 is fluoro or chloro.
- R 1 is fluoro.
- R 1 is chloro.
- R 1 is cyano.
- R 2 is optionally substituted phenyl or optionally substituted naphthyl.
- R 2 is optionally substituted phenyl.
- R 2 is monosubstituted phenyl.
- R 2 is bisubstituted phenyl.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, haloalkyl, (heterocyclyl)alkyl, alkoxy, aryloxy, aralkyloxy, halo, —C(O)NR a R b , and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S, or O.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, haloalkyl, (heterocyclyl)alkyl, alkoxy, phenyloxy, benzyloxy, halo, —C(O)NR a R b , and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O.
- R 2 is optionally substituted naphthyl.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, haloalkyl, (heterocyclyl)alkyl, alkoxy, phenyloxy, benzyloxy, halo, —C(
- Another embodiment provides a compound of Formula (IV):
- n is 1. In another embodiment is a compound of Formula (IV), wherein n is 2.
- a compound of Formula (IV) wherein R 3 is C 1-4 alkyl or optionally substituted phenyl. In another embodiment is a compound of Formula (IV), wherein R 3 is C 1-4 alkyl. In another embodiment is a compound of Formula (IV), wherein R 3 is optionally substituted phenyl.
- R 1 is H, C 1-4 alkyl, halo, CF 3 , optionally substituted phenyl, or cyano.
- R 1 is H, C 1-4 alkyl, halo, CF 3 , or cyano.
- R 1 is optionally substituted aryl.
- R 1 is optionally substituted phenyl.
- R 1 is monosubstituted phenyl.
- R 1 is bisubstituted phenyl.
- R 2 is CO 2 (t-Bu), C 1-4 alkyl, —C(O)R 3 , —SO 2 R 3 , optionally substituted phenyl, or optionally substituted heteroaryl.
- R 2 is —C(O)R 3 or —SO 2 R 3 .
- R 2 is C 1-4 alkyl.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, alkoxy, halo, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S, or O.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, alkoxy, halo, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O.
- R 1 is H, C 1-4 alkyl, halo, CF 3 , or cyano; and R 2 is —C(O)R 3 or —SO 2 R 3 .
- R 1 is H, C 1-4 alkyl, halo, CF 3 , or cyano; and R 2 is C 1-4 alkyl.
- R 1 is H, C 1-4 alkyl, halo, CF 3 , or cyano
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, alkoxy, halo, and NR a R b
- R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S, or O.
- R 1 is optionally substituted phenyl; and R 2 is —C(O)R 3 or —SO 2 R 3 .
- R 1 is optionally substituted phenyl; and R 2 is C 1-4 alkyl.
- R 1 is optionally substituted phenyl
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, alkoxy, halo, and NR a R b
- R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S, or O.
- Another embodiment provides a compound of Formula (V):
- R 1 is halo. In another embodiment is a compound of Formula (V), wherein R 1 is cyano. In another embodiment is a compound of Formula (V), wherein R 1 is CF 3 . In another embodiment is a compound of Formula (V), wherein R 1 is optionally substituted phenyl. In another embodiment is a compound of Formula (V), wherein R 1 is monosubstituted or bisubstituted phenyl. In another embodiment is a compound of Formula (V), wherein R 1 is monosubstituted phenyl. In another embodiment is a compound of Formula (V), wherein R 1 is bisubstituted phenyl. In another embodiment is a compound of Formula (V), wherein R 1 is chloro,
- Another embodiment provides a compound of Formula (VI):
- R 1 is H, C 1-4 alkyl, or cyano.
- R 1 is a compound of Formula (VI), wherein R 1 is methyl.
- R 1 is CF 3 .
- R 1 is chloro.
- R 1 is chloro or fluoro.
- R 1 is optionally substituted phenyl.
- R 1 is monosubstituted phenyl.
- R 1 is bisubstituted phenyl.
- a compound of Formula (VI), wherein Y is O; and R 1 is H, C 1-4 alkyl, or cyano.
- a compound of Formula (VI), wherein Y is O; and R 1 is methyl.
- a compound of Formula (VI), wherein Y is O; and R 1 is CF 3 .
- a compound of Formula (VI), wherein Y is O; and R 1 is chloro.
- Y is CH 2 ; and R 1 is chloro or fluoro.
- Another embodiment provides a compound of Formula (VII):
- a compound of Formula (VII) wherein R 1 is H, C 1-4 alkyl, cyano, CF 3 , halo, or —CO 2 R 4 .
- R 1 is H, C 1-4 alkyl, cyano, CF 3 , or halo.
- R 1 is chloro, iodo, bromo, CF 3 , methyl, —CO 2 Me, or phenyl.
- a compound of Formula (VII), wherein R 1 is halo.
- a compound of Formula (VII), wherein R 1 is iodo or bromo.
- a compound of Formula (VII), wherein R 1 is iodo.
- a compound of Formula (VII), wherein R 1 is bromo.
- a compound of Formula (VII), wherein R 1 is fluoro or chloro.
- R 2 is optionally substituted phenyl.
- R 2 is phenyl.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, CF 3 , halo, (cycloalkyl)alkyl, (heterocyclyl)alkyl, alkoxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted aryl, optionally substituted heteroaryl, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S or O.
- R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, halo, alkoxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted heteroaryl, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S or O.
- a compound of Formula (VII) wherein R 2 is —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 , or —NR 5 R 6 .
- R 2 is —NR 5 C(O)R 6 .
- R 2 is —NR 5 SO 2 R 6 .
- a compound of Formula (VII) wherein R 2 is —NR 5 R 6 .
- a compound of Formula (VII), wherein R 3 is H. In another embodiment is a compound of Formula (VII), wherein R 3 is C 1-4 alkyl. In another embodiment is a compound of Formula (VII), wherein R 3 is ethyl or methyl. In another embodiment is a compound of Formula (VII), wherein R 3 is methyl. In another embodiment is a compound of Formula (VII), wherein R 3 is ethyl.
- R 6 is C 1-4 alkyl.
- R 6 is optionally substituted phenyl or optionally substituted benzyl.
- R 6 is optionally substituted phenyl.
- R 6 is optionally substituted benzyl.
- n is 2.
- R 2 is —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 , or —NR 5 R 6 .
- n is 2; R 1 is H, C 1-4 alkyl, cyano, CF 3 , or halo; and R 2 is —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 , or —NR 5 R 6 .
- n 2; R 1 is optionally substituted phenyl; and R 2 is —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 , or —NR 5 R 6 .
- n is 1.
- R 2 is monosubstituted phenyl.
- n is 1; and R 2 is bisubstituted phenyl.
- n is 1; and R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, CF 3 , halo, (cycloalkyl)alkyl, (heterocyclyl)alkyl, alkoxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted aryl, optionally substituted heteroaryl, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S or O.
- n is 1; and R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, halo, alkoxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted heteroaryl, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S or O.
- n is 1; R 1 is optionally substituted phenyl; and R 2 is phenyl substituted with one or more substituents selected from the group consisting of C 1-4 alkyl, halo, alkoxy, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted heteroaryl, and NR a R b ; and R a and R b are independently selected from C 1-4 alkyl or R a and R b together with the nitrogen to which they are attached form an optionally substituted 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from N, S or O.
- n is 1; R 1 is H, C 1-4 alkyl, cyano, CF 3 , or halo; and R 2 is monosubstituted phenyl.
- n is 1; R 1 is optionally substituted phenyl; and R 2 is monosubstituted phenyl.
- n is 1; R 1 is H, C 1-4 alkyl, cyano, CF 3 , or halo; and R 2 is bisubstituted phenyl.
- n is 1; R 1 is optionally substituted phenyl; and R 2 is bisubstituted phenyl.
- Another embodiment provides a compound of Formula (VIII):
- R 2 is —C(O)R 3 , —SO 2 R 3 , optionally substituted benzyl, or C 1-4 alkyl.
- R 2 is —C(O)R 3 or —SO 2 R 3 .
- R 2 is —C(O)R 3 .
- R 2 is —SO 2 R 3 .
- R 2 is optionally substituted aralkyl.
- a compound of Formula (VIII) wherein Y is NR 2 ; and R 2 is —C(O)R 3 , —SO 2 R 3 , optionally substituted benzyl, or C 1-4 alkyl.
- a compound of Formula (VIII) wherein Y is NR 2 ; and R 2 is —C(O)R 3 or —SO 2 R 3 .
- a compound of Formula (VIII) wherein Y is NR 2 ; and R 2 is —C(O)R 3 .
- a compound of Formula (VIII) wherein Y is NR 2 ; and R 2 is optionally substituted aralkyl.
- Another embodiment provides a compound of Formula (Ia):
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H, C 1-4 alkyl, or C 3-8 cycloalkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H or C 1-4 alkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 are each independently H or C 3-8 cycloalkyl.
- R 1 is —C(O)NR 6 R 7 ; and R 6 and R 7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O.
- R 1 s is a compound of Formula (Ia), wherein R 1 s
- n 1, 2, 3, 4, or 5.
- R 1 is
- n 1, 2, 3, 4, or 5.
- R 1 is
- R 8 and R 9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R 10 is H, —CF 3 , or halo.
- R 10 is —CF 3 .
- R 10 is halo.
- R 10 is chloro.
- R 8 and R 9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine.
- R 2 is optionally substituted pyrazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl, or optionally substituted pyridinyl.
- R 2 is optionally substituted pyrazolyl, optionally substituted pyrimidinyl, optionally substituted thiazolyl, or optionally substituted pyridinyl.
- R 2 is
- Another embodiment provides a compound of Formula (IIIa):
- Another embodiment provides a compound of Formula (IVa):
- n is 1. In another embodiment is a compound of Formula (IVa), wherein n is 2.
- Another embodiment provides a compound of Formula (Va):
- Another embodiment provides a compound of Formula (VIa):
- Another embodiment provides a compound of Formula (VIIa):
- the compound disclosed herein has the structure provided in Table 1.
- the compounds used in the reactions described herein are made according to organic synthesis techniques, starting from commercially available chemicals and/or from compounds described in the chemical literature. “Commercially available chemicals” are obtained from standard commercial sources including Acros Organics (Geel, Belgium), Aldrich Chemical (Milwaukee, Wis., including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Ark Pharm, Inc. (Libertyville, Ill.), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, Pa.), Combi-blocks (San Diego, Calif.), Crescent Chemical Co.
- Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J.
- the pyrazole compounds are prepared by the general synthetic routes described below in Schemes 1-7, wherein R 1 is as defined herein, and Q 1 , Q 2 , and Q 3 are defined such that compounds of formula (D), formula (H), and formula (T) are compounds of Formulas (I), (Ia), (II), (III), (IIIa), (IV), (IVa), (V), (Va), (VI), (VIa), (VII), (VIIa), or (VIII).
- a method for preparing compounds of formula D is provided in Scheme 1. Reaction of a pyrazole of formula A with phosgene or triphosgene affords intermediate B. Coupling with an amine of formula C leads to a pyrazole compound of formula D.
- a method of preparing compounds of formula H is provided in Scheme 3.
- Compounds of formula F are prepared using routes similar to Schemes 1 or 2. Removal of the Boc protecting group under acidic conditions, using a reagent such as HCl or trifluoroacetic acid, provides intermediate G. Subsequent alkylation or reductive amination affords a pyrazole compound of formula H.
- a method of preparing intermediates L is provided in Scheme 4.
- Compound J is reacted with the appropriate alkylating reagent or undergoes reductive amination to provide intermediate K.
- Intermediate compound L is used subsequently as a compound of formula C in Schemes 1 or 2.
- a method of preparing intermediates Q is provided in scheme 6.
- Compound N is reacted with the appropriate alkylating reagent to provide intermediate P.
- Intermediate compound Q is used subsequently as a compound of formula C in Scheme 5.
- a method of preparing compounds of formula T is provided in Scheme 7.
- Compounds of formula R are prepared using routes similar to Schemes 1 and 2. Removal of the Boc protecting group under acidic conditions, using a reagent such as HCl or trifluoroacetic acid, provides intermediate S. Subsequent alkylation or reductive amination affords a pyrazole compound of formula T.
- the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti,
- Z isomers as well as the corresponding mixtures thereof. In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration, or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
- the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomers.
- dissociable complexes are preferred (e.g., crystalline diastereomeric salts).
- the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
- the compounds described herein exist in their isotopically-labeled forms.
- the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds.
- the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions.
- the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that are incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chloride, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- Compounds described herein, and the metabolites, pharmaceutically acceptable salts, esters, prodrugs, solvate, hydrates or derivatives thereof which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
- isotopically-labeled compounds for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i. e., 3 H and carbon-14, i. e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e., 2 H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
- the isotopically labeled compounds, pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof is prepared by any suitable method.
- the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
- the compounds described herein exist as their pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- the compounds described herein possess acidic or basic groups and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- these salts are prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- the compounds described herein exist as solvates.
- the invention provides for methods of treating diseases by administering such solvates.
- the invention further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and, in some embodiments, are formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents including, but not limited to, dioxane, tetrahydrofuran or methanol.
- the compounds provided herein exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- the compounds described herein exist in prodrug form.
- the invention provides for methods of treating diseases by administering such prodrugs.
- the invention further provides for methods of treating diseases by administering such prodrugs as pharmaceutical compositions.
- prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention.
- the amino acid residues include but are not limited to the 20 naturally occurring amino acids and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone.
- prodrugs include compounds wherein a nucleic acid residue, or an oligonucleotide of two or more (e.g., two, three or four) nucleic acid residues is covalently joined to a compound of the present invention.
- prodrugs of the compounds described herein also include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, metal salts and sulfonate esters.
- compounds having free amino, amido, hydroxy or carboxylic groups are converted into prodrugs.
- free carboxyl groups are derivatized as amides or alkyl esters.
- all of these prodrug moieties incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
- Hydroxy prodrugs include esters, such as though not limited to, acyloxyalkyl (e.g. acyloxymethyl, acyloxyethyl) esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, phosphate esters, sulfonate esters, sulfate esters and disulfide containing esters; ethers, amides, carbamates, hemisuccinates, dimethylaminoacetates and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews 1996, 19, 115.
- esters such as though not limited to, acyloxyalkyl (e.g. acyloxymethyl, acyloxyethyl) esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, phosphate esters, sulfonate esters, sulfate esters and disulfide containing esters;
- Amine derived prodrugs include, but are not limited to the following groups and combinations of groups:
- sites on any aromatic ring portions are susceptible to various metabolic reactions, therefore incorporation of appropriate substituents on the aromatic ring structures, reduce, minimize or eliminate this metabolic pathway.
- pyrazole compounds described herein are susceptible to various metabolic reactions. Therefore, in some embodiments, incorporation of appropriate substituents into the structure will reduce, minimize, or eliminate a metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of an aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group.
- pyrazole compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.
- the pyrazole compound as described herein is administered as a pure chemical.
- the pyrazole compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, Pa. (2005)).
- a pharmaceutical composition comprising at least one pyrazole compound described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers.
- the carrier(s) or excipient(s) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (III), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (IIIa), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (IV), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (IVa), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (V), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (Va), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (VI), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (VIa), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (VII), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (VIIa), or a pharmaceutically acceptable salt thereof.
- One embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula (VIII), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (III), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (IV), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (V), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (VI), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (VII), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (VIII), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (IIIa), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (IVa), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (Va), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (VIa), or a pharmaceutically acceptable salt thereof.
- Another embodiment provides a pharmaceutical composition consisting essentially of a pharmaceutically acceptable carrier and a compound of Formula (VIIa), or a pharmaceutically acceptable salt thereof.
- the pyrazole compound as described herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
- compositions include those suitable for oral, rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) rectal, vaginal, or aerosol administration, although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular compound being used.
- parenteral e.g., subcutaneous, intramuscular, intradermal, or intravenous rectal, vaginal, or aerosol administration
- disclosed compositions are formulated as a unit dose, and/or are formulated for oral or subcutaneous administration.
- Exemplary pharmaceutical compositions are used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which includes one or more of a disclosed compound, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
- the active ingredient is compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
- the active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
- the principal active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a disclosed compound or a non-toxic pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalc
- the subject composition is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as crospovidone, croscarmellose sodium, sodium starch glycolate, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding
- fillers or extenders such as starches, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose
- compositions comprise buffering agents.
- solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet is made by compression or molding, optionally with one or more accessory ingredients.
- compressed tablets are prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- molded tablets are made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent.
- tablets, and other solid dosage forms, such as dragees, capsules, pills and granules are scored or prepared with coatings and shells, such as enteric coatings and other coatings.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms contain inert diluents, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, cyclodextrins and mixtures thereof.
- inert diluents such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl be
- suspensions in addition to the subject composition, contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- formulations for rectal or vaginal administration are presented as a suppository, which are prepared by mixing a subject composition with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- suitable non-irritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the body cavity and release the active agent.
- Dosage forms for transdermal administration of a subject composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active component is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants as required.
- the ointments, pastes, creams and gels contain, in addition to a subject composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- powders and sprays contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- sprays additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- compositions and compounds disclosed herein alternatively are administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound.
- a non-aqueous (e.g., fluorocarbon propellant) suspension is used.
- sonic nebulizers are used because they minimize exposing the agent to shear, which results in degradation of the compounds contained in the subject compositions.
- an aqueous aerosol is made by formulating an aqueous solution or suspension of a subject composition together with conventional pharmaceutically acceptable carriers and stabilizers.
- the carriers and stabilizers vary with the requirements of the particular subject composition, but typically include non-ionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
- compositions suitable for parenteral administration comprise a subject composition in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which are reconstituted into sterile injectable solutions or dispersions just prior to use, which, in some embodiments, contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate and cyclodextrins.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate and cyclodextrins.
- Proper fluidity is maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants
- enteral pharmaceutical formulations including a disclosed compound and an enteric material; and a pharmaceutically acceptable carrier or excipient thereof.
- Enteric materials refer to polymers that are substantially insoluble in the acidic environment of the stomach, and that are predominantly soluble in intestinal fluids at specific pHs.
- the small intestine is the part of the gastrointestinal tract (gut) between the stomach and the large intestine, and includes the duodenum, jejunum, and ileum.
- the pH of the duodenum is about 5.5
- the pH of the jejunum is about 6.5
- the pH of the distal ileum is about 7.5.
- enteric materials are not soluble, for example, until a pH of about 5.0, of about 5.2, of about 5.4, of about 5.6, of about 5.8, of about 6.0, of about 6.2, of about 6.4, of about 6.6, of about 6.8, of about 7.0, of about 7.2, of about 7.4, of about 7.6, of about 7.8, of about 8.0, of about 8.2, of about 8.4, of about 8.6, of about 8.8, of about 9.0, of about 9.2, of about 9.4, of about 9.6, of about 9.8, or of about 10.0.
- Exemplary enteric materials include cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate, hydroxypropyl methylcellulose succinate, cellulose acetate succinate, cellulose acetate hexahydrophthalate, cellulose propionate phthalate, cellulose acetate maleate, cellulose acetate butyrate, cellulose acetate propionate, copolymer of methylmethacrylic acid and methyl methacrylate, copolymer of methyl acrylate, methylmethacrylate and methacrylic acid, copolymer of methylvinyl ether and maleic anhydride (Gantrez ES series), ethyl methyacrylate-methylmethacrylate-chlorotrimethylammonium ethyl acrylate copolymer, natural resins
- the dose of the composition comprising at least one pyrazole compound as described herein differs, depending upon the patient's (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors.
- compositions are administered in a manner appropriate to the disease to be treated (or prevented).
- An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
- an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
- Optimal doses are generally determined using experimental models and/or clinical trials. In some embodiments, the optimal dose depends upon the body mass, weight, or blood volume of the patient.
- Oral doses typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
- Contemplated methods for example, comprise exposing said enzyme to a compound described herein.
- the compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein, such as a compound of Formula (I), (Ia), (II), (III), (IIIa), (IV), (IVa), (V), (Va), (VI), (VIa), (VII), (VIIa), or (VIII).
- the ability of compounds described herein to modulate or inhibit one or more of MAGL, ABHD6, and FAAH is evaluated by procedures known in the art and/or described herein.
- Another aspect of this disclosure provides methods of treating a disease associated with expression or activity of one or more of MAGL, ABHD6, and FAAH in a patient.
- disclosed compounds are more selective in inhibition of MAGL as compared to ABHD6.
- disclosed compounds are selective in inhibiting MAGL, ABHD6, and FAAH over the inhibitor of other serine hydrolases e.g., PLA2G7.
- a disorder such as one or more of acute or chronic pain, obesity, metabolic disorders (such as syndrome X), vomiting or nausea, eating disorders such as anorexia and/or bulimia; dyslipidaemia, neuropathy such as diabetic neuropathy, pellagric neuropathy, alcoholic neuropathy, Beriberi neuropathy, burning feet syndrome, neurodegenerative disorders such as multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, amyotrophic lateral sclerosis, epilepsy, sleep disorders, cardiovascular diseases, hypertension, dyslipidemia, atherosclerosis, osteoporosis, osteoarthritis, emesis, epilepsy, mental disorders such as schizophrenia and depression, glaucoma, cachexia, insomnia, traumatic brain injury, spinal cord injury, seizures, excitotoxin exposure, ischemia, AIDS wasting syndrome, renal ischaemia, cancers (e.g., solid tumor cancers such as breast, lung
- a method for treating, ameliorating and/or preventing damage from ischemia for example, hepatic ischemia or reperfusion in a patient in need thereof, comprising administering a disclosed compound.
- Methods of treating patients with liver conditions resulting from oxidative stress and/or inflammatory damage are contemplated herein, e.g., contemplated herein are methods of treating liver fibrosis, iron overload, and/or corticosteroid therapy that result in liver damage, in a patient in need thereof.
- a method for treating chronic pain such as inflammatory pain, visceral pain, post operative pain, pain related to migraine, osteoarthritis, or rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
- chronic pain such as inflammatory pain, visceral pain, post operative pain, pain related to migraine, osteo
- contemplated herein are methods for treating neuropathic pain (e.g., neuropathic low back pain, complex regional pain syndrome, post trigeminal neuralgia, causalgia, toxic neuropathy, reflex sympathetic dystrophy, diabetic neuropathy, chronic neuropathy caused by chemotherapeutic agents) in a patient in need thereof, comprising administering a pharmaceutically effective amount of a disclosed compound.
- neuropathic pain e.g., neuropathic low back pain, complex regional pain syndrome, post trigeminal neuralgia, causalgia, toxic neuropathy, reflex sympathetic dystrophy, diabetic neuropathy, chronic neuropathy caused by chemotherapeutic agents
- exemplary patients suffering from Down's syndrome are a pediatric patient (e.g., a patient of age 0-11 years, 0-18 years, 0-6 years, or e.g., 12 to 18 years), an adult patient (e.g., 18 years or older), or e.g., an older patient e.g., 18-40 years, 20-50 years).
- such patients also suffer from further cognitive impairment and/or dementia, and/or seizures which, in some embodiments are due to production of prostaglandins and/or amyloid beta.
- such patients also are suffering from, or have one or more of the following symptoms associated with early-mid or late stage cognitive impairment: loss of language, impairment of social skills, progressive loss of activities of daily living, and include psychotic behavior.
- a method for treating a patient having Down's syndrome or Alzheimer's disease with cognitive impairment comprising administering an effective amount of a disclosed compound.
- Such disclosed methods result in cognitive improvement, for example, measured by IQ or the Arizona Cognitive Test Battery (e.g., measured with a cognitive test battery designed for use in individuals with Down's syndrome).
- a treated patient using a disclosed method has at least one of: increased memory, improved memory or improved speech.
- such disclosed methods result in a patient having an increased quality of life as measured by an adaptive behavior scale after said administration.
- a method for at least partially providing a Down's syndrome patient a neuroprotective (such as a disclosed compounds), that results in delayed onset of neurodegeneration or substantially prevents neurodegeneration, is provided.
- Administration to a patient is initiated before onset of neurodegeneration and/or onset of neurodegeneration symptoms.
- Contemplated herein are methods for treating and/or ameliorating cognitive decline, improving sleep duration and/or quality, and/or treating PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) in a patient in need thereof, comprising administering a disclosed compound.
- a disclosed compound utilized by one or more of the foregoing methods is one of the generic, subgeneric, or specific compounds described herein, such as a compound of Formula (I), (Ia), (II), (III), (IIIa), (IV), (IVa), (V), (Va), (VI), (VIa), (VII), (VIIa), or (VIII).
- Disclosed compounds are administered to patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be appreciated that the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors, with the appropriate dosage ultimately being at the discretion of the attendant physician.
- a contemplated compound disclosed herein is administered orally, subcutaneously, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Parenteral administration include subcutaneous injections, intravenous or intramuscular injections or infusion techniques.
- combination therapies for example, co-administering a disclosed compound and an additional active agent, as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
- the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
- Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually weeks, months or years depending upon the combination selected).
- Combination therapy is intended to embrace administration of multiple therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
- Substantially simultaneous administration is accomplished, for example, by administering to the subject a single formulation or composition, (e.g., a tablet or capsule having a fixed ratio of each therapeutic agent or in multiple, single formulations (e.g., capsules) for each of the therapeutic agents.
- Sequential or substantially simultaneous administration of each therapeutic agent is effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues.
- the therapeutic agents are administered by the same route or by different routes.
- a first therapeutic agent of the combination selected is administered by intravenous injection while the other therapeutic agents of the combination are administered orally.
- all therapeutic agents are administered orally or all therapeutic agents are administered by intravenous injection.
- Combination therapy also embraces the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies.
- the combination therapy further comprises a non-drug treatment
- the non-drug treatment is conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved.
- the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
- the components of the combination are administered to a patient simultaneously or sequentially. It will be appreciated that the components are present in the same pharmaceutically acceptable carrier and, therefore, are administered simultaneously. Alternatively, the active ingredients are present in separate pharmaceutical carriers, such as, conventional oral dosage forms, that are administered either simultaneously or sequentially.
- a disclosed compound is co-administered with another therapeutic for pain such as an opioid, a cannabinoid receptor (CB-1 or CB-2) modulator, a COX-2 inhibitor, acetaminophen, and/or a non-steroidal anti-inflammatory agent.
- additional therapeutics e.g., for the treatment of pain that are co-administered include morphine, codeine, hydromorphone, hydrocodone, oxymorphone, fentanyl, tramadol, and levorphanol.
- contemplated therapeutics for co-administration include aspirin, naproxen, ibuprofen, salsalate, diflunisal, dexibuprofen, fenoprofen, ketoprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, celecoxib, parecoxib, rimonabant, and/or etoricoxic.
- the examples were purified using preparative HPLC according to the following conditions: 20% CH 3 CN/80% Phase A increasing to 80% CH 3 CN over 10 min, then to 100% CH 3 CN over 0.1 min, holding at 100% CH 3 CN for 1.9 min, then reducing to 20% CH 3 CN over 0.1 min, and holding at 20% for 1.9 min, on a Waters 2767-5 Chromatograph.
- Mobile phase Phase A: aqueous NH 4 HCO 3 (0.05%); Phase B: CH 3 CN.
- Detector UV 220 & 254 nm.
- the crude carbamoyl chloride prepared above was then added dropwise.
- the resulting mixture was allowed to warm to room temperature and was stirred for 16 h.
- the reaction mixture was then diluted with EtOAc (10 mL), and the organic layer washed with saturate aqueous NaCl (2 ⁇ 10 mL).
- the organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure.
- the resulting colorless oil was purified by flash chromatography (60 g SiO 2 , 20% EtOAc-hexanes) to provide piperidin-1-yl(1H-pyrazol-1-yl)methanone (210 mg, 73%) as a white solid.
- the title compound was prepared from 4-methyl-1H-pyrazole (80 mg, 0.98 mmol) and piperidine (0.12 mL, 1.17 mmol) according to the representative procedure of Example 1 to provide (4-methyl-1H-pyrazol-1-yl)(piperidin-1-yl)methanone (105 mg, 55%) as a colorless oil.
- the title compound was prepared from 1H-pyrazole (40 mg, 0.57 mmol) and 4-Boc-piperazine (160 mg, 0.86 mmol) according to the representative procedure of Example 1 to provide tert-butyl 4-(1H-pyrazole-1-carbonyl)piperazine-1-carboxylate (102 mg, 65%) as a white solid.
- the title compound was prepared from 4-methyl-1H-pyrazole (45 mg, 0.31 mmol) and 4-Boc-piperazine (70 mg, 0.38 mmol) according to the representative procedure of Example 1 to provide tert-butyl 4-(4-methyl-1H-pyrazole-1-carbonyl)piperazine-1-carboxylate (60 mg, 65%) as a white solid.
- the title compound was prepared from 1H-pyrazole-4-carbonitrile (35 mg, 0.37 mmol) and 4-Boc-piperazine (80 mg, 0.45 mmol) according to the representative procedure of Example 1 to provide tert-butyl 4-(4-cyano-1H-pyrazole-1-carbonyl)piperazine-1-carboxylate (66 mg, 45%) as a white solid.
- Step 1 Preparation of tert-butyl 4-(naphthalen-2-ylmethyl)piperazine-1-carboxylate
- the title compound was prepared from 1H-pyrazole (30 mg, 0.44 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (100 mg, 0.44 mmol) according to the representative procedure of Example 1 to yield (4-(naphthalen-2-ylmethyl)piperazin-1-yl)(1H-pyrazol-1-yl)methanone (71 mg, 51%) as a white solid.
- Example 10 The title compound was prepared from 4-methyl-1H-pyrazole (20 mg, 0.24 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (Example 10, Step 2; 55 mg, 0.24 mmol) according to the representative procedure of Example 1 to provide (4-methyl-1H-pyrazol-1-yl)(4-(naphthalen-2-ylmethyl)piperazin-1-yl)methanone (38 mg, 48%) as a white solid.
- Example 10 The title compound was prepared from 1H-pyrazole-4-carbonitrile (20 mg, 0.21 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (Example 10, Step 2; 48 mg, 0.21 mmol) according to the representative procedure of Example 1 to provide 1-(4-(naphthalen-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazole-4-carbonitrile (35 mg, 49%) as a white solid.
- Example 10 The title compound was prepared from 4-bromo-1H-pyrazole (66 mg, 0.45 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (Example 10, Step 2; 122 mg, 0.54 mmol) according to the representative procedure of Example 1 to provide (4-bromo-1H-pyrazol-1-yl)(4-(naphthalen-2-ylmethyl)piperazin-1-yl)methanone (101 mg, 56%) as a white solid.
- Example 10 The title compound was prepared from 4-iodo-1H-pyrazole (75 mg, 0.40 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (Example 10, Step 2; 105 mg, 0.47 mmol) according to the representative procedure of Example 1 to provide (4-iodo-1H-pyrazol-1-yl)(4-(naphthalen-2-ylmethyl)piperazin-1-yl)methanone (96 mg, 57%) as a white solid.
- the title compound was prepared from methyl 1H-pyrazole-4-carboxylate (52 mg, 0.33 mmol) and 1-(naphthalen-2-ylmethyl)piperazine (Example 10, Step 2; 74 mg, 0.33 mmol) according to the representative procedure of Example 1 to provide methyl 1-(4-(naphthalen-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazole-4-carboxylate (54 mg, 43%) as a white solid.
- the title compound was prepared from 1-(bromomethyl)-4-phenoxybenzene, tert-butyl piperazine-1-carboxylate and 1H-pyrazole (10 mg, 0.15 mmol) according to the representative procedure of Example 10 to provide (4-(4-phenoxybenzyl)piperazin-1-yl)(1H-pyrazol-1-yl)methanone (22 mg, 40%) as a white solid.
- the title compound was prepared from 1-(bromomethyl)-4-phenoxybenzene, tert-butyl piperazine-1-carboxylate and 4-methyl-1H-pyrazole (11 mg, 0.13 mmol) according to the representative procedure of Example 10 to provide (4-methyl-1H-pyrazol-1-yl)(4-(4-phenoxybenzyl)piperazin-1-yl)methanone (21 mg, 44%) as a white solid.
- the title compound was prepared from 1-(bromomethyl)-4-phenoxybenzene, tert-butyl piperazine-1-carboxylate and 1H-pyrazole-4-carbonitrile (10 mg, 0.11 mmol) according to the representative procedure of Example 10 to provide 1-(4-(4-phenoxybenzyl)piperazine-1-carbonyl)-1H-pyrazole-4-carbonitrile (16 mg, 39%) as a white solid.
- the title compound was prepared from 1-(benzyloxy)-4-(bromomethyl)benzene, tert-butyl piperazine-1-carboxylate and 1H-pyrazole (20 mg, 0.32 mmol) according to the representative procedure of Example 10 to provide (4-(4-(benzyloxy)benzyl)piperazin-1-yl)(1H-pyrazol-1-yl)methanone (45 mg, 38%) as a white solid.
- the title compound was prepared from 1-(benzyloxy)-4-(bromomethyl)benzene, tert-butyl piperazine-1-carboxylate and 4-methyl-1H-pyrazole (10 mg, 0.12 mmol) according to the representative procedure of Example 10 to provide (4-(4-(benzyloxy)benzyl)piperazin-1-yl)(4-methyl-1H-pyrazol-1-yl)methanone (16 mg, 34%) as a white solid.
- the title compound was prepared from 1-(benzyloxy)-4-(bromomethyl)benzene, tert-butyl piperazine-1-carboxylate and 1H-pyrazole-4-carbonitrile (8 mg, 0.086 mmol) according to the representative procedure of Example 10 to provide 1-(4-(4-(benzyloxy)benzyl)piperazine-1-carbonyl)-1H-pyrazole-4-carbonitrile (13 mg, 40%) as a white solid.
- the title compound was prepared from 4-(bromomethyl)-1,1′-biphenyl, tert-butyl piperazine-1-carboxylate and 1H-pyrazole (10 mg, 0.15 mmol) according to the representative procedure of Example 10 to provide (4-([1,1′-biphenyl]-4-ylmethyl)piperazin-1-yl)(1H-pyrazol-1-yl)methanone (18 mg, 36%) as a white solid.
- the title compound was prepared from 4-(bromomethyl)-1,1′-biphenyl, tert-butyl piperazine-1-carboxylate and 4-methyl-1H-pyrazole (8 mg, 0.097 mmol) according to the representative procedure of Example 10 to provide (4-([1,1′-biphenyl]-4-ylmethyl)piperazin-1-yl)(4-methyl-1H-pyrazol-1-yl)methanone (11 mg, 34%) as a white solid.
- the title compound was prepared from 4-(bromomethyl)-1,1′-biphenyl, tert-butyl piperazine-1-carboxylate and 1H-pyrazole-4-carbonitrile (10 mg, 0.11 mmol) according to the representative procedure of Example 10 to provide 1-(4-([1,1′-biphenyl]-4-ylmethyl)piperazine-1-carbonyl)-1H-pyrazole-4-carbonitrile (15 mg, 38%) as a white solid.
- the title compound was prepared from 1H-pyrazole (12 mg, 0.18 mmol) and tert-butyl methyl(2-(methylamino)ethyl)carbamate (33 mg, 0.18 mmol) according to the representative procedure of Example 1 to provide tert-butyl methyl(2-(N-methyl-1H-pyrazole-1-carboxamido)ethyl)carbamate (26 mg, 52%) as a white solid.
- the title compound was prepared from 4-methyl-1H-pyrazole (12 mg, 0.15 mmol) and tert-butyl methyl(2-(methylamino)ethyl)carbamate (26 mg, 0.15 mmol) according to the representative procedure of Example 1 to provide tert-butyl (2-(N,4-dimethyl-1H-pyrazole-1-carboxamido)ethyl)(methyl)carbamate (20 mg, 48%) as a white solid.
- the title compound was prepared from 1H-pyrazole (20 mg, 0.29 mmol) and 4-phenylbutan-1-amine (44 mg, 0.29 mmol) according to the representative procedure of Example 1 to provide N-(4-phenylbutyl)-1H-pyrazole-1-carboxamide (44 mg, 62%) as a colorless oil.
- the title compound was prepared from 4-methyl-1H-pyrazole (20 mg, 0.24 mmol) and 4-phenylbutan-1-amine (36 mg, 0.24 mmol) according to the representative procedure of Example 1 to provide 4-methyl-N-(4-phenylbutyl)-1H-pyrazole-1-carboxamide (30 mg, 49%) as a colorless oil.
- the title compound was prepared from 1H-pyrazole-4-carbonitrile (10 mg, 0.11 mmol) and 4-phenylbutan-1-amine (17 mg, 0.11 mmol) according to the representative procedure of Example 1 to provide 4-cyano-N-(4-phenylbutyl)-1H-pyrazole-1-carboxamide (14 mg, 47%) as a colorless oil.
- the title compound was prepared from 1H-pyrazole (10 mg, 0.15 mmol) and 5-phenylpentan-1-amine (24 mg, 0.15 mmol) according to the representative procedure of Example 1 to provide N-(5-phenylpentyl)-1H-pyrazole-1-carboxamide (20 mg, 52%) as a colorless oil.
- the title compound was prepared from 4-methyl-1H-pyrazole (9 mg, 0.11 mmol) and 5-phenylpentan-1-amine (18 mg, 0.11 mmol) according to the representative procedure of Example 1 to provide 4-methyl-N-(5-phenylpentyl)-1H-pyrazole-1-carboxamide (14 mg, 49%) as a colorless oil.
- the title compound was prepared from 1H-pyrazole-4-carbonitrile (9 mg, 0.098 mmol) and 5-phenylpentan-1-amine (16 mg, 0.98 mmol) according to the representative procedure of Example 1 to provide 4-cyano-N-(5-phenylpentyl)-1H-pyrazole-1-carboxamide (12 mg, 45%) as a colorless oil.
- a flask was equipped with a magnetic stirbar and charged with triphosgene (46 mg, 0.160 mmol, 0.5 equiv) and CH 2 Cl 2 (3.0 mL). The solution was cooled to 0° C., and pyridine (0.030 mL, 0.310 mmol, 1.0 equiv) was added. After stirring at 0° C. for 5 min, 1-(bis(4-chlorophenyl)methyl)piperazine (100 mg, 0.310 mmol, 1.0 equiv) was added, and the reaction mixture was stirred at 0° C. for 30 min, then at rt for 1 h.
- Step 2 Preparation of tert-butyl 4-(4-chloro-2-morpholinobenzyl)piperazine-1-carboxylate
- Step 4 Preparation of (4-chloro-1H-pyrazol-1-yl)(4-(4-chloro-2-morpholinobenzyl)piperazin-1-yl)methanone
- the title compound was synthesized directly from 4-chloro-1H-pyrazole and 4-(5-chloro-2-(piperazin-1-ylmethyl)phenyl)morpholine according to the representative procedure of Example 46 to provide (4-chloro-1H-pyrazol-1-yl)(4-(4-chloro-2-morpholinobenzyl)piperazin-1-yl)methanone as an oil.
- Step 2 Preparation of (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(4-(pyrrolidine-1-carbonyl)-1H-pyrazol-1-yl)methanone
- the title compound was synthesized directly from (1H-pyrazol-4-yl)(pyrrolidin-1-yl)methanone and 1-(bis(4-chlorophenyl)methyl)piperazine according to the representative procedure of Example 46 to provide (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(4-(pyrrolidine-1-carbonyl)-1H-pyrazol-1-yl)methanone as a white solid.
- the title compound was synthesized from 4-chloro-2-fluorobenzaldehyde, pyrrolidine, tert-butyl piperazine-1-carboxylate and 4-chloro-1H-pyrazole according to the representative procedure of Example 47, steps 1-4 to provide (4-chloro-1H-pyrazol-1-yl)(4-(4-chloro-2-(pyrrolidin-1-yl)benzyl)piperazin-1-yl)methanone as a white solid.
- Step 2 Preparation of tert-butyl 4-(chlorocarbonyl)piperazine-1-carboxylate
- Step 3 Preparation of tert-butyl 4-(4-(morpholine-4-carbonyl)-1H-pyrazole-1-carbonyl)piperazine-1-carboxylate
- Step 5 Preparation of (4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)(4-(morpholine-4-carbonyl)-1H-pyrazol-1-yl)methanone
- Example 65 (4-((3-Methyl-[1,1′-biphenyl]-4-yl)methyl)piperazin-1-yl)(4-phenyl-1H-pyrazol-1-yl)methanone
- Example 94 The title compound was synthesized directly from commercially available 4-phenyl-1H-pyrazole, tert-butyl piperazine-1-carboxylate and 3-methyl-[1,1′-biphenyl]-4-carbaldehyde (Example 94, Step 1) according to the representative procedure of Example 51, Steps 2-5 to provide (4-((3-methyl-[1,1′-biphenyl]-4-yl)methyl)piperazin-1-yl)(4-phenyl-1H-pyrazol-1-yl)methanone as a white solid.
- Step 3 Preparation of tert-butyl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate
- Step 6 Preparation of (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(4-(piperidine-1-carbonyl)-1H-pyrazol-1-yl)methanone
- Example 68 Azetidin-1-yl(1-(4-(bis(4-chlorophenyl)methyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- Example 70 Piperidin-1-yl(1-(4-(pyridin-4-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- Example 72 Piperidin-1-yl(1-(4-(pyridin-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- Example 74 Piperidin-1-yl(1-(4-(thiazol-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- Example 86 Azetidin-1-yl(1-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and isonicotinaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(pyridin-4-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a white solid.
- Example 88 Azetidin-1-yl(1-(4-(pyridin-3-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and nicotinaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(pyridin-3-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a light yellow solid.
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and picolinaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(pyridin-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a yellow solid.
- Example 90 Azetidin-1-yl(1-(4-(pyrimidin-4-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and pyrimidine-4-carbaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(pyrimidin-4-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a yellow solid.
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and thiazole-2-carbaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(thiazol-2-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a light yellow solid.
- Example 92 Azetidin-1-yl(1-(4-(pyrimidin-5-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- the title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and pyrimidine-5-carbaldehyde according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-(pyrimidin-5-ylmethyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a white solid.
- Example 93 Azetidin-1-yl(1-(4-((3-methyl-[1,1′-biphenyl]-4-yl)methyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone
- Example 94 The title compound was synthesized directly from 1H-pyrazole-4-carboxylic acid, azetidine, tert-butyl piperazine-1-carboxylate and 3-methyl-[1,1′-biphenyl]-4-carbaldehyde (Example 94, Step 1) according to the representative procedure of Example 51, Steps 1-5 to provide azetidin-1-yl(1-(4-((3-methyl-[1,1′-biphenyl]-4-yl)methyl)piperazine-1-carbonyl)-1H-pyrazol-4-yl)methanone as a white solid.
- Step 2 Preparation of tert-butyl 4-((3-methyl-[1,1′-biphenyl]-4-yl)methyl)piperazine-1-carboxylate
- Step 4 Preparation of (3,5-dimethyl-1H-pyrazol-1-yl)(4-((3-methyl-[1,1′-biphenyl]-4-yl)methyl)piperazin-1-yl)methanone
- Step 3 Preparation of tert-butyl 4-(bis(1,3-dihydroisobenzofuran-5-yl)methyl)piperazine-1-carboxylate
- Step 6 Preparation of (4-(bis(1,3-dihydroisobenzofuran-5-yl)methyl)piperazin-1-yl)(4-chloro-1H-pyrazol-1-yl)methanone
- Step 2 Preparation of tert-butyl 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carboxylate
- Step 4 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride
- Step 5 Preparation of (4-chloro-1H-pyrazol-1-yl)(4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)methanone
- the title compound was prepared from 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride and 4-chloro-1H-pyrazole according to the representative procedure of Example 95, Step 6 to provide (4-chloro-1H-pyrazol-1-yl)(4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)methanone as a white solid.
- Step 3 Preparation of tert-butyl 4-((1-isopropyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate
- Step 4 Preparation of (4-chloro-1H-pyrazol-1-yl)(4-((1-isopropyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)methanone
- the title compound was prepared from tert-butyl 4-((1-isopropyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazine-1-carboxylate and 4-chloro-1H-pyrazole according to the representative procedure of Example 99, Steps 3-5 to provide (4-chloro-1H-pyrazol-1-yl)(4-((1-isopropyl-3-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)methanone as a white solid.
- Example 102 (4-Chloro-1H-pyrazol-1-yl)(4-(4-chloro-2-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)piperazin-1-yl)methanone
- the title compound was prepared from 4-chloro-2-fluorobenzaldehyde, 8-oxa-2-azaspiro[4.5]decane, tert-butyl piperazine-1-carboxylate and 4-chloro-1H-pyrazole according to the representative procedure of Example 99, Steps 1-5 to provide (4-chloro-1H-pyrazol-1-yl)(4-(4-chloro-2-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)piperazin-1-yl)methanone as a light yellow oil.
- the title compound was synthesized directly from pyrrolidine and 4-(4-chlorophenyl)-1H-pyrazole (prepared from 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 1-bromo-4-chlorobenzene according to the representative procedure of Example 104, Step 1) according to the representative procedure of Example 99, Steps 4 and 5 to provide (4-(4-chlorophenyl)-1H-pyrazol-1-yl)(pyrrolidin-1-yl)methanone as a white solid.
- the title compound was synthesized directly from 4-([1,1′-biphenyl]-4-yl)-1H-pyrazole (prepared from 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 4-bromo-1,1′-biphenyl according to the representative procedure of Example 104, Step 1) and pyrrolidine according to the representative procedure of Example 99, Steps 4 and 5 to provide (4-([1,1′-biphenyl]-4-yl)-1H-pyrazol-1-yl)(pyrrolidin-1-yl)methanone as a white solid.
- Steps 2-3 Preparation of (4-(2′-methoxy-[1,1′-biphenyl]-4-yl)-1H-pyrazol-1-yl)(pyrrolidin-1-yl)methanone
- Example 110 (4-(2-(Pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)(4-(trifluoromethyl)-1H-pyrazol-1-yl)methanone
- Example 99 The title compound was synthesized directly from 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride (Example 99, Steps 1-4) and 4-(trifluoromethyl)-1H-pyrazole according to the representative procedure of Example 109 to provide (4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)(4-(trifluoromethyl)-1H-pyrazol-1-yl)methanone as a light yellow oil.
- Example 99 The title compound was synthesized directly from 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride (Example 99, Steps 1-4) and 4-methyl-1H-pyrazole according to the representative procedure of Example 109 to provide (4-methyl-1H-pyrazol-1-yl)(4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)methanone as a yellow oil.
- Example 99 The title compound was synthesized directly from 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride (Example 99, Steps 1-4) and 4-isopropyl-1H-pyrazole according to the representative procedure of Example 109 to provide (4-isopropyl-1H-pyrazol-1-yl)(4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)methanone as a light yellow solid.
- Example 99 The title compound was synthesized directly from 4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazine-1-carbonyl chloride (Example 99, Steps 1-4) and 4-fluoro-1H-pyrazole according to the representative procedure of Example 109 to provide (4-fluoro-1H-pyrazol-1-yl)(4-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)piperazin-1-yl)methanone as a yellow solid.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
-
- R1 is H, —CF3, C1-4 alkyl, cyano, halo, optionally substituted phenyl, —CO2R5, or —C(O)NR6R7;
- R2 is optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted C3-8 cycloalkyl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- R5 is H or C1-4 alkyl; and
- R6 and R7 are each independently H, C1-4 alkyl, or C3-8 cycloalkyl; or R6 and R7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, —CF3, C1-4 alkyl, cyano, halo, optionally substituted phenyl, —CO2R5, —C(O)NR6R7;
- R2 is optionally substituted aryl or optionally substituted heteroaryl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- R5 is H or C1-4 alkyl; and
- R6 and R7 are each independently H, C1-4 alkyl, or C3-8 cycloalkyl; or R6 and R7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, —CF3, C1-4 alkyl, halo, optionally substituted phenyl,
-
- R2 is optionally substituted aryl or optionally substituted heteroaryl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- m is 1, 2 or 3; and
- n is 1, 2, 3, 4, or 5;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, CF3, cyano, halo, or —CO2R3;
- R2 is optionally substituted aryl; and
- R3 is H or C1-4 alkyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, cyano, halo, or —CO2R3;
- R2 is optionally substituted aryl; and
- R3 is H or C1-4 alkyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, halo, CF3, optionally substituted aryl, or cyano;
- R2 is CO2(t-Bu), C1-4 alkyl, —C(O)R3, —SO2R3, optionally substituted aryl, or optionally substituted heteroaryl;
- R3 is C1-4 alkyl or optionally substituted aryl; and
- n is 1 or 2;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, or cyano;
- R2 is CO2(t-Bu); and
- n is 1 or 2;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is halo, cyano, CF3, or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is halo or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- Y is O or CH2;
- R1 is H, C1-4 alkyl, CF3, halo, cyano, or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- Y is O or CH2;
- R1 is H, C1-4 alkyl, halo, or cyano;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, cyano, CF3, halo, —CO2R4, or optionally substituted phenyl;
- R2 is —N(Boc)CH3, —NR5C(O)R6, —NR5SO2R6, —NR5R6, optionally substituted phenyl or optionally substituted naphthyl;
- R3 is H or C1-4 alkyl;
- R4 is H or C1-4 alkyl;
- R5 is C1-4 alkyl;
- R6 is C1-4 alkyl, optionally substituted aryl, or optionally substituted aralkyl; and
- n is 0-6;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, cyano, halo, or —CO2R4;
- R2 is —N(Boc)CH3, optionally substituted phenyl or optionally substituted naphthyl;
- R3 is H or C1-4 alkyl;
- R4 is H or C1-4 alkyl; and
- n is 0-6;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- Y is CH2 or NR2;
- R1 is H, C1-4 alkyl, cyano, CF3, or halo;
- R2 is —C(O)R3, —SO2R3, optionally substituted aralkyl, or C1-4 alkyl; and
- R3 is C1-4 alkyl or optionally substituted aryl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, —CF3, C1-4 alkyl, cyano, halo, optionally substituted phenyl, —CO2R5, or —C(O)NR6R7;
- R2 is optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted C3-8 cycloalkyl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- R5 is H or C1-4 alkyl; and
- R6 and R7 are each independently H, C1-4 alkyl, or C3-8 cycloalkyl; or R6 and R7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
m is 1, 2 or 3; and n is 1, 2, 3, 4, or 5. In another embodiment is a compound of Formula (I), wherein R1 is
R8 and R9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R10 is H, —CF3, or halo. In another embodiment is a compound of Formula (I), wherein R10 is —CF3. In another embodiment is a compound of Formula (I), wherein R10 is halo. In another embodiment is a compound of Formula (I), wherein R10 is chloro. In another embodiment is a compound of Formula (I), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine. In another embodiment is a compound of Formula (I), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted piperidine. In another embodiment is a compound of Formula (I), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted morpholine.
-
- R1 is H, —CF3, C1-4 alkyl, halo, optionally substituted phenyl,
-
- R2 is optionally substituted aryl or optionally substituted heteroaryl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- m is 1, 2, or 3; and
- n is 1, 2, 3, 4, or 5;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
and R2 is optionally substituted aryl. In another embodiment is a compound of Formula (II), wherein R1 is,
and R2 is bisubstituted or monosubstituted phenyl. In another embodiment is a compound of Formula (II), wherein R1 is,
R2 is bisubstituted or monosubstituted phenyl; and R4 is H. In another embodiment is a compound of Formula (II), wherein R1 is,
R2 is bisubstituted or monosubstituted phenyl; and R4 is optionally substituted phenyl. In another embodiment is a compound of Formula (II), wherein R1 is,
R8 and R9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R10 is H, —CF3, or halo. In another embodiment is a compound of Formula (II), wherein R10 is —CF3. In another embodiment is a compound of Formula (II), wherein R10 is halo. In another embodiment is a compound of Formula (II), wherein R10 is chloro. In another embodiment is a compound of Formula (II), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine. In another embodiment is a compound of Formula (II), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted piperidine. In another embodiment is a compound of Formula (II), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted morpholine.
-
- R1 is H, C1-4 alkyl, CF3, cyano, halo, or —CO2R3;
- R2 is optionally substituted aryl; and
- R3 is H or C1-4 alkyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, halo, CF3, optionally substituted aryl, or cyano;
- R2 is CO2(t-Bu), C1-4 alkyl, —C(O)R3, —SO2R3, optionally substituted aryl, or optionally substituted heteroaryl;
- R3 is C1-4 alkyl or optionally substituted aryl; and
- n is 1 or 2;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is halo, cyano, CF3, or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
In another embodiment is a compound of Formula (V), wherein R1 is chloro. In another embodiment is a compound of Formula (V), wherein R1 is
-
- Y is O or CH2;
- R1 is H, C1-4 alkyl, CF3, halo, cyano, or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, cyano, CF3, halo, —CO2R4, or optionally substituted phenyl;
- R2 is —N(Boc)CH3, —NR5C(O)R6, —NR5SO2R6, —NR5R6, optionally substituted phenyl or optionally substituted naphthyl;
- R3 is H or C1-4 alkyl;
- R4 is H or C1-4 alkyl;
- R5 is C1-4 alkyl;
- R6 is C1-4 alkyl, optionally substituted aryl, or optionally substituted aralkyl; and
- n is 0-6;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- Y is CH2 or NR2;
- R1 is H, C1-4 alkyl, cyano, CF3, or halo;
- R2 is —C(O)R3, —SO2R3, optionally substituted aralkyl, or C1-4 alkyl; and
- R3 is C1-4 alkyl or optionally substituted aryl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, —CF3, C1-4 alkyl, cyano, halo, optionally substituted phenyl, —CO2R5, —C(O)NR6R7;
- R2 is optionally substituted aryl or optionally substituted heteroaryl;
- R3 is H;
- R4 is H or optionally substituted phenyl;
- R5 is H or C1-4 alkyl; and
- R6 and R7 are each independently H, C1-4 alkyl, or C3-8 cycloalkyl; or R6 and R7 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member heterocyclyl ring, optionally containing another heteroatom selected from S or O;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
m is 1, 2 or 3; and n is 1, 2, 3, 4, or 5. In another embodiment is a compound of Formula (Ia), wherein R1 is
R8 and R9 together with the nitrogen to which they are attached form a 4-, 5-, 6-, 7-, or 8-member optionally substituted heterocyclyl ring, optionally containing another heteroatom selected from S or O; and R10 is H, —CF3, or halo. In another embodiment is a compound of Formula (Ia), wherein R10 is —CF3. In another embodiment is a compound of Formula (Ia), wherein R10 is halo. In another embodiment is a compound of Formula (Ia), wherein R10 is chloro. In another embodiment is a compound of Formula (Ia), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted pyrrolidine. In another embodiment is a compound of Formula (Ia), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted piperidine. In another embodiment is a compound of Formula (Ia), wherein R8 and R9 together with the nitrogen to which they are attached form an optionally substituted morpholine.
-
- R1 is H, C1-4 alkyl, cyano, halo, or —CO2R3;
- R2 is optionally substituted aryl; and
- R3 is H or C1-4 alkyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, or cyano;
- R2 is CO2(t-Bu); and
- n is 1 or 2;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is halo or optionally substituted phenyl;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
In another embodiment is a compound of Formula (Va), wherein R1 is chloro. In another embodiment is a compound of Formula (Va), wherein R1 is
-
- Y is O or CH2;
- R1 is H, C1-4 alkyl, halo, or cyano;
or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
-
- R1 is H, C1-4 alkyl, cyano, halo, or —CO2R4;
- R2 is —N(Boc)CH3, optionally substituted phenyl or optionally substituted naphthyl;
- R3 is H or C1-4 alkyl;
- R4 is H or C1-4 alkyl; and
- n is 0-6;
- or a solvate, hydrate, tautomer, N-oxide, or pharmaceutically acceptable salt thereof.
| TABLE 1 | ||
| Chemical | ||
| Synthesis | ||
| Example | Structure | Name |
| 1 | | Piperidin-1-yl(1H-pyrazol-1- yl)methanone |
| 2 | | (4-Methyl-1H-pyrazol-1- yl)(piperidin-1-yl)methanone |
| 3 | | 1-(Piperidine-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 4 | | tert-Butyl 4-(1H-pyrazole-1- carbonyl)piperazine-1- carboxylate |
| 5 | | tert-Butyl 4-(4-methyl-1H- pyrazole-1-carbonyl)piperazine-1- carboxylate |
| 6 | | tert-Butyl 4-(4-cyano-1H- pyrazole-1-carbonyl)piperazine-1- carboxylate |
| 7 | | (4-Benzylpiperazin-1-yl)(1H- pyrazol-1-yl)methanone |
| 8 | | (4-Benzylpiperazin-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 9 | | 1-(4-Benzylpiperazine-1- carbonyl)-1H-pyrazol-4- carbonitrile |
| 10 | | (4-(Naphthalen-2- ylmethyl)piperazin-1-yl)(1H- pyrazol-1-yl)methanone |
| 11 | | (4-Methyl-1H-pyrazol-1-yl)(4- (naphthalen-2- ylmethyl)piperazin-1- yl)methanone |
| 12 | | 1-(4-(Naphthalen-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 13 | | (4-Bromo-1H-pyrazol-1-yl)(4- (naphthalen-2- ylmethyl)piperazin-1- yl)methanone |
| 14 | | (4-Iodo-1H-pyrazol-1-yl)(4- (naphthalen-2- ylmethyl)piperazin-1- yl)methanone |
| 15 | | Methyl 1-(4-(naphthalen-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carboxylate |
| 16 | | (4-(4-Phenoxybenzyl)piperazin-1- yl)(1H-pyrazol-1-yl)methanone |
| 17 | | (4-Methyl-1H-pyrazol-1-yl)(4-(4- phenoxybenzyl)piperazin-1- yl)methanone |
| 18 | | 1-(4-(4- Phenoxybenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 19 | | (4-(4- (Benzyloxy)benzyl)piperazin-1- yl)(1H-pyrazol-1-yl)methanone |
| 20 | | (4-(4- (Benzyloxy)benzyl)piperazin-1- yl)(4-methyl-1H-pyrazol-1- yl)methanone |
| 21 | | 1-(4-(4- (Benzyloxy)benzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 22 | | (4-([1,1′-Biphenyl]-4- ylmethyl)piperazin-1-yl)(1H- pyrazol-1-yl)methanone |
| 23 | | (4-([1,1′-Biphenyl]-4- ylmethyl)piperazin-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 24 | | 1-(4-([1,1′-Biphenyl]-4- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 25 | | tert-Butyl 4-(1H-pyrazole-1- carbonyl)-1,4-diazepane-1- carboxylate |
| 26 | | tert-Butyl 4-(4-methyl-1H- pyrazole-1-carbonyl)-1,4- diazepane-1-carboxylate |
| 27 | | tert-Butyl 4-(4-cyano-1H- pyrazole-1-carbonyl)-1,4- diazepane-1-carboxylate |
| 28 | | tert-Butyl methyl(2-(N-methyl- 1H-pyrazole-1- carboxamido)ethyl)carbamate |
| 29 | | tert-Butyl (2-(N,4-dimethyl-1H- pyrazole-1- carboxamido)ethyl)(methyl)- carbamate |
| 30 | | tert-Butyl (2-(4-cyano-N-methyl- 1H-pyrazole-1- carboxamido)ethyl)(methyl)- carbamate |
| 31 | | N-(3-Phenylpropyl)-1H-pyrazole- 1-carboxamide |
| 32 | | 4-Methyl-N-(3-phenylpropyl)-1H- pyrazole-1-carboxamide |
| 33 | | 4-Cyano-N-(3-phenylpropyl)-1H- pyrazole-1-carboxamide |
| 34 | | N-(4-Phenylbutyl)-1H-pyrazole- 1-carboxamide |
| 35 | | 4-Methyl-N-(4-phenylbutyl)-1H- pyrazole-1-carboxamide |
| 36 | | 4-Cyano-N-(4-phenylbutyl)-1H- pyrazole-1-carboxamide |
| 37 | | N-(5-phenylpentyl)-1H-pyrazole- 1-carboxamide |
| 38 | | 4-Methyl-N-(5-(5-phenylpentyl)-1H- pyrazole-1-carboxamide |
| 39 | | 4-Cyano-N-(5-phenylpentyl)-1H- pyrazole-1-carboxamide |
| 40 | | N-(Naphthalen-2-yl)-1H- pyrazole-1-carboxamide |
| 41 | | 4-Methyl-N-(naphthalen-2-yl)- 1H-pyrazole-1-carboxamide |
| 42 | | 4-Cyano-N-(naphthalen-2-yl)-1H- pyrazole-1-carboxamide |
| 43 | | N-(Naphthalen-2-ylmethyl)-1H- pyrazole-1-carboxamide |
| 44 | | 4-Methyl-N-(naphthalen-2- ylmethyl)-1H-pyrazole-1- carboxamide |
| 45 | | 4-Cyano-N-(naphthalen-2- ylmethyl)-1H-pyrazole-1- carboxamide |
| 46 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(1H-pyrazol-1-yl)methanone |
| 47 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- chloro-2- morpholinobenzyl)piperazin-1- yl)methanone |
| 48 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(pyrrolidine-1-carbonyl)- 1H-pyrazol-1-yl)methanone |
| 49 | | 1-(4-(Bis(4- chlorophenyl)methyl)piperazine- 1-carbonyl)-N-cyclopropyl-1H- pyrazole-4-carboxamide |
| 50 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- chloro-2-(pyrrolidin-1- yl)benzyl)piperazin-1- yl)methanone |
| 51 | | (4-(Benzo[d][1,3]dioxol-5- ylmethyl)piperazin-1-yl)(4- (morpholine-4-carbonyl)-1H- pyrazol-1-yl)methanone |
| 52 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(pyridin-4- ylmethyl)piperazin-1- yl)methanone |
| 53 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(pyridin-3- ylmethyl)piperazin-1- yl)methanone |
| 54 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(pyrimidin-4- ylmethyl)piperazin-1- yl)methanone |
| 55 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(thiazol-2- ylmethyl)piperazin-1- yl)methanone |
| 56 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(pyrimidin-5- ylmethyl)piperazin-1- yl)methanone |
| 57 | | (4-((3-Methyl-[1,1′-biphenyl]-4- yl)methyl)piperazin-1-yl)(4- (morpholine-4-carbonyl)-1H- pyrazol-1-yl)methanone |
| 58 | | (4-(Benzo[d][1,3]dioxol-5- ylmethyl)piperazin-1-yl)(4- phenyl-1H-pyrazol-1- yl)methanone |
| 59 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (pyridin-4-ylmethyl)piperazin-1- yl)methanone |
| 60 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (pyridin-3-ylmethyl)piperazin-1- yl)methanone |
| 61 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (pyridin-3-ylmethyl)piperazin-1- yl)methanone |
| 62 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (pyrimidin-4-ylmethyl)piperazin-1- yl)methanone |
| 63 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (thiazol-2-ylmethyl)piperazin-1- yl)methanone |
| 64 | | (4-Phenyl-1H-pyrazol-1-yl)(4- (pyrimidin-5-ylmethyl)piperazin- 1-yl)methanone |
| 65 | | (4-((3-Methyl-[1,1′-biphenyl]-4- yl)methyl)piperazin-1-yl)(4- phenyl-1H-pyrazol-1- yl)methanone |
| 66 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(piperidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 67 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(morpholine-4-carbonyl)- 1H-pyrazol-1-yl)methanone |
| 68 | | Azetidin-1-yl(1-(4-(bis(4- chlorophenyl)methyl)piperazine- 1-carbonyl)-1H-pyrazol-4- yl)methanone |
| 69 | | (4-(Benzo[d][1,3]dioxol-5- ylmethyl)piperazin-1-yl)(4- (piperidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 70 | | Piperidin-1-yl(1-(4-(pyridin-4- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 71 | | Piperidin-1-yl(1-(4-(pyridin-3- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 72 | | Piperidin-1-yl(1-(4-(pyridin-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 73 | | Piperidin-1-yl(1-(4-(pyrimidin-4- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 74 | | Piperidin-1-yl(1-(4-(thiazol-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 75 | | Piperidin-1-yl(1-(4-(pyrimidin-5- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 76 | | (4-((3-Methyl-[1,1′-biphenyl]-4- yl)methyl)piperazin-1-yl)(4- (piperidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 77 | | (4-(Morpholine-4-carbonyl)-1H- pyrazol-1-yl)(4-(pyridin-2- ylmethyl)piperazin-1- yl)methanone |
| 78 | | (4-(Benzo[d][1,3]dioxol-5- ylmethyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 79 | | (4-(Pyridin-4-ylmethyl)piperazin- 1-yl)(4-(pyrrolidine-1-carbonyl)- 1H-pyrazol-1-yl)methanone |
| 80 | | (4-(Pyridin-3-ylmethyl)piperazin- 1-yl)(4-(pyrrolidine-1-carbonyl)- 1H-pyrazol-1-yl)methanone |
| 81 | | (4-(Pyridin-2-ylmethyl)piperazin- 1-yl)(4-(pyrrolidine-1-carbonyl)- 1H-pyrazol-1-yl)methanone |
| 82 | | (4-(Pyrimidin-4- ylmethyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 83 | | Pyrrolidin-1-yl(1-(4-(thiazol-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 84 | | (4-(Pyrimidin-5- ylmethyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 85 | | (4-((3-Methyl-[1,1′-biphenyl]-4- yl)methyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 86 | | Azetidin-1-yl(1-(4- (benzo[d][1,3]dioxol-5- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 87 | | Azetidin-1-yl(1-(4-(pyridin-4- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 88 | | Azetidin-1-yl(1-(4-(pyridin-3- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 89 | | Azetidin-1-yl(1-(4-(pyridin-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 90 | | Azetidin-1-yl(1-(4-(pyrimidin-4- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 91 | | Azetidin-1-yl(1-(4-(thiazol-2- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 92 | | Azetidin-1-yl(1-(4-(pyrimidin-5- ylmethyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 93 | | Azetidin-1-yl(1-(4-((3-methyl- [1,1′-biphenyl]-4- yl)methyl)piperazine-1-carbonyl)- 1H-pyrazol-4-yl)methanone |
| 94 | | (4-((3-Methyl-[1,1′-biphenyl]-4- yl)methyl)piperazin-1-yl)(1H- pyrazol-1-yl)methanone |
| 95 | | (4-(Bis(1,3- dihydroisobenzofuran-5- yl)methyl)piperazin-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 96 | | (4-Chloro-1H-pyrazol-1- yl)(piperidin-1-yl)methanone |
| 97 | | (4-Chloro-1H-pyrazol-1- yl)(morpholino)methanone |
| 98 | | (4-Chloro-1H-pyrazol-1- yl)(pyrrolidin-1-yl)methanone |
| 99 | | (4-Chloro-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 100 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-chloro-1H-pyrazol-1- yl)methanone |
| 101 | | (4-Chloro-1H-pyrazol-1-yl)(4-((1- isopropyl-3-phenyl-1H-pyrazol-4- yl)methyl)piperazin-1- yl)methanone |
| 102 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- chloro-2-(8-oxa-2- azaspiro[4.5]decan-2- yl)benzyl)piperazin-1- yl)methanone |
| 103 | | (4-Phenyl-1H-pyrazol-1- yl)(pyrrolidin-1-yl)methanone |
| 104 | | Pyrrolidin-1-yl(4-(p-tolyl)-1H- pyrazol-1-yl)methanone |
| 105 | | (4-(4-Chlorophenyl)-1H-pyrazol- 1-yl)(pyrrolidin-1-yl)methanone |
| 106 | | (4-([1,1′-Biphenyl]-4-yl)-1H- pyrazol-1-yl)(pyrrolidin-1- yl)methanone |
| 107 | | (4-(2′-Methoxy-[1,1′-biphenyl]-4- yl)-1H-pyrazol-1-yl)(pyrrolidin-1- yl)methanone |
| 108 | | (4-(2′-Chloro[1,1′-biphenyl]-4- yl)-1H-pyrazol-1-yl)(pyrrolidin-1- yl)methanone |
| 109 | | (4-Phenyl-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 110 | | (4-(2-(Pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 111 | | (4-Methyl-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-6-(trifluoromethyl) benzyl)piperazin-1- yl)methanone |
| 112 | | (4-Isopropyl-1H-pyrazol-1-yl)(4- (2-(pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 113 | | (4-Fluoro-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 114 | | (4-(2-(Pyrrolidin-1-yl)-6- (trifluoromethyl)benzyl)piperazin- 1-yl)(4-(o-tolyl)-1H-pyrazol-1- yl)methanone |
| 115 | | (4-(2-(Pyrrolidin-1-yl)-4- (trifluoromethyl)benzyl)piperazin- 1-yl)(4-(2- (trifluoromethyl)phenyl)-1H- pyrazol-1-yl)methanone |
| 116 | | (4-(2-(Pyrrolidin-1-yl)-4- (trifluoromethyl)benzyl)piperazin- 1-yl)(4-(4- (trifluoromethyl)phenyl)-1H- pyrazol-1-yl)methanone |
| 117 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-methyl-1H-pyrazol-1- yl)methanone |
| 118 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 119 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-phenyl-1H-pyrazol-1- yl)methanone |
| 120 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-isopropyl-1H-pyrazol-1- yl)methanone |
| 121 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-fluoro-1H-pyrazol-1- yl)methanone |
| 122 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(o-tolyl)-1H-pyrazol-1- yl)methanone |
| 123 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(2-(trifluoromethyl)phenyl)- 1H-pyrazol-1-yl)methanone |
| 124 | | (4-(Bis(4- chlorophenyl)methyl)piperazin-1- yl)(4-(4-(trifluoromethyl)phenyl)- 1H-pyrazol-1-yl)methanone |
| 125 | | (4-Chloro-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-4- (trifluoromethyl)benzyl)piperazin-1- yl)methanone |
| 126 | | (4-Fluoro-1H-pyrazol-1-yl)(4-(2- (pyrrolidin-1-yl)-4- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 127 | | 4-Chloro-N-ethyl-N-(2- methoxybenzyl)-1H-pyrazole-1- carboxamide |
| 128 | | 4-Chloro-N-ethyl-N-(3- methoxybenzyl)-1H-pyrazole-1- carboxamide |
| 129 | | 4-Chloro-N-ethyl-N-(4- methoxybenzyl)-1H-pyrazole-1- carboxamide |
| 130 | | 4-Chloro-N-(2-chlorobenzyl)-N- ethyl-1H-pyrazole-1-carboxamide |
| 131 | | 4-Chloro-N-(4-chlorobenzyl)-N- ethyl-1H-pyrazole-1-carboxamide |
| 132 | | 4-Chloro-N-ethyl-N-(2- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 133 | | 4-Chloro-N-ethyl-N-(4- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 134 | | 4-Chloro-N-(3-chlorobenzyl)-N- ethyl-1H-pyrazole-1-carboxamide |
| 135 | | 4-Chloro-N-ethyl-N-(3- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 136 | | (4-Phenyl-1H-pyrazol-1- yl)(piperidin-1-yl)methanone |
| 137 | | (4-chloro-1H-pyrazol-1-yl)(4-((3- methylbiphenyl-4- yl)methyl)piperazin-1- yl)methanone |
| 138 | | 1-(4-((3-methylbiphenyl-4- yl)methyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 139 | | (4-chloro-1H-pyrazol-1-yl)(4-((3- chlorobiphenyl-4- yl)methyl)piperazin-1-yl)methanone |
| 140 | | 1-(4-((3-Chlorobiphenyl-4- yl)methyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 141 | | (4-Chloro-1H-pyrazol-1-yl)(4-((3- methoxybiphenyl-4- yl)methyl)piperazin-1- yl)methanone |
| 142 | | (4-((3-Methylbiphenyl-4- yl)methyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 143 | | (4-((3-Chlorobiphenyl-4- yl)methyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 144 | | (4-((3-Methoxybiphenyl-4- yl)methyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 145 | | 1-(4-((3-Methoxybiphenyl-4- yl)methyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 146 | | 1-(4-((3-(Benzyloxy)biphenyl-4- yl)methyl)piperazine-1-carbonyl)- 1H-pyrazole-4-carbonitrile |
| 147 | | (4-((3-(Benzyloxy)biphenyl-4- yl)methyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 148 | | (4-((3-(Benzyloxy)biphenyl-4- yl)methyl)piperazin-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 149 | | 1-(4-(4-(Trifluoromethyl)-1H- pyrazole-1-carbonyl)piperazin-1- yl)ethanone |
| 150 | | (4-(Methylsulfonyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 151 | | (4-Methylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 152 | | (4-Benzylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 153 | | (4-Benzoylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 154 | | 1-(4-(4-(trifluoromethyl)-1H- pyrazole-1-carbonyl)-1,4- diazepan-1-yl)ethanone |
| 155 | | (4-(Methylsulfonyl)-1,4-diazepan- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 156 | | (4-Methyl-1,4-diazepan-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 157 | | (4-Benzyl-1,4-diazepan-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 158 | | (4-Benzoyl-1,4-diazepan-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 159 | | N-Methyl-N-(2-(N- methylacetamido)ethyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 160 | | N-methyl-N-(2-(N- methylbenzamido)ethyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 161 | | 1-(4-(4-Methyl-1H-pyrazole-1- carbonyl)piperazin-1-yl)ethanone |
| 162 | | (4-Methyl-1H-pyrazol-1-yl)(4- (methylsulfonyl)piperazin-1- yl)methanone |
| 163 | | (4-Methyl-1H-pyrazol-1-yl)(4- methylpiperazin-1-yl)methanone |
| 164 | | (4-Benzoylpiperazin-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 165 | | 1-(4-(4-Methyl-1H-pyrazole-1- carbonyl)-1,4-diazepan-1- yl)ethanone |
| 166 | | (4-Methyl-1H-pyrazol-1-yl)(4- (methylsulfonyl)-1,4-diazepan-1- yl)methanone |
| 167 | | (4-Methyl-1,4-diazepan-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 168 | | (4-Benzyl-1,4-diazepan-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 169 | | (4-Benzoyl-1,4-diazepan-1-yl)(4- methyl-1H-pyrazol-1- yl)methanone |
| 170 | | N,4-Dimethyl-N-(2-(N- methylacetamido)ethyl)-1H- pyrazole-1-carboxamide |
| 171 | | N-(2- (benzyl(methyl)amino)ethyl)-N,4- dimethyl-1H-pyrazole-1- carboxamide |
| 172 | | N,4-Dimethyl-N-(2-(N- methylbenzamido)ethyl)-1H- pyrazole-1-carboxamide |
| 173 | | 1-(4-Acetylpiperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 174 | | 1-(4-(Methylsulfonyl)piperazine- 1-carbonyl)-1H-pyrazole-4- carbonitrile |
| 175 | | 1-(4-Methylpiperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 176 | | 1-(4-Benzoylpiperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 177 | | 1-(4-Acetyl-1,4-diazepane-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 178 | | 1-(4-(Methylsulfonyl)-1,4- diazepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 179 | | 1-(4-Benzyl-1,4-diazepane-1- carbnonyl)-1H-pyrazole-4- carbonitrile |
| 180 | | 1-(4-Benzoyl-1,4-diazepane-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 181 | | 4-Cyano-N-methyl-N-(2-(N- methylacetamido)ethyl)-1H- pyrazole-1-carboxamide |
| 182 | | 4-Cyano-N-methyl-N-(2-(N- methylbenzamido)ethyl)-1H- pyrazole-1-carboxamide |
| 183 | | 1-(4-(4-Chloro-1H-pyrazole-1- carbonyl)piperazin-1-yl)ethanone |
| 184 | | (4-Chloro-1H-pyrazol-1-yl)(4- (methylsulfonyl)piperazin-1- yl)methanone |
| 185 | | (4-Chloro-1H-pyrazol-1-yl)(4- methylpiperazin-1-yl)methanone |
| 186 | | (4-Benzylpiperazin-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 187 | | (4-Benzoylpiperazin-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 188 | | 1-(4-(4-Chloro-1H-pyrazole-1- carbonyl)-1,4-diazepan-1- yl)ethanone |
| 189 | | (4-Chloro-1H-pyrazol-1-yl)(4- (methylsulfonyl)-1,4-diazepan-1- yl)methanone |
| 190 | | (4-Chloro-1H-pyrazol-1-yl)(4- methyl-1,4-diazepan-1- yl)methanone |
| 191 | | (4-Benzyl-1,4-diazepan-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 192 | | (4-Benzoyl-1,4-diazepan-1-yl)(4- chloro-1H-pyrazol-1- yl)methanone |
| 193 | | 4-Chloro-N-methyl-N-(2-(N- methylacetamido)ethyl)-1H- pyrazole-1-carboxamide |
| 194 | | 4-Chloro-N-methyl-N-(2-(N- methylbenzamido)ethyl)-1H- pyrazole-1-carboxamide |
| 195 | | N-methyl-N-(2-(N- methylmethylsulfonamido)ethyl)- 4-(trifluoromethyl)-1H-pyrazole- 1-carboxamide |
| 196 | | N,4-dimethyl-N-(2-(N- methylmethylsulfonamido)ethyl)- 1H-pyrazole-1-carboxamide |
| 197 | | 4-Cyano-N-methyl-N-(2-(N- methylmethylsulfonamido)ethyl)- 1H-pyrazole-1-carboxamide |
| 198 | | 4-Chloro-N-methyl-N-(2-(N- methylmethylsulfonamido)ethyl)- 1H-pyrazole-1-carboxamide |
| 199 | | Pyrrolidin-1-yl(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 200 | | Piperidin-1-yl(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 201 | | Morpholino(4-(trifluoromethyl)- 1H-pyrazol-1-yl)methanone |
| 202 | | (4-Phenylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 203 | | 1-(Pyrrolidine-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 204 | | 1-(4-(4-Chlorobenzyl)piperazine- 1-carbonyl)-1H-pyrazole-4- carboxamide |
| 205 | | 1-(Morpholine-4-carbonyl)-1H- pyrazole-4-carbonitrile |
| 206 | | 1-(4-Phenylpiperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 207 | | (4-(2-Methylquinolin-4- yl)piperazin-1-yl)(4-phenyl-1H- pyrazol-1-yl)methanone |
| 208 | | (4-Chloro-1H-pyrazol-1-yl)(4-(2- methylquinolin-4-yl)piperazin-1- yl)methanone |
| 209 | | 1-(4-(2-Methylquinolin-4- yl)piperazine-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 210 | | (4-(2-Methylquinolin-4- yl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 211 | | (4-Chloro-1H-pyrazol-1-yl)(4- (3,4-dichlorobenzyl)piperazin-1- yl)methanone |
| 212 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- (pyrrolidin-1-yl)benzyl)piperazin- 1-yl)methanone |
| 213 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- (trifluoromethyl)benzyl)piperazin-1- yl)methanone |
| 214 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- (morpholinomethyl)benzyl)piperazin- 1-yl)methanone |
| 215 | | (4-Chloro-1H-pyrazol-1-yl)(4- (cyclopropylmethyl)piperazin-1- yl)methanone |
| 216 | | (4-Chloro-1H-pyrazol-1-yl)(4-(3- phenoxybenzyl)piperazin-1- yl)methanone |
| 217 | | (4-Chloro-1H-pyrazol-1-yl)(4-(4- morpholinobenzyl)piperazin-1- yl)methanone |
| 218 | | (4-Chloro-1H-pyrazol-1-yl)(4-(2- methyl-4- morpholinobenzyl)piperazin-1- yl)methanone |
| 219 | | N-Methyl-4-phenyl-N-(3- (pyridin-4-yl)benzyl)-1H- pyrazole-1-carboxamide |
| 220 | | 4-Chloro-N-methyl-N-(3-(pyridin- 4-yl)benzyl)-1H-pyrazole-1- carboxamide |
| 221 | | 4-Cyano-N-methyl-N-(3-(pyridin- 4-yl)benzyl)-1H-pyrazole-1- carboxamide |
| 222 | | N-methyl-N-(3-(pyridin-4- yl)benzyl)-4-(trifluoromethyl)- 1H-pyrazole-1-carboxamide |
| 223 | | 1-(4-(4-Chlorobenzyl)piperazine- 1-carbonyl)-N-methyl-1H- pyrazole-4-carboxamide |
| 224 | | (4-Chloro-1H-pyrazol-1-yl)(4-(2- chlorobenzyl)piperazin-1- yl)methanone |
| 225 | | (4-Chloro-1H-pyrazol-1-yl)(4-(3- chlorobenzyl)piperazin-1- yl)methanone |
| 226 | | (4-chloro-1H-pyrazol-1-yl)(4-(4- chlorobenzyl)piperazin-1- yl)methanone |
| 227 | | (4-(2-Chlorophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 228 | | (4-(3-Chlorophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 229 | | (4-(4-Chlorophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 230 | | (4-o-Tolylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 231 | | (4-m-Tolylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 232 | | (4-p-Tolylpiperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 233 | | (4-(2-Methoxyphenyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 234 | | (4-(3-Methoxyphenyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 235 | | (4-(4-Methoxyphenyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 236 | | (4-(2- Morpholinophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 237 | | (4-(3- Morpholinophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 238 | | (4-(4- Morpholinophenyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 239 | | (4-(2-(Pyrrolidin-1- yl)phenyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 240 | | (4-(3-(Pyrrolidin-1- yl)phenyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 241 | | (4-(4-(Pyrrolidin-1- yl)phenyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 242 | | 4-Cyano-N-ethyl-N-(3- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 243 | | N-(3-Chlorobenzyl)-4-cyano-N- ethyl-1H-pyrazole-1-carboxamide |
| 244 | | N-(3-Chlorobenzyl)-N-ethyl-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 245 | | N-(3-chlorobenzyl)-N-ethyl-4- methyl-1H-pyrazole-1- carboxamide |
| 246 | | 4-Cyano-N-ethyl-N-(3- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 247 | | N-Ethyl-N-(3-methylbenzyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 248 | | N-ethyl-4-methyl-N-(3- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 249 | | 4-Cyano-N-ethyl-N-(3- methoxybenzyl)-1H-pyrazole-1- carboxamide |
| 250 | | N-Ethyl-N-(3-methoxybenzyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 251 | | N-Ethyl-N-(3-methoxybenzyl)-4- methyl-1H-pyrazole-1- carboxamide |
| 252 | | N-(4-Chlorobenzyl)-4-cyano-N- ethyl-1H-pyrazole-1-carboxamide |
| 253 | | N-(4-Chlorobenzyl)-N-ethyl-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 254 | | N-(4-Chlorobenzyl)-N-ethyl-4- methyl-1H-pyrazole-1- carboxamide |
| 255 | | 4-Cyano-N-ethyl-N-(4- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 256 | | N-Ethyl-N-(4-methylbenzyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 257 | | N-Ethyl-4-methyl-N-(4- methylbenzyl)-1H-pyrazole-1- carboxamide |
| 258 | | 4-Cyano-N-ethyl-N-(4- methoxybenzyl)-1H-pyrazole-1- carboxamide |
| 259 | | N-Ethyl-N-(4-methoxybenzyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 260 | | N-Ethyl-N-(4-methoxybenzyl)-4- (trifluoromethyl)-1H-pyrazole-1- carboxamide |
| 261 | | N-Ethyl-N-(3-morpholinobenzyl)- 4-(trifluoromethyl)-1H-pyrazole- 1-carboxamide |
| 262 | | N-Ethyl-4-methyl-N-(3- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 263 | | 4-Cyano-N-ethyl-N-(4- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 264 | | N-Ethyl-N-(4-morpholinobenzyl)- 4-(trifluoromethyl)-1H-pyrazole- 1-carboxamide |
| 265 | | N-Ethyl-4-methyl-N-(4- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 266 | | 4-Chloro-N-ethyl-N-(3- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 267 | | 4-Chloro-N-ethyl-N-(4- morpholinobenzyl)-1H-pyrazole- 1-carboxamide |
| 268 | | (4-(3-Chlorobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 269 | | (4-(3-Fluorobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 270 | | (4-(3-Methylbenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 271 | | (4-(3-Methoxybenzyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 272 | | (4-(Trifluoromethyl)-1H-pyrazol- 1-yl)(4-(3- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 273 | | (4-(3-(Pyrrolidin-1- yl)benzyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 274 | | (4-(3- Morpholinobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 275 | | (4-(2-Chlorobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 276 | | (4-(2-Fluorobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 277 | | (4-(2-Methylbenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 278 | | (4-(2-Methoxybenzyl)piperazin- 1-yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 279 | | (4-(Trifluoromethyl)-1H-pyrazol- 1-yl)(4-(2- (trifluoromethyl)benzyl)piperazin- 1-yl)methanone |
| 280 | | (4-(2-(Pyrrolidin-1- yl)benzyl)piperazin-1-yl)(4- (trifluoromethyl)-1H-pyrazol-1- yl)methanone |
| 281 | | (4-(2- Morpholinobenzyl)piperazin-1- yl)(4-(trifluoromethyl)-1H- pyrazol-1-yl)methanone |
| 282 | | 1-(4-(2-Chloro-4-(piperidine-1- carbonyl)benzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 283 | | 1-(4-(4-(Azetidine-1-carbonyl)-2- chlorobenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 284 | | 1-(4-(2-Fluoro-4-(piperidine-1- carbonyl)benzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 285 | | 1-(4-(4-(Azetidine-1-carbonyl)-2- fluorobenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 286 | | 1-(4-(3- Phenoxybenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carboxamide |
| 287 | | N-Methyl-1-(4-(3- phenoxybenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carboxamide |
| 288 | | 1-(4-(4-Chlorobenzyl)piperazine- 1-carbonyl)-1H-pyrazole-4- carboxylic acid |
| 289 | | (4-((3-Chlorobiphenyl-4- yl)methyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 290 | | (4-((3-Methoxybiphenyl-4- yl)methyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 291 | | (4-((3-(Benzyloxy)biphenyl-4- yl)methyl)piperazin-1-yl)(4- (pyrrolidine-1-carbonyl)-1H- pyrazol-1-yl)methanone |
| 292 | | 1-(Azepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 293 | | N-(4-(Benzyloxy)benzyl)-4- methyl-1H-pyrazole-1- carboxamide |
| 294 | | (4-Methyl-1H-pyrazol-1-yl)(4-(3- phenoxybenzyl)piperazin-1- yl)methanone |
| 295 | | 1-(4-(3- Phenoxybenzyl)piperazine-1- carbonyl)-1H-pyrazole-4- carbonitrile |
| 296 | | (4-(3- (Benzyloxy)benzyl)piperazin-1- yl)(1H-pyrazol-1-yl)methanone |
| 297 | | (4-(3- (Benzyloxy)benzyl)piperazin-1- yl)(4-methyl-1H-pyrazol-1- yl)methanone |
| 298 | | (4-Methyl-1H-pyrazol-1-yl)(4-(3- phenoxybenzyl)-1,4-diazepan-1- yl)methanone |
| 299 | | 1-(4-(3-Phenoxybenzyl)-1,4- diazepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 300 | | 1-(4-(3-(Benzyloxy)benzyl)-1,4- diazepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 301 | | 1-(4-(4-Phenoxybenzyl)-1,4- diazepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
| 302 | | (4-(4-(Benzyloxy)benzyl)-1,4- diazepan-1-yl)(4-methyl-1H- pyrazol-1-yl)methanone |
| 303 | | 1-(4-(4-(Benzyloxy)benzyl)-1,4- diazepane-1-carbonyl)-1H- pyrazole-4-carbonitrile |
Preparation of the Compounds
| TABLE 2 | |||
| Mouse (IC50 value, nM) | |||
| Compd | MAGL | FAAH | ABHD6 | PLA2G7 |
| 9 | *** | ** | *** | |
| 10 | *** | |||
| 21 | *** | *** | *** | |
| 46 | *** | * | * | |
| 47 | *** | ** | *** | |
| 48 | ** | * | ** | |
| 49 | ** | * | ** | |
| 50 | *** | ** | *** | |
| 51 | ** | |||
| 57 | ** | *** | ** | |
| 58 | ** | |||
| 59 | ** | |||
| 60 | ** | |||
| 63 | ** | |||
| 66 | ** | * | ** | |
| 67 | ** | * | ** | |
| 68 | ** | * | ** | |
| 76 | ** | *** | ** | |
| 85 | ** | *** | ** | |
| 91 | * | |||
| 93 | ** | *** | ** | |
| 94 | *** | ** | * | |
| 100 | *** | * | ** | |
| 102 | *** | * | *** | |
| 107 | ** | |||
| 110 | *** | * | *** | |
| 111 | ** | * | ** | |
| 112 | ** | |||
| 113 | *** | * | ** | |
| 114 | ** | |||
| 115 | ** | |||
| 116 | * | |||
| 117 | *** | * | * | |
| 118 | *** | * | ** | |
| 121 | *** | * | * | |
| 125 | *** | * | ** | |
| 126 | *** | ** | ** | |
| 128 | * | ** | * | |
| 129 | * | ** | * | |
| 131 | * | *** | * | |
| 133 | * | *** | * | |
| 134 | * | ** | * | |
| 135 | * | ** | * | |
| 137 | *** | *** | ** | * |
| 138 | *** | *** | *** | *** |
| 139 | *** | *** | ** | * |
| 141 | *** | ** | ** | |
| 142 | *** | *** | ** | |
| 143 | *** | *** | ** | |
| 157 | * | ** | * | * |
| 158 | * | * | * | * |
| 179 | * | *** | * | * |
| 180 | ** | ** | * | * |
| 186 | *** | ** | *** | * |
| 200 | * | ** | ** | ** |
| 204 | *** | ** | *** | * |
| 210 | *** | * | ** | *** |
| 211 | *** | *** | *** | |
| 212 | *** | ** | ** | |
| 213 | *** | *** | *** | ** |
| 216 | *** | *** | *** | * |
| 218 | *** | ** | ** | ** |
| 219 | * | *** | ** | *** |
| 220 | *** | *** | ** | * |
| 223 | ** | ** | *** | |
| 224 | *** | ** | ** | ** |
| 225 | *** | *** | ** | * |
| 226 | *** | *** | *** | * |
| 227 | *** | *** | *** | *** |
| 233 | *** | *** | *** | *** |
| 234 | *** | *** | *** | *** |
| 235 | *** | *** | *** | *** |
| 241 | *** | *** | *** | *** |
| 243 | ** | *** | * | * |
| 244 | * | *** | * | * |
| 246 | ** | *** | ** | * |
| 247 | ** | ** | ** | * |
| 249 | ** | *** | * | |
| 250 | * | *** | * | |
| 252 | ** | *** | * | |
| 253 | * | *** | * | * |
| 255 | ** | *** | * | * |
| 256 | * | *** | * | * |
| 258 | ** | *** | * | * |
| 259 | * | *** | * | * |
| 261 | ** | *** | * | * |
| 263 | ** | *** | * | * |
| 264 | ** | *** | * | * |
| 266 | * | ** | * | * |
| 268 | *** | *** | *** | ** |
| 269 | *** | *** | *** | *** |
| 271 | *** | *** | *** | *** |
| 272 | *** | *** | *** | ** |
| 273 | *** | *** | *** | *** |
| 274 | *** | ** | *** | *** |
| 275 | *** | *** | *** | *** |
| 276 | *** | *** | *** | *** |
| 279 | *** | *** | *** | ** |
| 280 | *** | ** | ** | *** |
| 286 | *** | *** | *** | ** |
| 287 | *** | *** | *** | *** |
| 292 | * | ** | * | * |
| *** is less than or equal to 100 nM; | ||||
| ** is between 1000 and 100 nM; | ||||
| * is greater than or equal to 1000 nM | ||||
| TABLE 3 | |||
| % Inhibition at 1 μM* | % Inhibition at 10 μM* | ||
| Compd | A | B | C | D | A | B | C | D |
| 1 | # | # | # | # | ## | ### | ### | ## |
| 2 | # | # | ## | # | ## | ### | ### | ### |
| 3 | ### | ### | ### | ### | ### | ### | ### | ### |
| 4 | # | ### | ## | # | ## | ### | ### | ### |
| 5 | # | # | ## | ### | ## | ### | ### | ### |
| 6 | ### | ### | ### | ### | ### | ### | ### | ### |
| 7 | ### | # | # | # | ### | ### | ### | # |
| 8 | ## | # | ### | # | ### | ## | ### | ### |
| 9 | ### | ### | ### | ### | ### | ### | ### | ### |
| 10 | ### | ### | ### | # | ### | ### | ### | # |
| 11 | ### | # | ### | # | ### | ## | ### | ### |
| 12 | ### | ### | ### | ### | ### | ### | ### | ### |
| 13 | ### | ### | ### | ### | ### | ### | ### | ### |
| 14 | ### | ### | ### | ### | ### | ### | ### | ### |
| 15 | ### | ### | ### | ### | ### | ### | ### | ### |
| 16 | ### | # | ### | # | ### | ### | ### | ### |
| 17 | ### | ## | ### | ## | ### | ### | ### | # |
| 18 | ### | ### | ### | ### | ### | ### | ### | ### |
| 19 | ## | ### | # | # | ### | ### | ### | # |
| 20 | ## | # | ## | # | ### | ### | ### | ## |
| 21 | ### | ### | ### | # | ### | ### | ### | ### |
| 22 | ### | # | # | # | ### | ### | ### | # |
| 23 | ### | # | ## | # | ### | ## | ### | ### |
| 24 | ### | ### | ### | ### | ### | ### | ### | ### |
| 25 | # | # | # | # | # | # | ## | # |
| 26 | # | ## | ## | # | ## | ### | ### | # |
| 27 | ### | ### | ### | ### | ### | ### | ### | ### |
| 28 | # | # | # | # | ## | ## | ## | # |
| 29 | # | # | # | # | ## | ## | ### | # |
| 31 | # | # | # | # | ||||
| 32 | # | # | # | # | ||||
| 33 | # | # | # | # | # | ### | # | # |
| 34 | # | # | # | # | ||||
| 35 | # | # | # | # | ||||
| 36 | # | ## | # | # | ## | ### | ## | # |
| 37 | # | # | # | # | ||||
| 38 | # | # | # | # | ||||
| 39 | # | # | # | # | ## | ### | # | # |
| 40 | # | # | # | # | ### | # | # | # |
| 41 | # | # | # | # | ### | # | # | # |
| 42 | # | # | # | # | ### | # | # | # |
| 43 | # | # | # | # | ## | ### | # | # |
| 44 | # | # | # | |||||
| 45 | # | # | # | # | ## | ### | # | # |
| 51 | # | # | ### | # | ### | ### | ### | ### |
| 52 | ## | # | # | # | ### | ### | ||
| 53 | # | # | ## | # | ### | ### | ||
| 54 | # | # | ## | # | ## | ### | ||
| 55 | ## | # | # | ## | ### | ### | ||
| 56 | # | # | # | # | ### | ### | ||
| 57 | ### | ### | ### | # | ### | ### | ### | ### |
| 58 | # | ### | ### | ### | ### | ### | ### | ### |
| 59 | ### | ### | ## | ### | ### | ### | ||
| 60 | ### | ### | ## | ### | ### | ### | ||
| 61 | ### | ### | # | ### | ### | ### | ||
| 62 | ### | ### | # | ### | ### | ### | ||
| 63 | ### | ### | # | ### | ### | ### | ||
| 64 | ### | ### | # | # | ### | ### | ||
| 65 | # | ### | ### | ### | ### | ### | ### | ### |
| 66 | ### | # | ### | ### | ## | ### | ||
| 67 | ### | # | ### | ### | ### | ## | ### | ### |
| 68 | ### | # | ### | ### | ### | ### | ||
| 69 | ## | ### | ### | ### | ### | ### | ### | ### |
| 70 | # | # | ## | ### | # | ## | ### | ### |
| 71 | # | # | ## | ### | # | ## | ### | ### |
| 72 | # | # | # | ### | # | ### | ### | ### |
| 73 | # | # | # | ### | # | ## | ### | ### |
| 74 | # | # | ### | ### | # | ### | ### | ### |
| 75 | # | # | # | ### | # | # | ### | ### |
| 76 | ### | ### | ### | ### | ### | ### | ### | ### |
| 77 | # | # | # | # | ### | ### | ||
| 78 | # | ### | ### | # | ### | ### | ### | ### |
| 79 | ## | # | # | ## | ### | ### | ||
| 80 | ## | # | # | ## | ### | ### | ||
| 81 | # | # | # | ### | ### | ### | ||
| 82 | # | # | # | ## | ### | ### | ||
| 83 | # | # | # | # | # | ### | ### | ### |
| 84 | # | # | # | # | # | # | ## | ### |
| 85 | ### | ### | ### | # | ### | ### | ### | ### |
| 86 | # | ### | ## | # | ### | ### | ### | ### |
| 87 | # | # | # | # | # | ### | ### | ### |
| 88 | # | ## | ### | ### | ||||
| 89 | # | ### | ## | ### | ||||
| 90 | # | # | # | ## | ### | ### | ||
| 91 | # | # | # | ### | ### | ### | ||
| 92 | # | # | # | # | ### | ### | ||
| 93 | ### | ### | ### | # | ### | ### | ### | ### |
| 95 | ### | # | ### | |||||
| 96 | ### | ### | ### | |||||
| 97 | # | ### | # | |||||
| 98 | ## | ### | # | |||||
| 99 | ### | ### | ### | |||||
| 101 | ### | ### | ### | |||||
| 102 | ### | # | ### | |||||
| 103 | # | ### | # | ### | ||||
| 104 | # | ### | ### | |||||
| 105 | # | ### | ### | |||||
| 106 | ## | # | # | # | ### | ## | ||
| 107 | # | # | ### | # | ### | # | ### | ## |
| 108 | # | # | ### | |||||
| 109 | ## | ### | ### | |||||
| 110 | ### | # | ### | ### | ### | ### | ### | ### |
| 111 | ### | ## | ### | |||||
| 112 | # | # | ### | # | ### | # | ### | ### |
| 113 | ### | ## | ### | ### | ### | ### | ||
| 114 | # | # | ### | # | ## | ### | ||
| 115 | # | # | ### | ## | ## | ## | ## | ### |
| 116 | ## | # | ### | ### | # | ### | ### | |
| 117 | ### | # | # | ### | # | ### | ||
| 118 | ### | # | ### | ### | ### | ### | ||
| 119 | ## | # | # | ### | # | ### | ||
| 120 | ## | # | ## | ### | # | ### | ||
| 121 | ### | # | # | ### | ### | ### | ||
| 122 | # | ## | ## | # | ### | ### | ||
| 123 | ## | # | ## | # | ### | ## | ||
| 124 | ### | ## | ## | # | ### | ### | ||
| 125 | ### | # | ### | |||||
| 126 | ### | ### | ### | |||||
| 127 | # | # | # | # | ### | ### | ### | # |
| 128 | ### | ### | ### | # | ||||
| 129 | # | ### | # | # | ### | ### | ## | # |
| 130 | # | # | # | # | ||||
| 131 | # | ### | # | # | ||||
| 132 | # | # | # | # | ||||
| 133 | # | ### | # | # | ### | ### | ### | # |
| 134 | ## | ### | # | # | ### | ### | ### | # |
| 135 | ## | ### | # | # | ### | ### | ### | # |
| 136 | # | ### | ### | ### | # | ### | ### | ### |
| 137 | ### | ### | ### | # | ### | ### | ### | ## |
| 138 | ### | ### | ### | ### | ### | ### | ### | ### |
| 139 | ### | ### | ### | # | ### | ### | ### | ### |
| 140 | ### | ### | ### | ### | ### | ### | ### | ### |
| 141 | ### | ### | ### | # | ### | ### | ### | ### |
| 142 | ### | ### | ### | ### | ### | ### | ### | ### |
| 143 | ### | ### | ### | ## | ### | ### | ### | ### |
| 144 | ### | ### | ### | ### | ### | ### | ### | ### |
| 145 | ### | ### | ### | ### | ### | ### | ### | ### |
| 146 | ### | ### | ### | # | ### | ### | ### | ### |
| 147 | ### | ### | ### | # | ### | ### | ### | ### |
| 148 | ### | ### | ### | # | ### | ### | ### | # |
| 149 | # | # | # | ### | ## | # | ## | ### |
| 150 | # | # | ### | ### | ## | ## | ### | ### |
| 151 | # | ### | ### | ## | ### | ### | ### | ### |
| 152 | ### | ### | ### | ### | ### | ### | ### | ### |
| 153 | ### | # | # | ### | ### | ## | ### | ### |
| 154 | # | # | # | ## | # | ## | ### | ### |
| 155 | # | ## | # | ### | ## | ### | ### | ### |
| 156 | # | # | # | # | # | ## | # | ### |
| 157 | ### | ### | ### | # | ### | ### | ### | ### |
| 158 | ### | ### | ### | ### | ### | ### | ### | ### |
| 159 | # | # | # | # | # | ## | ### | ### |
| 160 | # | ### | # | ### | ### | ### | ### | ### |
| 161 | # | # | # | # | # | # | # | ### |
| 162 | # | # | # | # | # | # | ## | ### |
| 163 | # | # | # | # | # | # | ## | # |
| 164 | # | # | # | # | ## | # | # | ### |
| 165 | # | ## | # | # | ||||
| 166 | # | # | # | # | ||||
| 167 | # | # | # | # | ||||
| 168 | # | # | # | # | ||||
| 169 | ## | # | ## | # | ||||
| 170 | # | # | # | # | ||||
| 171 | # | # | # | # | ||||
| 172 | # | # | # | # | ||||
| 173 | # | # | # | ### | ## | # | ## | ### |
| 174 | # | # | ### | ### | ## | ## | ### | ### |
| 175 | ## | ## | ### | # | ### | ### | ### | ### |
| 176 | ### | # | # | ### | ### | ## | ### | ### |
| 177 | # | # | # | # | # | ### | ### | ### |
| 178 | # | # | # | # | ### | ### | ### | ## |
| 179 | ### | ### | ### | # | ### | ### | ### | ### |
| 180 | ### | ### | ### | # | ### | ### | ### | ### |
| 181 | # | # | # | # | # | ### | ### | ### |
| 182 | # | ### | # | # | ### | ### | ### | ### |
| 183 | # | # | # | # | # | # | # | ### |
| 184 | # | # | ### | ### | # | ## | ### | ### |
| 185 | # | # | ### | # | ## | ### | ### | ### |
| 186 | ### | ### | ### | # | ### | ### | ### | ### |
| 187 | ## | # | # | ### | ### | ### | ## | ### |
| 188 | # | # | ## | |||||
| 189 | # | ### | ### | # | ## | ### | ### | # |
| 190 | # | # | # | |||||
| 191 | # | ### | ## | # | ### | ### | ### | # |
| 192 | ## | # | ## | # | ### | ### | ### | ### |
| 193 | # | # | # | # | ||||
| 194 | # | ## | # | # | ## | ### | # | # |
| 195 | # | # | # | # | # | ### | ### | ## |
| 196 | # | # | # | |||||
| 197 | # | ## | # | # | # | ### | ## | |
| 198 | # | # | # | # | ||||
| 199 | # | ### | ## | ## | ### | ### | ### | ### |
| 200 | ### | ### | ### | ### | ### | ### | ### | ### |
| 201 | # | ### | ### | ### | ## | ### | ### | ### |
| 202 | ### | ### | ### | ### | ### | ### | ### | ### |
| 203 | # | ### | # | # | ### | ### | ### | ### |
| 204 | ### | ### | ### | # | ||||
| 205 | # | ### | ## | ### | ## | ### | ### | ### |
| 206 | ### | ### | ### | ### | ### | ### | ### | ### |
| 207 | ## | ### | ### | ## | ### | ### | ### | ### |
| 208 | ### | ### | ### | ### | ### | ### | ### | ### |
| 209 | ### | ### | ### | ### | ### | ### | ### | ### |
| 210 | ### | ### | ### | ## | ### | ### | ### | ### |
| 211 | ### | ### | ### | # | ### | ### | ### | ### |
| 212 | ### | ### | ### | # | ### | ### | ### | ### |
| 213 | ### | ### | ### | # | ### | ### | ### | ### |
| 214 | ### | ### | ### | ### | ||||
| 215 | ## | ### | ### | # | ### | ### | ### | ### |
| 216 | ### | ### | ### | # | ||||
| 217 | ### | ### | ### | ### | ||||
| 218 | ### | ### | ### | ### | ||||
| 219 | ### | ### | ### | ### | ### | ### | ### | ### |
| 220 | ### | ### | ### | ## | ### | ### | ### | ### |
| 221 | ### | ### | ### | ## | ### | ### | ### | # |
| 222 | ### | ### | ### | ## | ### | ### | ### | # |
| 223 | ### | ### | ### | ### | ||||
| 224 | ### | ### | ### | # | ||||
| 225 | ### | ### | ### | # | ||||
| 226 | ### | ### | ### | # | ||||
| 227 | ### | ### | ### | ### | ### | ### | ### | ### |
| 228 | ### | ### | ### | ### | ### | ### | ### | ### |
| 229 | ### | ### | ### | ### | ### | ### | ### | ### |
| 230 | ### | ### | ### | ### | ### | ### | ### | ### |
| 231 | ### | ### | ### | ### | ### | ### | ### | ### |
| 232 | ### | ### | ### | ### | ### | ### | ### | ### |
| 233 | ### | ### | ### | ### | ### | ### | ### | ### |
| 234 | ### | ### | ### | ### | ### | ### | ### | ### |
| 235 | ### | ### | ### | ### | ### | ### | ### | ### |
| 236 | ### | ## | ### | ### | ### | ### | ### | ### |
| 237 | ### | ### | ### | ### | ### | ### | ### | ### |
| 238 | ### | ### | ### | ### | ### | ### | ### | ### |
| 239 | ### | ### | ### | ### | ### | ### | ### | ### |
| 240 | ### | ### | ### | ### | ### | ### | ### | ### |
| 241 | ### | ### | ### | ### | ### | ### | ### | ### |
| 242 | ### | ### | ## | # | ||||
| 243 | ### | ### | ### | # | ||||
| 244 | ## | ### | ## | # | ||||
| 245 | # | # | # | # | ||||
| 246 | ### | ### | ### | # | ||||
| 247 | # | ### | ## | # | ### | ### | ### | # |
| 248 | # | # | # | # | ||||
| 249 | ### | ### | # | # | ### | ### | ### | ## |
| 250 | ### | ### | ## | # | ### | ### | ### | ### |
| 251 | # | # | # | # | ||||
| 252 | ### | ### | # | # | ### | ### | ### | ## |
| 253 | ## | ### | # | # | ||||
| 254 | # | # | # | # | ||||
| 255 | ### | ### | # | # | ||||
| 256 | ## | ### | # | # | ||||
| 257 | # | # | # | # | ||||
| 258 | ### | ### | # | # | ||||
| 259 | ### | ### | # | # | ||||
| 260 | # | # | # | # | ||||
| 261 | ## | ### | ## | # | ||||
| 262 | # | # | # | # | ||||
| 263 | ### | ### | ## | # | ||||
| 264 | ### | ### | # | # | ||||
| 265 | # | # | # | # | ||||
| 266 | # | ### | # | # | ### | ### | ### | # |
| 267 | ## | ## | # | # | ||||
| 268 | ### | ### | ### | ### | ||||
| 269 | ### | ### | ### | ### | ||||
| 270 | ### | ### | ### | ### | ||||
| 271 | ### | ### | ### | ### | ||||
| 272 | ### | ### | ### | ### | ||||
| 273 | ### | ### | ### | ### | ||||
| 274 | ### | ### | ### | ### | ||||
| 275 | ### | ### | ### | ### | ||||
| 276 | ### | ### | ### | ### | ||||
| 277 | ### | ### | ### | ### | ||||
| 278 | ### | ### | ### | ### | ||||
| 279 | ### | ### | ### | ### | ||||
| 280 | ### | ### | ### | ### | ||||
| 281 | ### | ### | ### | ### | ||||
| 282 | ### | ### | ### | ### | ### | ### | ### | ### |
| 283 | ### | ### | ### | ### | ### | ### | ### | ### |
| 284 | ### | ### | ### | ### | ### | ### | ### | ### |
| 285 | ### | ### | ### | ### | ### | ### | ### | ### |
| 286 | ### | ### | ### | ## | ||||
| 287 | ### | ### | ### | ### | ||||
| 288 | # | ## | # | # | # | ### | # | # |
| 289 | ### | ### | ### | ### | ### | ### | ### | ### |
| 290 | ### | ### | ### | # | ### | ### | ### | ### |
| 291 | ### | ### | ### | # | ### | ### | ### | ## |
| 292 | ## | ### | ## | # | ### | ### | ### | ### |
| 293 | # | # | # | # | ||||
| 294 | ### | ### | ### | # | ||||
| 295 | ### | ### | ### | # | ||||
| 296 | ### | ### | ### | # | ||||
| 297 | ### | ### | ### | # | ||||
| 298 | ### | # | # | # | ||||
| 299 | ### | ### | ### | # | ||||
| 300 | ### | ### | ### | # | ||||
| 301 | ### | ### | ### | # | ||||
| 302 | ## | # | # | # | ||||
| 303 | ### | ### | # | # | ||||
| *A = MAGL, B = FAAH, C = ABHD6, D = PLA2G7 | ||||||||
| ### is ≥75%; | ||||||||
| ## is between 25 and 75%; | ||||||||
| # is ≤25% | ||||||||
Claims (16)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/312,998 US10093630B2 (en) | 2014-05-21 | 2015-05-20 | Pyrazole compounds and methods of making and using same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001491P | 2014-05-21 | 2014-05-21 | |
| US15/312,998 US10093630B2 (en) | 2014-05-21 | 2015-05-20 | Pyrazole compounds and methods of making and using same |
| PCT/US2015/031834 WO2015179559A2 (en) | 2014-05-21 | 2015-05-20 | Pyrazole compounds and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20170190669A1 US20170190669A1 (en) | 2017-07-06 |
| US10093630B2 true US10093630B2 (en) | 2018-10-09 |
Family
ID=54554966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/312,998 Active US10093630B2 (en) | 2014-05-21 | 2015-05-20 | Pyrazole compounds and methods of making and using same |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US10093630B2 (en) |
| WO (1) | WO2015179559A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655217B2 (en) | 2017-05-23 | 2023-05-23 | H. Lundbeck A/S | Pyrazole MAGL inhibitors |
| US12258340B2 (en) | 2017-05-23 | 2025-03-25 | H. Lundbeck A/S | Pyrazole MAGL inhibitors |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| WO2015179559A2 (en) | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| JP6640840B2 (en) * | 2014-09-22 | 2020-02-05 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for treating fibrosis |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10519134B2 (en) | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190107A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | monoacylglycerol lipase (MAGL) inhibitors |
| PL3541807T3 (en) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| JOP20190267A1 (en) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | Pyrazole MAGL . Inhibitors |
| UA126685C2 (en) * | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Spirocycle compounds and methods of making and using same |
| AR114136A1 (en) * | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| EP3886844A4 (en) * | 2018-11-28 | 2022-08-24 | H. Lundbeck A/S | METHODS OF TREATMENT OF DISEASES WITH MAGL INHIBITORS |
| EP3953360B1 (en) * | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| CN114072405A (en) | 2019-07-03 | 2022-02-18 | 豪夫迈·罗氏有限公司 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors |
| KR20220034104A (en) | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | Novel heterocyclic compounds |
| BR112021013917A2 (en) * | 2019-11-15 | 2022-05-24 | H Lundbeck As | Crystalline form of a magl inhibitor, pharmaceutical composition and use |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| PE20231372A1 (en) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibition of monoacylglycerol lipase (MAGL) |
| JP2025530372A (en) * | 2022-09-15 | 2025-09-11 | クルゲン(シャンハイ),インク. | Modified proteins and protein binders and degraders |
| WO2024168426A1 (en) * | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3308130A (en) | 1962-04-26 | 1967-03-07 | Du Pont | N-disubstituted carbamyl pyrazoles |
| WO2010074588A2 (en) | 2008-12-24 | 2010-07-01 | BIAL - PORTELA & Cª, S.A. | Pharmaceutical compounds |
| WO2013078771A1 (en) | 2011-11-30 | 2013-06-06 | 成都地奥制药集团有限公司 | Poly (adp-ribose) polymerase inhibitor |
| WO2015179559A2 (en) | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
-
2015
- 2015-05-20 WO PCT/US2015/031834 patent/WO2015179559A2/en not_active Ceased
- 2015-05-20 US US15/312,998 patent/US10093630B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3308130A (en) | 1962-04-26 | 1967-03-07 | Du Pont | N-disubstituted carbamyl pyrazoles |
| WO2010074588A2 (en) | 2008-12-24 | 2010-07-01 | BIAL - PORTELA & Cª, S.A. | Pharmaceutical compounds |
| WO2013078771A1 (en) | 2011-11-30 | 2013-06-06 | 成都地奥制药集团有限公司 | Poly (adp-ribose) polymerase inhibitor |
| WO2015179559A2 (en) | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
Non-Patent Citations (14)
| Title |
|---|
| Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977). |
| Blankman et al. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14:1347-1356 (2007). |
| Fleisher et al. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Advanced Drug Delivery Reviews 19:115-130 (1996). |
| Horig, H., Pullman, W. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. Journal of Translational Medicine. Dec. 2004, 2, 44. * |
| Kohnz et al., Chemical Approaches to Therapeutically Target the Metabolism and Signaling of the Endocannabinoid 2-AG and Eicosanoids. Chemical Society Review, 2014, 43, 6859-6869. * |
| Long et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 5(1):37-44 (2009). |
| Lysenko et al., Monoacylglycerol Lipase Inhibitors JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome. PloS ONE, 2014, 9:e114521, p. 1-25. * |
| Morren et al. The filaricidal derivatives of 1-methylpiperazine. Bulletin des Societes Chimiques Belges 59(3-4):228-237 (1950). |
| Mulvihill et al., Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. Life Science, 2013, 92, 492-497. * |
| Niphakis et al. O-Hydroxyacetamide Carbamates as a Highly Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors. ACS Chem. Neurosci. 3(5):418-426 (2012/Web2011). |
| Otrubova et al. Discovery libraries targeting the major enzyme classes: the serine hydrolases. Bioorg Med Chem Lett 24(16):3807-3813 (2014). |
| PCT/US2015/031834 International Preliminary Report on Patentability dated Dec. 1, 2016. |
| PCT/US2015/031834 International Search Report and Written Opinion dated Apr. 20, 2016. |
| Schafer, S., Kolkhof, P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discovery Today. Nov. 2008, 13, 913-916. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655217B2 (en) | 2017-05-23 | 2023-05-23 | H. Lundbeck A/S | Pyrazole MAGL inhibitors |
| US12258340B2 (en) | 2017-05-23 | 2025-03-25 | H. Lundbeck A/S | Pyrazole MAGL inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170190669A1 (en) | 2017-07-06 |
| WO2015179559A2 (en) | 2015-11-26 |
| WO2015179559A3 (en) | 2016-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170190669A1 (en) | Pyrazole compounds and methods of making and using same | |
| US10323038B2 (en) | Pyrazole compounds and methods of making and using same | |
| US10385057B2 (en) | Pyrazole compounds and methods of making and using same | |
| US11149037B2 (en) | Pyrazole MAGL inhibitors | |
| US10519134B2 (en) | Pyrazole compounds and methods of making and using same | |
| US10626104B2 (en) | Inhibitors of lysine specific demethylase-1 | |
| US9994537B2 (en) | Piperazine carbamates and methods of making and using same | |
| US12318383B2 (en) | Dual MAGL and FAAH inhibitors | |
| US9828379B2 (en) | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | |
| US11655217B2 (en) | Pyrazole MAGL inhibitors | |
| US10583137B2 (en) | Triazole DAGLα inhibitors | |
| US12258340B2 (en) | Pyrazole MAGL inhibitors | |
| HK40036787B (en) | Carbamate compounds for use in therapy | |
| HK40021173A (en) | Dual magl and faah inhibitors | |
| HK40021173B (en) | Dual magl and faah inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOGER, DALE L.;OTRUBOVA, KATERINA;SIGNING DATES FROM 20170228 TO 20170301;REEL/FRAME:041866/0531 Owner name: ABIDE THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CISAR, JUSTIN S.;GRICE, CHERYL A.;JONES, TODD K.;SIGNING DATES FROM 20170301 TO 20170302;REEL/FRAME:041866/0511 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| CC | Certificate of correction | ||
| AS | Assignment |
Owner name: LUNDBECK LA JOLLA RESEARCH CENTER, INC., CALIFORNIA Free format text: MERGER;ASSIGNOR:ABIDE THERAPEUTICS, INC.;REEL/FRAME:057434/0784 Effective date: 20190506 Owner name: H. LUNDBECK A/S., DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LUNDBECK LA JOLLA RESEARCH CENTER, INC.;REEL/FRAME:055679/0885 Effective date: 20191129 |
|
| AS | Assignment |
Owner name: H. LUNDBECK A/S, DENMARK Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 055679 FRAME: 0885. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LUNDBECK LA JOLLA RESEARCH CENTER, INC.;REEL/FRAME:056544/0697 Effective date: 20191129 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |





















































































































































































































































































































































































































































































































































































































































































































































































































































